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Abstract 
Human induced pluripotent stem cells (hiPSCs) offer significant opportunities for cardiac re-
search. With this technology, it is possible to create patient-specific stem cell lines and differen-
tiate them into cardiomyocytes for cardiac research. hiPSC technology has created many expec-
tations for new therapeutic possibilities, and it holds promise for use in drug-testing platforms 
and in patient-specific drug therapy optimization, as well as later in regenerative medicine. 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited, highly le-
thal arrhythmogenic cardiac disorder. It is primarily caused by cardiac ryanodine receptor gene 
(RyR2) mutations that result in abnormal calcium release from the sarcoplasmic reticulum to the 
cytosol, leading to the generation of afterdepolarizations and triggered activity. The estimated 
clinical prevalence of CPVT is 1:10000. Intracellular calcium ions are crucial to the function of 
the heart muscle, and disturbances in this process can have fatal consequences, as observed in 
CPVT. Understanding the mechanisms of arrhythmia and the role of intracellular calcium in 
CPVT pathophysiology is important for improving disease prevention, diagnosis, and treatment. 
The main objective of this work was to develop and characterize models of cardiac cells and 
to develop and improve techniques for studying electrical field stimulation and calcium cycling 
of cardiomyocytes. Utilizing electrical field stimulation, the orientation and maturation of neo-
natal rat cardiomyocytes and the increase in the beating rate of an in vitro disease model for 
CPVT were studied. For the cell model of CPVT, human iPSC-derived cardiomyocytes were 
obtained from CPVT patients carrying RyR2 mutations. These iPSCs disease models were used 
to study the disease mechanisms of CPVT, mutation-specific differences in intracellular calcium 
cycling and the effect of antiarrhythmic treatment of the cells. Mechanistic insights regarding 
CPVT arrhythmias and drug responses were also validated in the index patients. Additionally, a 
new calcium cycling analysis software tool was developed for characterizing abnormal intracel-
lular calcium transients of disease-specific cardiomyocytes.  
The results of this work demonstrate that patient-specific iPSC-derived cardiomyocytes cor-
responded to the clinical phenotype in both the pathophysiology and drug responses of CPVT 
and encourages the continuation of disease modeling utilizing iPSCs. These studies also pre-
sented a new mechanism for arrhythmias in CPVT. These findings encourage the translation of 
findings in basic research to benefit patients in clinical practice, e.g., in the form of potentially 
new medications.  
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1 Introduction 
Cardiac diseases including heart failure (HF) are continuously increasing global health issues 
that impose a significant medical and economic burden. Currently, cardiac biotechnology is 
focused on studying the mechanisms, pathophysiology and treatment options of cardiac ar-
rhythmias and diseases as well as the development, physiology and maturity of cardiomyocytes 
(CMs). Human pluripotent stem cell (hPSC)-derived CMs serve as an important tool in these 
studies. Other cell and animal models have also been used, but they may fail to recapitulate 
human physiology. One major problem in culturing hPSC-derived CMs has been the immature 
phenotype; however, primary CMs have a tendency to dedifferentiate quickly in culture. These 
limitations interfere with the functional and morphological stability of the cells and are therefore 
continuously studied by altering and optimizing the culture conditions and environment of the 
CMs.  
Human induced pluripotent stem cells (hiPSCs) (Takahashi et al., 2007; Yu et al., 2007) 
derived from differentiated somatic cells have a great potential for cardiac research. iPSCs can 
be differentiated into the desired cell type while retaining the original genotype. Therefore, with 
this technology, patient-specific stem cell lines and CMs can be created, providing a way to 
model and study the pathophysiology of various cardiac disorders in human cells. iPSC tech-
nology is expected to be utilized in studies of cell development and diseases, in regenerative 
medicine, in drug-testing platforms and in patient-specific drug therapy optimization. Before 
iPSCs can be used in clinical applications, these cells need to overcome various challenges. 
Nevertheless, cardiac disease models and drug testing platforms exploiting iPSC technology 
have already been established by several research groups with some promising results (Caspi et 
al., 2009; Moretti et al., 2010; Braam et al., 2010; Itzhaki et al., 2011b; Yazawa et al., 2011; 
Jung et al., 2012; Itzhaki et al., 2012), including the results presented in this thesis. 
The main objective of this work was the development and functional characterization of 
cardiac cell models. In addition, techniques to improve electrical field stimulation (EFS) and to 
analyze the calcium (Ca2+) cycling of CMs were developed. Neonatal rat cardiomyocytes 
(NRCs) were exposed to EFS to study the morphological and functional properties of these cells 
using a novel EFS platform. An in vitro cell model for catecholaminergic polymorphic ventricu-
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lar tachycardia (CPVT), a potentially lethal inherited cardiac syndrome, was generated with 
iPSC-derived CMs generated from CPVT patients carrying cardiac ryanodine receptor gene 
(RyR2) mutations. With these CMs, the mechanisms of arrhythmias, the role of intracellular 
Ca2+ cycling and mutation-specific differences in intracellular Ca2+ cycling were studied. Mech-
anistic insights regarding CPVT arrhythmias in iPSC-derived CMs were also studied in the in-
dex patients. The antiarrhythmic potential of dantrolene, an inhibitor of Ca2+ release from the 
sarcoplasmic reticulum (SR), was assessed in the clinical treatment of CPVT patients carrying 
various RyR2 mutations, and results were compared to in vitro studies using iPSC-derived CMs 
generated from the same patients. Additionally, Ca2+ cycling analysis software was developed to 
analyze the abnormal intracellular Ca2+ cycling of these CMs.  
In this thesis, molecular and cellular research exploiting iPSC-derived CMs is compared to 
clinical patient data to provide important insight regarding how these cells resemble the clinical 
phenotype of the patients. This relationship has not yet been widely shown by others, and this 
report is the first to demonstrate mutation-specific differences both in patients and in iPSCs. 
Most importantly, these studies will help to translate insights gained in basic research to benefit 
patients in clinical practice. Additionally, because the abnormal Ca2+ transients in CPVT resem-
ble those observed in patients with HF, the results of our studies could be beneficial for other 
patients in addition to CPVT patients. 
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2 Literature review 
2.1  Human heart and cardiomyocytes  
The heart is a muscular organ that pumps blood to all the tissues in the body through a network 
of blood vessels. The heart consists of four chambers, namely, the right and left atria and ventri-
cles (Figure 1), as well as four heart valves, which control blood flow from the atria to the ven-
tricles and out of the ventricles. The endocardium is the inner layer of the heart and is composed 
of endothelial cells, which provide a smooth, non-adherent surface for the pumping blood. The 
myocardium is the muscle tissue of the heart and is composed of CMs, which are able to con-
tract and to conduct electricity. The epicardium is a thin layer that consists of connective tissue 
and fat, which protect the heart. The pericardium is a fibrous connective tissue layer that covers 
the heart. The sinoatrial node (SAN) in the right atrium generates impulses to initiate heart con-
tractions, and the atrioventricular node (AVN) between the atria and ventricles conducts im-
pulses from the atria to the ventricles (Figure 1). These nodes consist of self-excitatory pace-
maker cells (Figure 1) that, together with electrical conducting cells, are called nodal cells. Elec-
trical conducting cells deliver the cardiac current from the SAN to the distant regions of the 
heart. (Katz, 2006; Thaler, 1999) 
The adult human heart is composed of 30% CMs (atrial, ventricular and nodal cells) and 
70% non-myocytes, mainly fibroblasts but also vascular cells such as smooth muscle and endo-
thelial cells (Figure 1) (Porter and Turner, 2009). Cardiac fibroblasts are responsible for homeo-
static maintenance of extracellular matrix (ECM) in the normal heart. Cardiac ECM is com-
posed of fibrillar collagens I (80%) and III (10%), with smaller amounts of collagens IV, V, VI; 
elastin; laminin; proteoglycans; glycosaminoglycans; growth factors and proteases. (Brown et 
al., 2005) A population of cardiac stem cells called cardiac progenitor cells (CPCs) have also 
been identified in the hearts of several species; however, the origin of these cells is unclear. 
They compose less than 1% of the cells in the heart and may be able to differentiate into fully 
mature CMs. (Bollini et al., 2011; Henning, 2011) 
CMs are cylindrical and striated cells that are approximately 10-20 μm in diameter and 100 
μm in length; these cells can have multiple centrally located, slightly elongated nuclei. CMs can 
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be branched and connected to adjacent CMs along the longitudinal axis through the intercalated 
discs (Figure 1). Intercalated discs include the following components: 1) desmosomes, which 
help to resist shearing forces of contractions; 2) adherens junctions, which serve as attachment 
points for the actin filaments of terminal sarcomeres, and 3) gap junctions formed by connexins, 
which function in ion transport between adjacent CMs. (Katz, 2006; Sarantitis et al., 2012) 
Sarcomeres are responsible for the contraction of the CM, and the sarcomeric cytoskeleton 
consists of thin actin filaments and thick myosin filaments (Figure 1). Sarcomeres are approxi-
mately 2.2 μm long during relaxation and 1.6 μm during contraction and are connected serially 
to form a myofibril. The thin filaments consist of cardiac actin, α-tropomyosin and C-, Ι- and Τ- 
troponin subunits. Thick myosin filaments are found among the actin filaments, and each actin 
monomer has a binding area for myosin to allow the contraction of the sarcomere. The thick 
filaments consist primarily of myosin and C-, H- and X-myosin binding proteins. The myosin 
binding protein C (cMyBP-C), which has structural and regulatory characteristics, plays the 
most important role. Myosin molecules may be divided into two similar heavy chains (MYH6 
and MYH7 genes which enccodes α-MHC and β-MHC) and two pairs of light chains (MLC1 
and MLC2). (Katz, 2006; Sarantitis et al., 2012) 
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Figure 1. Structure and cell types of the human heart. Cardiac muscle is composed of CMs, 
which are composed of myofibrils that form the highly organized alignment of sarcomeres. Ac-
tin and myosin filaments form the sarcomere structure, which is responsible for the contraction 
and relaxation of the entire CM. The figure depicting collage is modified from (Xin et al., 2013). 
2.2  Electrophysiology of the heart and cardiomyocytes 
2.2.1 The cardiac action potential 
In excitation–contraction coupling (ECC), the electrical excitation of a CM is translated into 
mechanical contraction. Continuous cardiac contraction is based on the generation of cyclic 
action potentials (APs) in the heart. APs result from the transfer of various ions between the 
outside and inside of the cell through specialized ion channels, which results in changes in the 
membrane potential. (Grant, 2009) As the membrane potential reaches a certain threshold, ion 
channels open or close. The direction of the ion currents in or out of the cell is determined by 
the electrochemical gradient of the corresponding ions. The current amplitude depends on the 
membrane potential and on the conductivity of the responsible ion channels. (Amin et al., 2010; 
Bers, 2002) 
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The AP initiates by the spontaneous excitation of nodal cells in the SAN located in the right 
atrium. The AP depolarizes adjacent atrial CMs by traveling through the intercellular gap junc-
tions, ultimately resulting in excitation of the atria. The AP propagates via the AVN between the 
atria and the ventricles and then along Purkinje fibers to the ventricles, where ventricular CMs 
are depolarized, resulting in excitation of the ventricular myocardium. The shape and duration 
of the AP varies between nodal, atrial and ventricular CMs because of different ion channel 
expression (Figure 2). (Amin et al., 2010; Bers, 2002) 
The AP is divided into four phases, which are each characterized by tightly controlled ion 
currents (Figure 2). During phase 4, also called the resting phase, the resting potential of atrial 
and ventricular myocytes is stable and negative (approximately -85 mV). The negative resting 
potential results primarily from an inward rectifying potassium (K+) current (IK1), where K+ ions 
flow out of the cell (Figure 2). When an AP reaches the cell, voltage-gated sodium (Na+) chan-
nels open and permit an inward Na+ current (INa), which increases the membrane potential and 
partly depolarizes the cell (phase 0, Figure 2). Simultaneously, the inward rectifying K+ chan-
nels close, which also closes the voltage-gated Na+ channels and briefly opens transient K+ 
channels. The movement of positively charged K+ ions from the intracellular to the extracellular 
space results in transient outward K+ currents (Ito), in which the transmembrane voltage decreas-
es and causes early repolarization (phase 1, Figure 2). The plateau phase of the AP (phase 2) 
results from a balance between the depolarizing L-type inward Ca2+ current (ICaL) through volt-
age-dependent L-type Ca2+ channels (LTCCs), and the repolarizing rapid (IKr) and slow (IKs) 
delayed rectifier outward K+ currents (Figure 2). Phase 2 is absent in nodal cells. At phase 3, 
LTCCs close while IKs remain open, and more K+ channels (IKr and IK1) open, resulting in K+ 
efflux (Figure 2) through the IK1 channels, which causes rapid repolarization. When the mem-
brane potential is restored to -85 mV, the delayed rectifier K+ channels close. Simultaneously, 
IK1 continues passing K+ ions out of the cell throughout phase 4, which helps to set the resting 
membrane potential; this potential is also sustained by the sarcolemmal Na+/Ca2+-exchanger 
(NCX). In contrast to atrial and ventricular CMs, in nodal CMs, the inward pacemaker current 
(If) and the absence of IK1 enable slow depolarization of the resting potential during phase 4. 
Additionally, in nodal cells, AP depolarization is mainly achieved by ICaL and the T-type Ca2+ 
current (ICaT) (Figure 2). (Amin et al., 2010; Bers, 2002) 
AP duration (APD) or phases can be altered by Ca2+ ion movements that affect the mem-
brane potential. APD can be prolonged when NCX operates in forward mode by receiving three 
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Na+ ions and removing Ca2+ ions by creating a positive depolarizing inward current. In return, 
cell repolarization and APD shortening occur if NCX operates in reverse mode by removing 
three Na+ ions for every entered Ca2+ ion. For this reason, an increase in the intracellular Ca2+ 
concentration ([Ca2+]i) will usually increase APD. (Casini et al., 2009) High [Ca2+]i can also 
increase IKs and shorten APD, cause a decrease in the maximal upslope velocity of the AP in 
phase 0 by reducing INa, and decrease the conduction velocity of APs between cells by closing 
gap junctions. In addition, it can inactivate LTCC, thus shortening APD. (Laurita and Rosen-
baum, 2008; Peracchia, 2004) 
 
 
 
Figure 2. Cardiac APs and electrical activity. A) APs of CMs from different cardiac regions and 
their correspondence to the clinical electrocardiograph (ECG). Inward and outward currents 
during different phases of AP in B) ventricular CMs and C) in sinoatrial nodes. D) Active ion 
movements during different phases of AP in ventricular CMs. ECF, extracellular fluid; ICF, 
intracellular fluid. Parts A-C are modified from (Amin et al., 2010), and part D is modified from 
the image at http://www.pathophys.org/physiology-of-cardiac-conduction-and-contractility/. 
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2.2.2 Calcium cycling 
Myofilament activation and cardiac contraction during systole are controlled by cytosolic Ca2+ 
ions. Thus, strict regulation of intracellular Ca2+ fluxes is critical for normal cardiac function and 
mishandling of Ca2+ is a central cause of both contractile failure and pathophysiological ar-
rhythmias. (Bers, 2002; Neef and Maier, 2013) 
During the plateau phase of an AP, membrane depolarization causes the opening of LTCC 
and influx of a small amount of Ca2+ ions from the extracellular space into the cytosol. This 
influx subsequently triggers the opening of the SR Ca2+ release channel cardiac ryanodine re-
ceptor (RyR2) and causes a much greater amount of Ca2+ ions being released rapidly from the 
SR into the cytosol (Figure 3). This entire process is called Ca2+-induced Ca2+ release (CICR). 
(Bers, 2002; Neef and Maier, 2013) SR Ca2+ release during AP is also regulated by intracellular 
Na+ ions (Ramirez et al., 2011). The combination of Ca2+ influx and outflux raises the free 
[Ca2+]i from diastolic values of 0.1 μmol/l up to systolic values of approximately 1 μmol/l and 
allows Ca2+ to bind to the myofilament protein cardiac troponin C (cTnC) in the sarcomere 
structures. This binding moves tropomyosin aside, allows the binding between actin and myosin 
filaments, and switches on the shortening and contraction of the entire sarcomere (Figure 3). 
(Bers, 2002; Neef and Maier, 2013). Transverse tubules (T-tubules), invaginations of the sarco-
lemma, have an important role in enabling the rapid communication between the sarcolemma 
and intracellular structures (Ferrantini et al., 2013). Overall, the cardiac contraction strength can 
be varied by altering the amplitude or duration of the Ca2+ transient and the sensitivity of the 
myofilaments to Ca2+ ions, which is dynamically regulated by a number of processes, including 
Ca2+ binding to TnC and de-inhibition of actin-myosin interactions by the thin filament and 
actin-myosin cross-bridge properties (Venkataraman et al., 2013). Myofilament sensitivity can 
be enhanced by caffeine or certain inotropic drugs; dynamically affected by stretching the my-
ofilaments; or reduced by acidosis, elevated phosphate and magnesium (Mg2+) concentrations, 
or adrenergic stimulation. (Bers, 2002; Neef and Maier, 2013) Myofilament Ca2+ sensitization 
has been reported to increase the susceptibility to ventricular tachycardias (VT), and this sensiti-
zation is partially due to decreased phosphorylation of cardiac troponin I (cTnI) (Huke and 
Knollmann, 2010). 
For relaxation to occur, Ca2+ ions have to be dissociated from cTnC and removed from the 
cytosol to lower [Ca2+]i. The main mechanisms for this removal are Ca2+ reuptake into the SR 
via SR Ca2+-ATPase (SERCA2a) and Ca2+ removal through NCX, which removes one Ca2+ ion 
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in exchange for three Na+ ions (Figure 3). SERCA2a accounts for approximately 70% and NCX 
approximately 28% of total Ca2+ removal from cytosol. Other rather slow pathways include 
mitochondrial Ca2+ uniport and sarcolemmal Ca2+-ATPase, accounting for approximately 2% of 
total Ca2+ removal. CMs contain an abundance of mitochondria, many of which are near SR 
Ca2+ release sites. (Bers, 2002; Neef and Maier, 2013) Mitochondrial Ca2+ is an important regu-
lator of cell metabolism and survival. Mitochondria can influence Ca2+ cycling indirectly by 
changing the concentrations of adenosine triphosphate (ATP), nicotinamide adenine dinucleo-
tide phosphate (NADPH), pyruvate and reactive oxygen species. This change in concentration 
causes Ca2+ buffering, release from internal stores, influx from the extracellular solution, uptake 
into cellular organelles and extrusion by plasma membrane Ca2+ pumps. Mitochondria can di-
rectly influence the [Ca2+]i of the cell by importing Ca2+ via the mitochondrial Ca2+ uniporter or 
transporting Ca2+ from the interior of the organelle into the cytosol. As a Ca2+ buffering system, 
mitochondria usually display fast Ca2+ uptake followed by slow Ca2+ extrusion. Mitochondria 
are thought to be capable of regulating all components of the Ca2+ signaling machinery, includ-
ing Ca2+ release via inositol 1,4,5-trisphosphate (IP3R) and RyR, Ca2+ influx via store-operated 
channels, Ca2+ uptake and Ca2+ extrusion. (Walsh et al., 2009) 
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Figure 3. Black arrows allocate the Ca2+ cycling in a CM. Gray arrows show the main signaling 
proteins that affect Ca2+ cycling. Abbreviations: L-type Ca2+ channel (LTCC), Ca2+/calmodulin-
dependent protein kinase II (CaMKII), sodium-calcium exchanger (NCX), calstabin2/FKBP12.6 
(FKPB), protein kinase A (PKA), cardiac ryanodine receptor (RyR2), cardiac calsequestrin 
(CASQ2), sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), phospholamban (PLB), cyclic 
adenosine monophosphate (cAMP), sarcoplasmic reticulum (SR), β-adrenergic receptor (β-AR), 
transverse tubule (T-tubule). Modified from 
http://physiologyonline.physiology.org/content/23/1/6/F1 and (Priori and Chen, 2011). 
 
2.2.3 Cardiac ryanodine receptors and intracellular Ca2+ release  
RyR2 is a large homotetrameric ligand-gated SR Ca2+ release channel and a scaffolding protein. 
This protein is composed of four pore-forming monomers and is often complexed with several 
accessory proteins. RyRs are arranged in large organized arrays, which are up to 200 nm in di-
ameter, with more than 100 RyRs. The RyR2 monomer contains almost 5000 amino acids and is 
organized as a series of discrete domains. It has a relatively small carboxyl (C)–terminal, a 
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transmembrane domain, which crosses the SR membrane. The larger part of the protein (~90%), 
the N-terminal domain, is in the cytosol between the SR and T-tubule membranes beneath 
LTCC channels. (Bers, 2002; Camors and Valdivia, 2014) 
The cytoplasmic N-region of RyR2 contains multiple regulatory domains, including Ca2+ 
activation and inactivation sites and binding sites for energy sensors (such as ATP), inorganic 
phosphate, metabolites (such as pyruvate), and ions (such as Mg2+). This region also harbors 
multiple phosphorylation epitopes and can therefore integrate different cytosolic signals such as 
Ca2+ fluctuations or adrenergic stimulation and transduce these signals to the channel pore to 
release appropriate amounts of Ca2+ ions. Ca2+ release is also influenced by intra-SR factors such 
as Ca2+ content and protein interactions and can be regulated by protein–protein interactions 
when RyR2 binds to smaller and independently regulated accessory proteins. (Bers, 2002; Ca-
mors and Valdivia, 2014) 
The N-domain of RyR2 is stabilized by the FKBP12.6 (calstabin2) protein, which is essen-
tial for receptor closure. The hyper-phosphorylation of RyR2 due to adrenergic stimulation by 
protein kinase A (PKA) causes calstabin2 dissociation from RyR2, which increases the open 
probability of RyR2 (Figure 3). This protein also has anchoring sites for regulatory proteins, 
including calmodulin (inhibits Ca2+ release), protein phosphatases 1 and 2A, phosphodiesterase 
4D3 (PDE4D3), Ca2+/calmodulin-dependent protein kinase II (CaMKII), S100A1 (regulates 
RyR2 function) and sorcin (inhibits Ca2+ release in a Ca2+-dependent manner). In the C-terminal, 
at the luminal SR surface, RyRs are coupled to other proteins such as triadin, junctin and calse-
questrin2 (CASQ2), which participate in intra-SR Ca2+ buffering and modulation of the Ca2+ 
release process (Figure 3). (Bers, 2002; Camors and Valdivia, 2014) Polycystin-2 (PC2), a Ca2+-
activated Ca2+ channel on the SR membrane, plays an important role in regulating RyR2 func-
tion by inhibiting RyR2 channel activity in its open state. PC2 also modulates the channel activ-
ity of IP3R, which is a dominant second messenger that leads to the release of Ca2+ from SR. 
(Anyatonwu et al., 2007)  
RyR2 is also responsible for Ca2+ sparks or spontaneous local Ca2+ transients, which reflect 
the nearly synchronous activation of a cluster of approximately 6–20 RyRs at a single junction. 
Ca2+ sparks SR Ca2+ release both at rest and during ECC. During ECC, several thousand Ca2+ 
sparks in each cell are synchronized in time by the AP, making the Ca2+ transient appear spatial-
ly uniform. Resting Ca2+ sparks are normally rare and isolated by the space between couplons 
but occur when the cellular and SR Ca2+ load rise. Then, Ca2+ released at one junction can acti-
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vate a neighboring junction and lead to propagated Ca2+ waves and oscillations. (Bers, 2002; 
Sauer et al., 2001) 
2.2.4 Important signaling proteins related to calcium cycling 
ECC is regulated by signaling proteins. PKA is an essential controller of cardiac Ca2+ cycling. 
This protein is activated by adrenergic stimulation, which activates a guanosine diphosphate 
(GTP)-binding protein through conversion of adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP) (Figure 3). It regulates the effects of catecholamines by phosphory-
lating key Ca2+ cycling proteins, such as RyR2 and LTCC, which leads to increased Ca2+-release 
into the cytosol. For example, RyR2 phosphorylation can cause the modulation of the channel 
open probability, leading to increased Ca2+ release from the SR to the cytosol. PKA also phos-
phorylates phospholamban (PLB), which results in accelerated SR Ca2+ uptake and increased SR 
Ca2+ loading. Phosphorylation of these proteins increases the heart rate and contractility; there-
fore, PKA is thought to play a central role in the classic fight or flight response. (Bers, 2002; 
Neef and Maier, 2013) PKA also phosphorylates myosin binding protein C and cTnI, accelerat-
ing the unbinding of Ca2+ from cTnC and speeding up the [Ca2+]i decay and relaxation phase (Li 
et al., 2000). 
CaMKII is another important regulator of Ca2+ cycling. CaMKII is activated by a rise in 
[Ca2+]i, which can be due to reactive adrenergic stimulation (Figure 3). CaMKII phosphorylates 
RyR2 and increases Ca2+ transient magnitude and spontaneous Ca2+ release from the SR. 
CaMKII phosphorylation of PLB prevents its inhibition of SERCA2a, therefore causing SR 
Ca2+ reuptake (Figure 3). CaMKII also phosphorylates LTCC, Na+ channels, K+ channels, titin 
and inositol IP3R. CaMKII is thought to have an important role in the pathophysiology of ECC. 
Upregulation of CaMKII activity and expression can cause arrhythmias or HF due to the altered 
cardiac repolarization and Ca2+ cycling. (Bers, 2002; Camors and Valdivia, 2014; Neef and 
Maier, 2013) Inhibition of CaMKII improves cardiac function in HF and may represent a poten-
tial novel therapeutic approach of HF and arrhythmias (Sossalla et al., 2010). 
2.2.5 Failure of electrical activity and calcium cycling 
In the case of ventricular arrhythmias abnormal automaticity and triggered activity of the elec-
trical impulse formation causes early afterdepolarizations (EADs) and delayed afterdepolariza-
tions (DADs). Prolongation of APD can lead to EADs, which are depolarizing oscillations in 
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membrane potential that occur during repolarization, at phase 2 or 3 of the AP (Figure 4). Elec-
trolyte abnormalities, hypoxia and increased amount of catecholamines may cause EADs, which 
are also observed in HF. Triggered activity causing EADs may initiate torsades de pointes, a 
potentially lethal form of VT. At the cellular level, EADs are associated with reduced repolariz-
ing K+ currents, increased Ca2+ current, increased NCX activity, and increased late Na+ current. 
EADs are primarily caused by the reactivation of LTCCs, and this reactivation is dependent on 
the repolarization time. (Volders et al., 2000; Weiss et al., 2010)  
DADs are depolarizing oscillations in the membrane potential that follow an AP after com-
pletion of repolarization in phase 4 (Figure 4). These oscillations can cause triggered activity if 
depolarization reaches a threshold and induces an AP (Figure 4). DADs and DAD-induced trig-
gered activity may lead to multiple forms of VT. DADs are associated with high [Ca2+]i, for 
example, due to catecholamines in CPVT disease. DADs can be a cause of disturbed Ca2+ re-
lease from the SR, which leads to positive depolarizing inward currents through activation of 
NCX. (Laurita and Rosenbaum, 2008; Volders et al., 2000) 
 
 
 
Figure 4. Schematic illustrations of delayed afterdepolarizations (DADs) and early afterdepo-
larizations (EADs). A) DADs can occur after repolarization (left) and trigger a beat (black ar-
row, right) if it reaches certain threshold. B) EADs interrupt the repolarization by occurring 
before the end of the AP (phases 2 and 3) and can lead to the production of a triggered beat 
(black arrow, right). Figure is modified from (Khan, 2004). 
 
Abnormal Ca2+ cycling has been recognized as a key factor behind arrhythmias in the failing 
heart. In HF, the expression and activity of SERCA2a are often reduced; this reduction is partly 
counterbalanced by increased NCX activity, causing reduced Ca2+ reuptake into the SR. Re-
duced SR Ca2+ content and impaired contractility can cause RyR2 open probability in HF, creat-
ing a diastolic SR Ca2+ leak that leads to arrhythmias. In addition, PKA and CaMKII have roles 
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in SR Ca2+ leak. (Neef and Maier, 2013) On the sarcomere level, Ca2+ leak from the SR has 
been shown to induce cTnI degradation in skeletal muscle fibers (Li et al., 2009b). Moreover, 
when studying left ventricular dysfunction of rat hearts, degradation of cTnI has been evident, 
together with hyperphosphorylation of RyR2, leading to diastolic Ca2+ leak (Hall et al., 2005).  
High [Ca2+]i can cause arrhythmias and can alter the expression and activity of different 
Ca2+ cycling proteins. For example, high [Ca2+]i or spatial heterogeneities in [Ca2+]i can affect 
the APD via the NCX. During VT, the rise in the intracellular Na+ concentration can cause re-
verse-mode operation of NCX. This action is more rapid than inactivation of LTCC and can 
therefore cause CICR, which can prolong or aggravate the arrhythmia. In addition, high [Ca2+]i 
can cause CaMKII to become particularly activated, which can promote arrhythmias. For exam-
ple, phosphorylation of LTCCs and Na+ channels promotes the formation of EADs and expo-
sure to DADs, whereas phosphorylation of RyR2s increases SR Ca2+ release and promotes 
DADs. (Hund and Mohler, 2014; Luo and Anderson, 2013) Dyssyncronous Ca2+ release and 
impaired contractility can cause defective LTCC coupling with RyR2 due to loss of organized 
T-tubule structure (Song et al., 2006; Wagner et al., 2012).  
Arrhythmogenic Ca2+ alternans is defined as beat-to-beat alternation of intracellular Ca2+ 
transient amplitude and corresponds to APD alternans (Wang et al., 2014a). Alternans have 
been thought to be the cause of several, and even contradictory, effects, such as impaired SR 
Ca2+ release (Diaz et al., 2004), slow recovery from RyR2 inactivation (Picht et al., 2006; Re-
strepo et al., 2008), decreased RyR2 open probability and increased channel refractoriness (Diaz 
et al., 2002; Xie et al., 2008), increased RyR2 open probability (Lehnart et al., 2006), and weak-
ened SR Ca2+ reuptake by SERCA2a (Pieske et al., 1995). 
Activation of the SR stress response has been demonstrated to cause mitochondrial dysfunc-
tion, triggering oxidative stress and further exacerbating SR stress. Mitochondrial morphology 
has been shown to be abnormal and ROS generation increased in CPVT compared with wild 
type (WT) β cells; depletion of SR Ca2+ stores due to leaky RyR2 channels reduces glucose-
induced mitochondrial Ca2+ uptake. These results suggest that chronic SR Ca2+ leak triggers SR 
stress and mitochondrial dysfunction, causing a bioenergetic deficit with decreased ATP synthe-
sis. (Santulli et al., 2015) Mitochondrial Ca2+ overload in HF leads to increased production of 
reactive oxygen species, decreased production of energy, and apoptosis of CMs. (Luo and An-
derson, 2013) 
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2.2.6 Clinical characterization of the electrical activity using ECG and MAP re-
cordings 
Electrocardiography (ECG) is a noninvasive clinical recording of the electrical activity of the 
heart (Figure 5) and is measured by electrodes that are placed on the surface of the body. Nor-
mally, 12-lead ECG consists of six precordial leads (V1-6), three limb leads (I-III), and three 
augmented limb leads (aVR, aVL and aVF). When a wave of depolarization is approaching the 
positive electrode, a positive deflection occurs on the ECG. The depolarization of the atria re-
sults in a P-wave in which the first part corresponds to the right atrial depolarization and the 
latter part reflects the left atrial depolarization. This atrial depolarization is followed by ventric-
ular depolarization, which is observed on the ECG as the QRS complex. The beginning of the 
QRS complex reflects the depolarization of the interventricular septum. The latter portion pri-
marily represents the depolarization of the left ventricle because the signal from the right ventri-
cle is covered by the simultaneously depolarizing left ventricle. Atrial repolarization occurs 
during the QRS complex; however, due to the weakness of the signal, this repolarization is ob-
scured by the electrical activity of the ventricles. The contraction ends by repolarization of the 
ventricles, which is observed as a T wave on the ECG. Occasionally, the T wave is followed by 
a small U-wave, which is thought to represent repolarization of the Purkinje fibers and to have 
the same polarity as the T wave but less than one-third the amplitude of the T wave. (Thaler, 
1999) 
Monophasic action potentials (MAPs) are extracellularly recorded waveforms from the en-
docardium and epicardium of the in situ beating heart and are therefore suitable for studying the 
characteristics of local myocardial electrophysiology in a clinical setting. MAPs reflect the re-
polarization time course of transmembrane APs. MAPs resemble intracellularly recorded AP 
(Figure 5), and therefore form an important bridge between basic and clinical electrophysiology. 
APs are recorded with MAP electrode catheters via the femoral vein or artery into the right or 
left ventricle (Figure 5). Under fluoroscopic guidance, the catheter tip is brought into contact 
with the endocardium, and APs can be recorded. In clinical settings, MAP recordings can be 
used to study, for example, the effects of drugs, heart rate and rhythm, and afterdepolarizations, 
mainly in investigational settings. (Franz, 1999) 
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Figure 5. Clinical characterization of the electrical activity of the heart by ECG and MAP re-
cordings. A) Electrical conduction systems of the heart (SAN and AVN), and their correspond-
ing signals on the surface ECG. B) MAP catheter in the right ventricle muscle and the recorded 
ventricular AP. Figure is modified from (Amin et al., 2010). 
2.3  Stem cells 
2.3.1 Stem cell renewal and potency 
Stem cells are undifferentiated cells and they are capable of self-renewal but can also differenti-
ate into specialized cells. Self-renewal can occur through either symmetrical division, where 
two identical copies of the original cell are produced, or asymmetrical division, where one 
daughter cell remains a stem cell and another begins to differentiate toward a certain cell type. 
(Mountford, 2008; Wolpert et al., 2006) 
Stem cell potency defines the cell’s ability to differentiate into specialized cell types. The 
more cell types a cell can differentiate into, the greater its potency is. During the process of stem 
cell development, the cell gradually loses its differentiation capacity (Figure 6). Totipotent stem 
cells can differentiate into all the cell types of a developing organism, including extraembryonic 
tissues such as placenta (Figure 6). The only totipotent cells are the fertilized egg and the cells 
in the embryo until the 8-cell morula stage. After gastrulation, stem cells in the inner cell mass 
of the blastocyst are pluripotent and have the ability to differentiate into cells of the three germ 
layers, the ecto-, meso-, and endoderm (Figure 6), and these cells are called pluripotent stem 
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cells (PSCs). (Wolpert et al., 2006; Yamanaka et al., 2008) PSCs can be derived either from a 4-
7-day-old blastocyst-stage embryo (Figure 7) (human embryonic stem cells, hESCs) (Thomson 
et al., 1998) or produced in vitro from somatic cells with induction of the expression of genes 
that are important in embryonic cells (induced pluripotent stem cells, iPSCs) (Takahashi and 
Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007). Multipotent or tissue-specific stem 
cells can only differentiate into a limited number of cell types (Figure 6), usually into the cell 
types that can be found in the same tissue where the stem cells reside. For example, the bone 
marrow contains multipotent hematopoietic stem cells that give rise to all the cells of the blood 
but not to other types of cells. Unipotent stem cells can differentiate into only one cell type. For 
example hepatoblasts, which differentiate into hepatocytes, are unipotent. (Wolpert et al., 2006; 
Yamanaka et al., 2008) 
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Figure 6. Stem cell potency. During the process of stem cell development, the cell gradually 
loses its differentiation capacity. Totipotent stem cells can differentiate into all the cell types. 
PSCs, such as hESCs and iPSCs, have the ability to differentiate in the ecto-, meso-, and endo-
derm. Multipotent or tissue-specific stem cells differentiate into a limited number of cell types. 
Figure is modified from the image at http://www.stemcellclinic.com/main-
en/klinika/kletochnaya-terapiya/. 
2.3.2  Induced pluripotent stem cells 
Derivation of the first stable pluripotent hESC lines (Thomson et al., 1998) initiated the wide-
spread research into early human development and regenerative medicine. However, the ethical 
concerns, limited supply of human embryos and obscurity of the genetic background of the cell 
lines have been problematic for the application of hESCs. (Yamanaka, 2008) For these reasons 
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together with the breakthrough insight that somatic cells can be reprogrammed back to PSCs 
(Figure 7), the discovery of iPSC technology revolutionized the field of biomedical technology 
(Takahashi et al., 2007; Yu et al., 2007). iPSCs share the characteristics of hESCs, such as plu-
ripotency marker expression and differentiation capacity, as well as a need for supporting matrix. 
In addition, the cell culture and differentiation methods are similar for both stem cell types 
(Takahashi et al., 2007). 
 
 
 
Figure 7. Production of hESCs from the inner cell mass of the early stage embryo blastocyst 
and of iPSCs from the patient’s somatic cells using reprogramming factors. Pluripotent hESCs 
and iPSCs can be differentiated into various cell types using specific differentiation protocols. 
 
The pioneering work of iPSCs was published in 2006, when the first mouse iPSC lines were 
generated from mouse embryonic fibroblasts with retroviral transfections (Takahashi and Ya-
manaka, 2006). The first human iPSCs (hiPSCs) were discovered in two separate studies 
(Takahashi et al., 2007; Yu et al., 2007). In these studies, human skin fibroblasts were repro-
grammed back to a pluripotent state using combinations of retrovirally transfected transgenes of 
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OCT4 (octamer-binding transcription factor 4), SOX2 (sex determining region Y-box 2), c-MYC 
(myelocytomatosis viral oncogene homolog) and KLF4 (Kruppel-like factor 4) (Figure 7) 
(Takahashi et al., 2007) or of lentivirally transfected factors of OCT4, SOX2, NANOG (Nanog 
homeobox) and LIN28 (lin-28 homolog A) (Yu et al., 2007). These genes are involved in 
maintaining the self-renewal capacity, undifferentiated state, pluripotency and proliferation of 
PSCs (Takahashi et al., 2007; Yu et al., 2007). Some variations of these gene combinations have 
been tested for reprogramming. For example, combinations of all six factors, OCT4, SOX2, c-
MYC, KLF4, NANOG and LIN28, have increased the reprogramming efficiency (Liao et al., 
2008). Reducing the number of reprogramming factors takes advantage of endogenously ex-
pressed genes, decreasing the need for ectopic expression of pluripotency factors (Lai et al., 
2011). For example, OCT4 alone has been shown to reprogram human neural stem cells into 
iPSCs (Kim et al., 2009), and c-MYC has been excluded when reprogramming human fibro-
blasts because these cells express c-MYC endogenously (Nakagawa et al., 2008). To date, hiP-
SCs have been generated from a wide spectrum of somatic cells, including keratinocytes (Aasen 
et al., 2008), neural stem cells or progenitor cells (Kim et al., 2009), astrocytes (Ruiz et al., 
2010), amniotic cells (Li et al., 2009a), adipose tissue (Sun et al., 2009), cord blood cells 
(Takenaka et al., 2010), T lymphocytes (Seki et al., 2011), skeletal muscle stem cells (Tan et al., 
2011), peripheral blood cells (Loh et al., 2010; Staerk et al., 2010), and human urine-derived 
cells (Zhou et al., 2011).  
Originally developed virus-based iPSC technology (Takahashi et al., 2007; Yu et al., 2007) 
utilizes vectors that can integrate into the genome and that could have harmful consequences, 
e.g., cell death, residual expression, reprogramming factor re-activation, immunogenicity, un-
controlled transgene silencing, and insertional mutagenesis (Hu, 2014). To overcome these 
problems, different strategies for iPSC reprogramming have been developed (Figure 8). 
Transgene reprogramming can be classified into three groups: DNA-based reprogramming, 
RNA-based reprogramming and protein transduction. Chemical reprogramming with small 
molecules has also been studied with or without transgene reprogramming (Bayart and Cohen-
Haguenauer, 2013; Hu, 2014); for example, the small molecule tranylcypromine and a specific 
glycogen synthase kinase 3 (GSK-3) inhibitor (CHIR99021), together with OCT4 and KLF4 
transgenes (Li et al., 2009c), have been used in chemical reprogramming.  
DNA-based technologies are the most widely used methods of reprogramming, and they uti-
lize three major forms: virus particles, transposons, and plasmids. Viruses can be retroviruses 
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(Takahashi et al., 2007), lentiviruses (Yu et al., 2007) or adenoviruses (Stadtfeld et al., 2008), 
although adenoviruses have not been shown to reprogram human cells. (Hu, 2014) Transposons 
are mobile genetic elements that can move from one position to another within the genome 
through an excision/insertion mechanism. For example, a piggyback transposon-based non-viral 
vector that can induce stable genomic integration and persistent gene expression in mammalian 
cells quite efficiently has been exploited in iPSC production. (Kaji et al., 2009) Reprogramming 
plasmids can be linearized to enhance integration into the genome for efficient reprogramming. 
Non-integrating plasmids include conventional and episomal plasmids, as well as minicircle 
DNA grouped into plasmids. (Hu, 2014) 
Sendai virus is an RNA virus that enables efficient reprogramming of somatic cells and that 
is already exploited widely in iPSC derivation. It is non-integrating and can therefore be repli-
cated in the host cell cytoplasm without entering the nucleus. (Fusaki et al., 2009) Another non-
integrating RNA strategy for iPSC generation is to deliver synthetic messenger RNA (mRNA) 
encoding reprogramming factors directly into the cells. RNA replicons have also been delivered 
into cells in the form of packaged virions or as synthetic RNA genomes to avoid the integration 
of transgenes into the genome. One problem with RNA replicons and Sendai viruses is that they 
can be converted into complementary DNA (cDNA) by possible reverse transcriptases in the 
human genome; therefore, they can potentially integrate into the genome. (Hu, 2014) Mi-
croRNAs (miRNAs), short RNA molecules that bind to complementary sequences on messen-
ger RNA and block expression of a gene, have also been used as a reprogramming method. This 
technique is quite efficient but requires repeated transfection of the miRNAs into the cells 
(Anokye-Danso et al., 2011; Miyoshi et al., 2011). One method for the generation of transgene-
free iPSCs is protein transduction, where reprogramming can be done with mammalian or bac-
terial recombinant proteins. (Hu, 2014) 
iPSCs may hold great promise for regenerative medicine due to the possibility of generating 
autologic transplantable cells with this technology. iPSC lines generated with methods causing 
transgene integrations are not applicable for clinical use because of potentially harmful genetic 
modification. (Ebert et al., 2012) Some studies have also reported substantial differences in 
genetic or epigenetic profiles of iPSCs versus hESCs, which must be further investigated before 
therapeutic application of iPSCs in humans (Kim et al., 2010b). Due to these problems, many 
methods of reduction or complete elimination of transgene integration into genomes have been 
studied widely. These methods include the use of a polycistron to reduce the number of integra-
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tions or the use of the Cre-LoxP system to excise the transgenes (such as lentiviral vectors) from 
the reprogrammed genome. In addition, transposon transposition of transgenes into the repro-
grammed genomes and subsequent excision of transgenes from the reprogrammed genomes 
have been studied. Repeated transfections of cells with nonreplicating plasmids, the use of non-
integrating and replicating episomal plasmids and direct RNA delivery of reprogramming fac-
tors (synthetic mRNA, RNA virus, RNA replicon, or miRNA) have also been investigated, and 
protein transduction and chemical reprogramming methods to eliminate transgene integration 
into the genome have been studied (Figure 8). (Hu, 2014) 
 
 
 
Figure 8. Transgene genome integrating (red) and non-integrating (blue) strategies for iPSC 
reprogramming and transgene integration reduction methods. The efficiency of each method is 
categorized as very high (++), high (+), low (-) or very low (--). The figure is modified from 
(Hu, 2014). 
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2.3.3 Characterization of induced pluripotent stem cells 
iPSCs can be characterized by their morphology because they proliferate in cell culture broadly 
and form dense colonies with clearly defined edges (Thomson et al., 1998). Despite their clear 
visual features, the pluripotency of iPSCs must be confirmed using several methods. Teratoma 
formation is a way to confirm pluripotency by injecting iPSCs into immunodeficient mice to 
form tumors that include tissues from all three germ layers. In vitro differentiation into three-
dimensional embryoid bodies (EBs) is another way to characterize the ability of iPSCs to differ-
entiate into cell types of all three germ layers. (Brivanlou et al., 2003; Hoffman and Carpenter, 
2005; Thomson et al., 1998) In addition to these methods, pluripotency can be confirmed by 
studying the expression of genes at the mRNA or protein level. Pluripotency markers that are 
known to be expressed in iPSCs include Oct4, Nanog, Sox2, RNA exonuclease 1 (Rex1), stage-
specific embryonic antigens 3 and 4 (SSEA3 and SSEA4), tumor-related antigens 1-60 and 1-81 
(TRA1-60 and TRA1-81) and alkaline phosphatase (ALP). (Adewumi et al., 2007) The expres-
sion of the exogenous transgenes in iPSCs must be confirmed and this expression must be fully 
silenced to demonstrate complete cell reprogramming. (Maherali et al., 2007; Okita et al., 2007) 
The karyotype of iPSC lines must also be confirmed after the derivation of the lines and repeat-
edly if the cell lines are kept in culture for longer periods. Telomerase and alkaline phosphate 
activities are also often studied when pluripotency is evaluated. (Hoffman & Carpenter, 2005). 
2.4  Stem cell-differentiated cardiomyocytes and their characteriza-
tion 
2.4.1 Cardiac differentiation 
Primary CMs are challenging to obtain from human donors and they easily start to dedifferenti-
ate (Mitcheson et al., 1996). Therefore, primary animal CMs and hPSC-differentiated CMs are 
widely used for cardiac studies. CM differentiation methods are constantly being improved to 
increase the differentiation efficiency and the maturation of the hPSC-differentiated CMs. The 
problems of using these cells compared to primary adult CMs include their immature morphol-
ogy, structural organization and functionality. (Lieu et al., 2009; Luna et al., 2011) The different 
cell lines and their differentiation capacities can vary (Osafune et al., 2008; Pekkanen-Mattila et 
al., 2009), for example, due to epigenetic variation (Kim et al., 2010b). 
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In vitro differentiation of hPSCs to CMs mimics the stages of embryonic cardiac develop-
ment. A simplified model of the CM lineage differentiation process and of the transcription 
factors, cell-surface markers and signaling pathways affecting this process is presented in Table 
1. 
 
Table 1. Simplified model shows the differentiation of hPSCs toward the CM lineage and the 
transcription factors and cell-surface markers identified in this process. Some of the best-
characterized signaling pathways that are responsible for the sequential transitions in cell fate 
are shown. BMP4, bone morphogenetic protein 4; Dkk1, dickkopf Wingless and Integrase-1 
(WNT) signaling pathway inhibitor; NKX2.5, NK2 transcription factor-related gene, locus 5; 
Gata4, GATA binding protein 4; MIXL1, homeodomain protein; Mesp1, mesoderm posterior 1; 
SSEA, stage-specific embryonic antigen; EpCAM, epithelial cell adhesion molecule; Isl1, Insu-
lin gene enhancer 1; Tbx, T-box transcription factor; NCAM, neuronal cell adhesion molecule; 
KDR, kinase insert domain receptor; PDGFR, platelet-derived growth factor receptor; SIRPA, 
signal regulatory protein-α; VCAM, vascular cell adhesion molecule. Table modified from 
(Mummery et al., 2012). 
 
Signaling pathways Cell stage 
Transcription 
factors 
Cell-surface markers 
 
 
 
Epithelial-mesenchymal transition 
 
 
 
BMP4, Activin A, FGF2, Wnt3a 
Insulin inhibition 
 
 
 
BMP4, Activin A, FGF2, Wnt3a 
 
 
 
Dkk1 
 
 
 
 
 
hPSC Oct4, Nanog, Sox2 
Tra-1-60, SSEA4, 
EpCAM 
Mesoderm 
Progenitor 
Oct4 NCAM, SSEA1 
Precardiac 
Mesoderm 
Brachyury T, 
MIXL1 
 
Cardiac  
Mesoderm 
Mesp1 KDR, PDGFRα 
Heart Speci-
fic Progenitor 
Nkx2.5, Gata4 
(Tvx5/Isl1/Tbx20) 
SIRPA 
Embryonic 
CM 
Nkx2.5, Gata4 SIRPA, VCAM-1 
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hPSCs can be differentiated into CMs using several techniques. CMs can be derived from 
hESCs and iPSCs by spontaneous differentiation in EBs, in which cells are cultured in a suspen-
sion. Differentiation efficiency has usually been under 10%. (Kehat et al., 2001) The EB proto-
col has been further tested with different medias such as APEL and STEMPro-34 that include 
growth factors such as BMP4, basic fibroblast growth factor (bFGF), activin A, vascular endo-
thelial growth factor (VEGF), dickkopf homolog 1 (DKK1), stem cell factor (SCF) and WNT3a 
(Elliott et al., 2011; Yang et al., 2008). The differentiation process is dependent on the time of 
addition and on the removal of growth factors. EB formation efficiency has also been enhanced 
by methods that control EB size. In the spin EB method, hESCs are cultured in a suspension and 
aggregated by centrifugation to control the aggregate size precisely (Ng et al., 2005). Microfab-
rication of microwells with defined sizes also provides a way to control the size of the EBs 
(Khademhosseini et al., 2006), plating cells onto micropatterned ECM (Matrigel) matrix is an-
other option for controlling their size (Bauwens et al., 2008). 
hPSCs can be differentiated into CMs by co-culturing stem cells with mouse endodermal-
like cells (END-2) in the absence of serum and with ascorbic acid (Mummery et al., 2003; 
Passier et al., 2005). The role of END-2 cells in this cardiac differentiation method remains 
unclear; however, the removal of insulin and secretion of prostaglandin I2 (PGI2) by END-2 
cells are thought to influence the differentiation process (Xu et al., 2008). Differentiation has 
also been successful with END-2-conditioned medium instead of co-culturing (Graichen et al., 
2008). 
Another cardiac differentiation method for hPSCs is monolayer cultures. hESCs are cultured 
on Matrigel as a monolayer, and activin A and BMP4 induce a cardiogenic fate with a differen-
tiation efficiency of over 30% when used at the beginning of the differentiation protocol 
(Laflamme et al., 2007). Single-cell dissociated hESCs on Matrigel have been differentiated into 
CMs with APEL medium containing cytokines such as BMP4, activing A and WNT3a that in-
duce cardiac mesoderm (Ng et al., 2008). In the matrix sandwich differentiation method, hPSCs 
are differentiated into CMs by layering stem cells that were cultured as monolayers on Matrigel 
and Matrigel is subsequently overlaid; the matrix sandwich can also be combined with applica-
tion of growth factors such as Activin A, BMP4 and bFGF (Zhang et al., 2012). Monolayer 
differentiation methods based on small-molecule activation and canonical Wnt signaling inhibi-
tion by treatment with CHIR99021 or IWP2 have been shown to produce high-yield CMs (Lian 
et al., 2012). CHIR99021 is an aminopyrimidine, which activates Wnt signaling and initiates 
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mesodermal differentiation by inhibiting glycogen synthase kinase 3β (GSK-3β). After initiation, 
Wnt signaling is inhibited by some specific Wnt inhibitors (IWP-4, KY02111, XAV939, Wnt-
C59), which direct the mesodermal cells toward CMs. (Burridge et al., 2014; Lian et al., 2012; 
Minami et al., 2012) 
In direct reprogramming, transcription factors are used to differentiate cells directly into 
other differentiated cell types. Direct reprogramming of mouse post-natal cardiac or dermal 
fibroblasts into functional induced CMs (iCMs) in vitro has been achieved by expressing three 
transcription factors: GATA binding protein 4 (Gata4), myocyte-specific enhancer factor 2C 
(Mef2c), and T-box transcription factor 5 (Tbx5) (GMT factors) (Ieda et al., 2010). In addition, 
GMT factors combined with a basic helix-loop-helix transcription factor (Hand2) (GMHT fac-
tors) have been able to convert fibroblasts into functional beating iCMs (Song et al., 2012) as 
well as a combination of miRNAs (Jayawardena et al., 2012). Upon cardiac injury, resident 
non-myocytes in the murine heart can be reprogrammed into CM-like cells in vivo by retroviral 
delivery of GMT factors (Qian et al., 2012). With human cells, neither GMT nor GHMT have 
been able to reprogram human fibroblasts into iCMs alone; however, combinations of these 
factors with other factors have seemed more promising (Fu et al., 2013; Nam et al., 2013; Wada 
et al., 2013). For example, GHT factors without Mef2C but with myocardin and two muscle-
specific miRNAs could reprogram human fibroblasts into iCMs (Nam et al., 2013).  
2.4.2 Properties and maturation markers of cardiomyocytes 
Functional hPSC-derived CMs can be detected by their ability to form spontaneously beating 
cells (Kehat et al., 2002; Mummery et al., 2003). Sarcomere markers, myofilament striation 
detection, myocyte morphology, Ca2+ cycling and action potential shape are often characterized 
(Kehat et al., 2001; Lundy et al., 2013; Pekkanen-Mattila et al., 2009; Radisic et al., 2004) when 
determining the maturation stage of the cells. 
The gene expression pattern of differentiating CMs reflects that of the early embryogenesis, 
where the first up-regulated genes are primary mesodermal and continue with the activation of 
the cardiac progenitor genes and the fetal CM genes (Beqqali et al., 2006; Synnergren et al., 
2008). Because CMs originate from the mesoderm an early mesodermal marker, Brachyury T, 
is traditionally used in cardiac cell lineage characterization (Beqqali et al., 2006; Kispert and 
Herrmann, 1994). Brachyury T belongs to a family of transcription factors that are encoded by 
the T-box genes and is an endogenous activator of mesodermal genes that are induced by trans-
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forming growth factor β (TGF-β) and FGF signaling (Showell et al., 2004). During CM differ-
entiation, several cardiac transcription factor genes are expressed, including Islet-1 (ISL-1), 
mesoderm posterior 1 and 2 (MESP1 and MESP2), NKX2.5, Gata4 and T-box transcription 
factor 6 (Tbx6) (Brand, 2003; Graichen et al., 2008; Yang et al., 2008). 
One major challenge in translating hPSC-derived CMs to therapeutic use is that these cells 
are quite immature when compared to primary adult CMs (Ieda et al., 2010; Qian et al., 2012). 
Morphologically, these cells are smaller than adult cells, and their intracellular structures are 
deficiently organized (Luna et al., 2011). Additionally, the lack of clear T-tubules (Li et al., 
2013; Lieu et al., 2009; Novak et al., 2012; van den Heuvel et al., 2014), which usually occurs 
relatively late in mammalian CM development, may affect the fast spread of an electrical signal 
inside the CMs, causing problems in Ca2+ release and contraction of the cell (Ferrantini et al., 
2013). Long-term cultivation (80–120 days) of hPSC-derived CMs has been considered one 
way to achieve the properties of adult CMs because these cells have shown more mature func-
tional and morphological properties following long-term cultivation compared to cells following 
short-term cultivation of 20-40 days (Lundy et al., 2013). In addition, the modification of func-
tional properties occurring over the maturation process of 15-40 and 50-110-day-old hESC-CMs 
has been able to be simulated with a computational modeling tool (Paci et al., 2012).  
Thus far, no clear agreement exists regarding which marker can accurately track the differ-
entiation status of hPSC-derived CMs. Structural protein cTnT (encoded by the TNNT2 gene) 
(Thierfelder et al., 1994) has been widely used in cardiac lineage characterization (Chan et al., 
2013; Hazeltine et al., 2014; Kawamura et al., 2013; Park et al., 2014; Rebuzzini et al., 2013), 
but is also expressed in non-cardiac cells such as smooth muscle cells (Bedada et al., 2014; 
Lundy et al., 2013). cTnI (encoded by TNNI1 gene) has been proposed as a good marker for 
tracking CM maturation (Bedada et al., 2014; Kehat et al., 2001). Nevertheless, in continuously 
beating hPSC-derived CMs, cTnI was shown to retain a fetal-like state regardless of differentia-
tion conditions and culture duration (Bedada et al., 2014). Cardiac α-actinin has also been used 
as a marker for a more mature cardiac phenotype (Kehat et al., 2001; Mummery et al., 2003). 
The structural protein α-myosin heavy chain (α-MHC) is more highly expressed in fast-beating 
CMs and atrial samples, and this expression increases during the aging process. β-MHC is sub-
sequently expressed at higher levels in ventricular samples. However, a transition in the myosin 
isoform content in disease complicates its use for lineage or maturation assignment. (Bedada et 
al., 2014; Nakao et al., 1997; Reiser et al., 2001; Sasse et al., 1993) The cardiac-specific con-
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nexin (Cx) proteins of gap junctions (Cx-43, Cx-40 and Cx-45) (Gaborit et al., 2007) are also 
used as CM markers as well as expression of certain ion channels (Lundy et al., 2013; Sartiani 
et al., 2007).  
2.4.3 Electrical field stimulation of cardiomyocytes 
In EFS, cells are imposed to extracellular electric fields that electrically excite active tissue, 
resulting in transmembrane potential changes. In CMs, this excitation causes a cell to be depo-
larized on one side and hyperpolarized on the other along the field direction. (Tung and Border-
ies, 1992) EFS of CMs has been primarily studied with NRCs (Boudou et al., 2012; Chiu et al., 
2008; Hirt et al., 2014; Radisic et al., 2004; Sathaye et al., 2006), but has more recently been 
studied with hESC- and hiPSC-derived CMs (Serena et al., 2009; Chan et al., 2013; Nunes et al., 
2013; Xiao et al., 2014; Hirt et al., 2014). Electrical fields have also been used to induce cardiac 
differentiation of mouse embryonic stem cells (Sauer et al., 1999) and to modify cardiac progen-
itor cells toward a cardiogenic phenotype (Llucia-Valldeperas et al., 2014).  
EFS has been considered an option to generate more mature cardiac constructs by improv-
ing contractile and electrophysiological functionality as well as cell alignment and mechanical 
stability. Previous studies have shown that EFS improves CM functionality (Boudou et al., 2012; 
Chan et al., 2013; Chiu et al., 2008; Hirt et al., 2014; Miklas et al., 2014; Radisic et al., 2004; 
Sathaye et al., 2006), for example, by inducing the ECC and amplitude of synchronous contrac-
tions (Chiu et al., 2008; Radisic et al., 2004) and by improving the Ca2+ cycling of CMs (Chan 
et al., 2013; Holt et al., 1997). EFS has also been shown to increase the expression of cardiac-
specific genes such as MHC and Cx-43 (Au et al., 2009; Barash et al., 2010; Chan et al., 2013; 
Chiu et al., 2008; Hirt et al., 2014; Miklas et al., 2014; Radisic et al., 2004). Stimulation has also 
induced cell elongation (Au et al., 2007; Au et al., 2009; Barash et al., 2010; Chiu et al., 2008; 
Hirt et al., 2014; Radisic et al., 2004) and orientation (Radisic et al., 2004), which has also been 
enhanced with topographical cues in many studies (Au et al., 2007; Au et al., 2009; Boudou et 
al., 2012; Chiu et al., 2012). Well-aligned sarcomeres have also been reported as a result of EFS 
(Hirt et al., 2014; Miklas et al., 2014; Radisic et al., 2004). 
In addition to basic commercial and custom-made EFS platforms, different types of 3D 
stimulation systems and bioreactors that exploit electrical fields have been generated for CM 
maturation studies and pharmaceutical testing. The effects of stimulation have been studied on 
the maturation of 3D cardiac constructs composed of biomaterials combined with CMs such as 
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engineered heart tissues made of fibrinogen or Matrigel (Hirt et al., 2014), migrogrooved colla-
gen-chitosan hydrogels (Chiu et al., 2012), collagen/fibrin 3D matrices (Boudou et al., 2012) 
and collagen gel around a template suture (Nunes et al., 2013). For high-throughput pharmaco-
logical studies, perfusable 3D micro-tissue platforms exploiting EFS have been generated 
(Agarwal et al., 2013; Xiao et al., 2014), in addition to possibile cyclic stretch (Lu et al., 2013). 
EFS has also been exploited with disease modeling of iPSC-derived CMs to study the effect of 
stimulation on the disease phenotype (Siu et al., 2012; Jung et al., 2012; Ji et al., 2013). 
2.4.4 Methods to study the functionality of cardiomyocytes 
2.4.4.1 Microelectrode array 
Microelectrode arrays (MEAs) or multielectrode arrays are platforms than can be used to meas-
ure the functionality of electrically active cell aggregates and sheets. These arrays provide plat-
forms for electrophysiological studies of CMs and allow the recordings of the changes in the 
field potential (FP). FP resembles an ECG measurement (Reppel et al., 2004). The field poten-
tial duration (FPD) can be measured from MEA recordings; the FPD correlates closely with the 
QT interval in the ECG. MEA signals reflect rapid depolarization, a plateau phase, and repolari-
zation of the AP. (Halbach et al., 2006; Meyer et al., 2004)  
The MEA platform consists of an MEA plate, which has a cell culture well that allows long-
term cell culturing, and electrodes for recording electrical activity. MEA plates are manufac-
tured with different electrode configurations, which can be used for different applications. The 
contact between the cells and the MEA electrode affects the signal, and current MEA electrodes 
are not sensitive enough to record signals from single CMs. The MEA method is usually used 
for cell aggregates or sheets, and it is a rather easy and fast method that is suitable for larger 
scale screenings. 
CMs of various origins have been investigated with MEAs, e.g., NRCs (Berdondini et al., 
2005), hESC-derived CMs (Binah et al., 2007; Kehat et al., 2001; Pekkanen-Mattila et al., 2009) 
and iPSC-derived CMs (Itzhaki et al., 2011a; Itzhaki et al., 2012; Lahti et al., 2012; Mehta et al., 
2011). The MEA method has also been used extensively in in vitro drug testing (Braam et al., 
2010; Caspi et al., 2009; Liang et al., 2010; Reppel et al., 2004). 
  
30 
 
2.4.4.2 Patch clamp method 
Electrophysiology of single cells can be studied using a patch clamp, which is regarded as the 
gold standard method of cellular electrophysiology (Hamill et al., 1981; Sakmann and Neher, 
1984). With this technique, a cardiac AP can be recorded from a single CM. To measure ion 
currents, a glass micropipette containing an electrode with ionic solution is brought into tightly 
sealed contact with the cell membrane. The tight gigaohm seal is formed between the cell mem-
brane and the recording electrode by applying suction to the micropipette. This isolates the 
membrane patch from the external environment electronically and allows the measurement of 
changes in the membrane potential or ion channel currents at the level of single cells or even 
single channels across this patch of membrane. (Molleman, 2002) 
Many variations of the patch clamp technique exist. In the whole-cell patch technique, cur-
rent or voltage changes can be studied. In the voltage clamp method, the ion currents through 
the membranes of excitable cells are measured, and in the current-clamp method, changes in 
voltage across the plasma membrane are measured while the current is held constant. Another 
technique is the perforated patch method, where the cell membrane is ruptured with chemical 
agents such as amphotericin-B, thus generating many small holes in the membrane. (Hamill et 
al., 1981; Molleman, 2002) Traditional patch clamp is a very time consuming method, and in 
recent years, automated planar patch clamp technology has been developed to generate high-
quality data with high-throughput capabilities (Milligan and Moller, 2013). Many automated 
patch clamp platforms have been developed during last years but this method is not yet selective 
enough to study iPSC-derived CMs accurately. 
The patch clamp method have been utilized in studying the maturation of both hESC and 
IPSC derived CMs (Sartiani et al., 2007; Pekkanen-Mattila et al., 2010; Ma et al., 2011; Lundy 
et al., 2013). It has also been widely used in disease modeling studies to characterize the pheno-
type of iPSC-derived CMs (Moretti et al., 2010; Yazawa et al., 2011; Itzhaki et al., 2011a; No-
vak et al., 2012; Lahti et al., 2012; Jung et al., 2012; Itzhaki et al., 2012; Di Pasquale et al., 
2013) as well as drug responses of these cells (Yazawa et al., 2011; Itzhaki et al., 2011a; Itzhaki 
et al., 2012). 
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2.4.4.3 Calcium imaging 
Ca2+ imaging is a technique that quantitatively measures the fast cyclic increases and decreases 
in [Ca2+]i which causes the Ca2+ transients. The intracellular free Ca2+ levels are measured using 
cytoplasmic Ca2+ indicator dyes, which are fluorescent molecules that respond to the binding of 
Ca2+ ions by emitting fluorescent light. (Adams, 2010; Paredes et al., 2008)  
Ca2+ indicators can be non-ratiometric or ratiometric. Non-ratiometric dyes such as Fluo-4 
utilize only one wavelength and are optimal for detecting more than one fluorophore. One ad-
vantage of non-ratiometric indicators is that an increase in fluorescence signal can be related 
directly to an increase in [Ca2+]i. However, fluorescence intensity depends on many factors such 
as probe concentration and acquisition conditions not related to [Ca2+]i. Ratiometric indicators 
such as Fura-2 utilize two wavelengths, and the amount of intracellular Ca2+ can be determined 
by the ratio between the two emission amplitudes, which show Ca2+ free- and Ca2+-bound -forms 
of the indicator. The benefit of ratiometric indicators is that those indicators can be calibrated 
precisely to minimize the problems associated with uneven dye loading, dye leakage, photo-
bleaching and cell volume variability. (Grynkiewicz et al., 1985; Paredes et al., 2008)  
Indicator dyes usually contain an acetoxymethyl (AM) ester group, which makes the mole-
cule lipophilic and which allows easy entrance into the cell. Once the indicator is in the cell, 
esterases cleave off the AM group, the dye is captured inside the cell, and carboxyl groups are 
exposed, which will be able to bind Ca2+. (Paredes et al., 2008) 
Ca2+ imaging method have been utilized widely when studying CMs, for example to inves-
tigate the basic Ca2+ cycling properties and maturity of hESC and iPSC-derived CMs (Itzhaki et 
al., 2011b; Lee et al., 2011; Lundy et al., 2013). Ca2+ cycling of iPSC-derived CMs has also 
been characterized in disease modeling of long QT syndrome (LQT) (Spencer et al., 2014) and 
more widely in CPVT disease with Ca2+ cycling defects (Di Pasquale et al., 2013; Fatima et al., 
2011; Itzhaki et al., 2012; Jung et al., 2012; Zhang et al., 2013). In addition, the drug effects of 
diseased CMs have been evaluated with this method (Jung et al., 2012; Yazawa et al., 2011). 
2.4.4.4 Analysis of the mechanical beating behavior 
It has been shown that in addition to defective electrophysiology of a CM, genetic cardiac dis-
eases alter also the mechanical beating behavior, like beating motion or contractile force (Chang 
et al., 2013; Kiviaho et al., 2015; Lahti et al., 2012).  Therefore, novel approaches for analyzing 
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the mechanical beating of the CMs have been developed. The electrophysiology, contractile 
force and mechanical beating behavior of a CM are connected, and the comparison of this data 
has been under investigation.(Laurila et al., 2015) 
Mechanical beating behavior can be analyzed with different non-invasive methods. The 
force exerted by hPSC derived CMs during a contraction has been estimated with a traction 
force microscopy, where fluorescent beads are embedded in a cell culture substrate. Cell activity 
can be tracked with optical methods from the displacement of the fluorescent beads due to the 
cell contraction. (Hazeltine et al., 2012)  Atomic force microscopy (AFM), where a small canti-
lever is brought in contact with the beating CM to measure the vertical movement of the cell 
membrane, has also been used to measure beating behavior of hPSC derived CMs(Liu et al., 
2012). Impedance assays, where cells are seeded on a plate containing electrodes, can detect the 
beating of CMs indirectly from the varying impedance signal based on mechanical movement of 
the cells (Peters et al., 2015). The video microscopy is a new and fast method for the analysis of 
mechanical CM beating behavior. Different light microscopy methods have been published in 
recent years, which all are based on a video recording of a beating cell or area, which is then 
analyzed by different computational methods. (Kamgoue et al., 2009; Hayakawa et al., 2012; 
Ahola et al., 2014; Maddah et al., 2015; Laurila et al., 2015)  
2.5 Catecholaminergic polymorphic ventricular tachycardia 
2.5.1 Clinical features of CPVT 
CPVT is a severe autosomally inherited cardiac disorder that is characterized by physical activi-
ty or intense emotion -induced premature ventricular contractions (PVCs) and polymorphic VT 
in a structrually normal heart (Figure 9). In CPVT, stress-induced release of catecholamines 
causes dysfunction of Ca2+ cycling in CMs, which induces ventricular arrhythmias that can 
cause ventricular fibrillation. (Coumel et al., 1978; Leenhardt et al., 1995; Swan et al., 1999) In 
many cases, the first clinical outcome of CPVT is syncope, and spontaneous recovery from the 
arrhythmia is possible; however, in the worst cases, sudden cardiac death (SCD) can be the first 
symptom. Approximately 30% of CPVT patients have symptoms even before the age of 10. 
(Cerrone et al., 2009) The mortality of CPVT can reach 30–35% by the age of 30 years (Swan et 
al., 1999). CPVT equally affects men and women and the prevalence of the disease is estimated 
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to be 1:10000 (Liu et al., 2008). Penetrance of CPVT is estimated at 60–70%, and asymptomatic 
individuals are a minority (Napolitano et al., 2014). However, current insights into disease pene-
trance and expression are limited. 
The diagnosis of CPVT may be challenging because the resting ECG and structure of the 
heart appear to be normal. Therefore, the diagnosis is frequently missed unless patient under-
goes an exercise stress test (Figure 9), or the electrical activity of the heart is continuously 
monitored, usually for 24 hours with a Holter ECG-device, to catch the ventricular arrhythmias. 
(Liu et al., 2008) Diagnosis can be complicated due to the variable disease penetrance, the lack 
of established genotype-phenotype correlations, and the high amount of de novo mutations 
(Leenhardt et al. 2012). Current therapeutic options include beta-antiadrenergic drugs, 
flecainide (Nav1.5 sodium channel blocker), implantable cardioverter-defibrillators (ICDs) 
(Leenhardt et al., 2012; Priori et al., 2013; van der Werf and Wilde, 2013) and left cardiac sym-
pathetic denervation (Hayashi et al., 2009; Wilde et al., 2008). However, these treatments often 
fail to prevent even fatal arrhythmias. 
 
 
 
Figure 9. Exercise stress test of a CPVT patient with RyR2 mutation. The occurrence of ven-
tricular arrhythmias increases during exercise but decreases during recovery. Modified from 
(Liu et al., 2008). 
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2.5.2 Genetic background of CPVT 
Even before CPVT disease was identified and linked to specific genes, several reports intro-
duced patient cases with polymorphic ventricular arrhythmias in the absence of structural heart 
disease. (Coumel et al., 1978; Leenhardt et al., 1995) In 1999, Swan and his coworkers linked 
the CPVT phenotype to a disease locus on chromosome 1q42-q43, suggesting an autosomal 
dominant inheritance pattern of this CPVT form in two Finnish families (Swan et al., 1999). 
The disease-causing gene on this locus was the RyR2 gene (Laitinen et al., 2001; Priori et al., 
2001). RyR2 gene mutations are detected in approximately 70% of patients with CPVT, and 
over a hundred different RyR2 gene mutations have been identified (Liu et al., 2008; Medeiros-
Domingo et al., 2009). The disease-causing mutations are primarily point mutations in which a 
single nucleotide has changed. Clustering and hotspots of these RyR2 mutations appear to be 
relatively common in CPVT. RyR2 mutations cluster in four specific regions of the protein 
(Figure 10) that are on the N-terminal region, calstabin2-protein binding domain, and trans-
membrane C-terminal domain. However, approximately 24% of mutations occur outside these 
clusters. (Cerrone et al., 2009; Napolitano and Priori, 2007)  
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Figure 10. RyR2 mutations cluster in specific regions of the protein. A) Clusters are represent-
ed as black lines numbered from 1 to 4. Clusters from 1 to 3 are located in the N-terminal and 
central regions of the protein, and they form the cytoplasmic domain. Cluster 4 forms the trans-
membrane domain, which is located in the C-terminal region. B) Cluster 1 includes amino acids 
(AA) 44-466, cluster 2 AA 2246-2534, cluster 3 AA 3778-4201, and cluster 4 AA 4497-4959. 
This figure is modified from (Priori and Chen, 2011). 
 
The CPVT phenotype can also be caused by mutations in the CASQ2 gene in the chromo-
some 1p13-21 (Lahat et al., 2001). CASQ2 is the major Ca2+ storage protein in the SR and is 
capable of binding luminal Ca2+ during diastole to prevent Ca2+ precipitation and to reduce the 
Ca2+ concentration (Bers, 2002). CASQ2 gene mutations have been detected in approximately 3-
5% of CPVT patients. These mutations are recessively inherited, and over twenty mutations 
have been identified, of which half of them are point mutations and half of them are nonsense 
mutations. (Ackerman et al., 2011; Leenhardt et al., 2012) Mutations in triadin (TRDN), a 
transmembrane SR protein, and another component of Ca2+ homeostasis, have been found to 
underlie an autosomal recessive form of CPVT (Roux-Buisson et al., 2012). One autosomal 
recessive form of CPVT in an Arabic family was mapped to chromosome 7p14-p22; however, 
the disease-causing gene is unknown (Bhuiyan et al., 2007). 
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2.5.3 Disease pathophysiology 
All different CPVT-causing mutations involve proteins associated with intracellular Ca2+ release, 
and it is thought that these mutations result in increased release, or leak, of Ca2+ from the SR, 
which leads to diastolic oscillations of intracellular Ca2+, DADs, and polymorphic VT (Wehrens, 
2007). However, the understanding of the detailed pathomechanisms behind these mutations 
remains incomplete.  
In the case of RyR2 gene mutations, these mutations are thought to lose the capability to 
control Ca2+ release. At the molecular level, three different mechanisms for why RyR2 muta-
tions lead to abnormal diastolic Ca2+ release have been hypothesized. (Cerrone et al., 2009) 
Reduced binding affinity of the RyR2-stabilizing calstabin2 protein has been presumed to be a 
reason for Ca2+ leak. Marx and coworkers suggested that increased dissociation of calstabin2 
from RyR2 might cause triggered activity. They stated that mutant RyR2 channels have a weak 
calstabin2-RyR2 interaction that is further worsened by PKA phosphorylation during adrenergic 
stimulation (Marx et al., 2000) However, there has also been conflicting evidence that mutant 
RyR2 can interact normally with calstabin2 at baseline and during adrenergic stimulation 
(George et al., 2003; Jiang et al., 2005). The complexity of understanding this mechanism has 
been increased due to new findings, which indicate that SR Ca2+ leak is worsened by RyR2 
dephosphorylation, which is in conflict with previous studies that implicate increased RyR2 
phosphorylation in SR Ca2+ leak (Liu et al., 2014). Conflicting results may be the cause of muta-
tion-specific mechanism differences. 
 One hypothesis implicates defective interdomain interactions as the cause of spontaneous 
Ca2+ leak in CPVT. Unzipping between the N-terminal and central regions of the RyR2 protein 
can hyperactivate RyR2 and cause diastolic Ca2+ leak. (Ikemoto and Yamamoto, 2002) RyR2 
mutations may also cause an unstable channel structure through different mechanisms depend-
ing on their location (George et al., 2003; Suetomi et al., 2011). This possibility also supports 
the hypothesis of mutation-specific mechanisms in the molecular pathophysiology of CPVT. 
Some studies have suggested that RyR2 and CASQ2 mutations cause the Ca2+ release unit 
to open spontaneously without being triggered by voltage-gated Ca2+ influx (Jiang et al., 2002; 
Priori and Chen, 2011). RyR2 may have increased open probability to luminal or cytosolic Ca2+ 
at a given Ca2+ concentration, which can lead to abnormal Ca2+ release. This is particularly en-
hanced under conditions of adrenergic stimulation and is thought to cause spontaneous store 
overload-induced Ca2+ release (SOICR) (Figure 11). (Jiang et al., 2002; Jiang et al., 2005) For 
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example, activation of β-adrenergic receptors leads to increased expression of cAMP, which 
activates PKA and leads to phosphorylation of LTCC and PLB. Phosphorylation of LTCC in-
creases Ca2+ influx, whereas phosphorylation of PLB relieves its inhibition on SERCA2a and 
consequently increases SR Ca2+ uptake, which may result in SR Ca2+ overload and subsequent 
SOICR. This can activate NCX and thereby generate a transient inward, which can depolarize 
the surface membrane after the AP is ended and trigger intracellular Ca2+ alternans and sudden 
changes in APD or EADs and DADs (Figure 11). These changes may then trigger premature 
ventricular beats and ventricular arrhythmias, which are called triggered activity (Figure 11). 
(Priori and Chen, 2011) 
 
 
 
Figure 11. The mechanism of SOICR, in which spontaneous SR Ca2+ release or Ca2+ spillover 
occurs under conditions of SR Ca2+ overload caused, for example, by stress via the β-
AR/cAMP/PKA/LTCC/PLB signaling pathway. SOICR can activate NCX, which can lead to 
DADs and triggered activities. Modified from (Priori and Chen, 2011). 
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Mutations in CASQ2 are thought to cause CPVT by several independent mechanisms. 
CASQ2 may lead to a reduced direct inhibitory effect on RyR2, leading to spontaneous Ca2+ 
release. Other hypotheses are that mutated CASQ2 can result in a loss of Ca2+ buffering or that 
CASQ loss may lead to remodeling of the SR structure and proteins, particularly a reduction of 
the CASQ2 binding proteins triadin and junctin. Triadin mutations may cause CPVT by an im-
paired calstabin2–RyR2 interaction or CASQ2 reduction. (Knollmann et al., 2006; Kornyeyev 
et al., 2012) The absence of triadin has also been linked to CPVT symptoms (Roux-Buisson et 
al., 2012). 
2.5.4 Modeling of CPVT 
Although the pathomechanisms of CPVT have been clinically studied in patients with exercise 
stress tests (Lehnart et al., 2004), genetically engineered mouse models have been of signifi-
cance to the mechanistic understanding of the disease. Most of the RyR2 mutation-related 
CPVT studies have been performed in transgenic knock-in mouse models expressing mutations 
and have shown that Ca2+ leaks to the cytosol mediated the arrhythmogenesis (Cerrone et al., 
2005; Liu et al., 2006). These models have been pivotal to the understanding of both autosomal-
dominant and recessive forms of CPVT. However, the observed phenotypes have not always 
resembled the human disease (Cerrone et al., 2005; Kannankeril et al., 2006; Liu et al., 2006; 
Knollmann et al., 2006; Song et al., 2007; Lehnart et al., 2008). CPVT has also been studied by 
expressing mutations in human embryonic kidney cells (HEK 293) (Jiang et al., 2002; Paavola 
et al., 2007) and in atrial tumor (HL-1) cells (George et al., 2003). However, these expression 
systems lack a cardiac intracellular environment that includes accessory proteins and cell struc-
ture, which complicate the understanding of how mutations induce cardiac arrhythmias in native 
CMs. 
Different experimental drugs have been tested with CPVT mouse models. The affinity of 
RyR2 to calstabin2 has been increased with the 1,4-benzothiazepine derivative K201, which has 
been shown to reduce RyR2 opening and to prevent the onset of arrhythmias in mouse models 
of CPVT or HF (Wehrens et al., 2004). Treatment with another RyR2-specific compound, the 
1,4-benzothiazepine derivative S107, restored the interaction between RyR2 and calstabin2 in a 
mouse model (Lehnart et al., 2008). The CaMKII inhibitor KN-93 has been able to prevent cat-
echolamine-induced sustained ventricular tachyarrhythmia in RyR2-mutated mouse models 
both in vivo and in vitro (Liu et al., 2011). Flecainide has reduced stress-induced arrhythmias in 
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a CASQ2 knockout mouse model as well in humans (Watanabe et al., 2009). In addition, stabi-
lization of RyR2 by JTV-519 has been shown to reduce CPVT-triggered arrhythmias at the cel-
lular level (Sedej et al., 2010). 
Novel iPSC technology has increased the study of CPVT pathophysiology and cardiac ar-
rhythmias in human CM models in recent years. Several groups have reported the generation of 
CPVT patient-specific iPSCs from individuals carrying a CASQ2 gene mutation (Novak et al., 
2012) and RyR2 gene mutations (Di Pasquale et al., 2013; Fatima et al., 2011; Itzhaki et al., 
2012; Jung et al., 2012; Zhang et al., 2013) with the physiological characteristics of the disease. 
The similarities and differences in the pathophysiological consequences of RyR2 versus CASQ2 
mutations have also been studied with iPSC-CMs (Novak et al., 2015). In some of these studies, 
the phenotype of CPVT could be rescued with drugs. These drugs include dantrolene, an inhibi-
tor of Ca2+ release through RyR channels (Jung et al., 2012), flecainide, thapsigargin, an inhibi-
tor of the SERCA2a, (Itzhaki et al., 2012) and KN-93 (Di Pasquale et al., 2013). 
2.6  The potential use and challenges of iPSC-derived cardiomyocytes 
in disease modeling and drug screening 
Despite the immature nature of iPSC-derived CMs, the possibility of generating disease- and 
patient-specific CMs with iPSC technology has opened new possibilities for cardiac research. 
These cells can be used to study the developmental process of the heart as well as to model dis-
eases in vitro, studying the basic pathology of cardiac diseases, drug screening, designing per-
sonalized medications for patients, and developing and screening new drugs (Figure 12). Previ-
ously, non-cardiac human cells, animal cells or transgenic mouse models have been studied to 
understand the functional changes of genetic mutations identified in patients with inherited dis-
eases. However, these animal organisms or animal cell models do not always demonstrate the 
same phenotypes as those observed in humans, primarily because of species differences. (Ebert 
et al., 2012) Additionally, obtaining primary human CMs from cardiac biopsies and maintaining 
them in vitro are challenging (Mitcheson et al., 1996). 
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Figure 12. Potential use of iPSC-derived CMs. Figure modified from (Bellin et al., 2012). 
 
After the discovery of iPSC technology, the potential of this technology for creating disease 
models from patients with complex genetic defects has been studied increasingly. Several genet-
ic diseases have been studied with iPSCs, including hematopoietic, hepatic, endothelial, neuro-
logical, and cardiovascular diseases. (Ebert et al., 2012) Disease modelling with iPSCs has been 
successfully exploited to study multiple cardiac diseases recapitulating the characteristic pheno-
type of each specific disease: CPVT (Fatima et al., 2011; Jung et al., 2012; Novak et al., 2012; 
Itzhaki et al., 2012; Zhang et al., 2013; Di Pasquale et al., 2013), LQT1 (Moretti et al., 2010), 
LQT2 (Itzhaki et al., 2011a; Matsa et al., 2011; Lahti et al., 2012), LQT3 (Ma et al., 2013), di-
lated cardiomyopathy (Sun et al., 2012), hypertrophic cardiomyopathy (Han et al., 2014; Lan et 
al., 2013), Timothy syndrome (Yazawa et al., 2011) and LEOPARD syndrome (Carvajal-
Vergara et al., 2010). 
In addition to disease modeling, iPSC-derived CMs could offer a safe potential platform for 
cardiovascular drug evaluation for early stage drug screening and pharmacokinetic studies (Fig-
ure 12). The heart has been shown to be particularly sensitive to the toxic effects of non-
cardiovascular drugs, and several of those types of drugs have been withdrawn from clinical use 
because they prolonged the QT interval. (Ebert et al., 2012) Prolonged QT intervals and other 
clinically relevant drug responses have been demonstrated from iPSC-derived CMs with differ-
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ent drugs (Itzhaki et al., 2011a; Lahti et al., 2012; Matsa et al., 2011); therefore, iPSC-CMs 
could also be used in non-cardiovascular drug studies where they could reveal possible cardiac 
side effects. 
The greatest challenges of iPSC technology are related to the safety, efficiency and kinetics 
of the method, and more knowledge of the reprogramming process is needed. Optimal and effi-
cient non-integrating reprogramming factors need to be found to avoid problems related to ge-
netic alterations, such as risk of mutagenesis and tumors, and possible re-activation of silenced 
reprogramming genes. Challenges for iPSC technology also include the high costs of iPSC line 
derivation and culturing, as well as the efficiency of the derivation methods, which would need 
to be higher for larger scale applications. Especially for clinical cell therapy applications, iPSC 
derivation and differentiation techniques need to be developed toward xenofree production, and 
genomic alterations and chromosomal abnormalities during reprogramming and culturing need 
to be avoided.  
The differentiation of CMs from iPSCs has its own challenges, including the efficiency of 
differentiation, together with complex and expensive differentiation protocols. The epigenetic 
memory of iPSCs can also influence the differentiation capacity of the cells (Kim et al, 2010b). 
In addition, cardiac differentiation protocols produce a heterogenous population of CMs and 
non-cardiac cells, and the sorting and enrichment of CMs is challenging and time-consuming. 
Currently, all cardiac differentiation methods produce a mixture of all types of cardiomyocytes 
(ventricular, atrial and conduction types of CMs). Immaturity of iPSC-derived CMs may result 
in an incomplete phenotype of the cells, which can distort the actual disease characteristics. 
Immaturity of iPSC-derived CMs has been observed as inadequate sarcomeric structures (Lieu 
et al., 2009; Luna et al., 2011), changes in ion channel expression (Sartiani et al., 2007), fluctu-
ating electrophysiological properties (Doss et al., 2012), a lack of clear t-tubule structures (Lieu 
et al., 2009; Novak et al., 2012) and a reduced repolarization reserve (Paci et al., 2014).  
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3 Aims of the study 
The main objective of this work was functional characterization of differentiated CMs and gen-
eration of an iPSC-derived CPVT disease cell model to study and characterize the arrhythmic 
events of these CMs both in vivo and in vitro. To achieve the main objective, the following spe-
cific aims were set: 
 
1. Investigate whether EFS with a novel EFS platform could enhance CM orientation and 
maturation as well as improve functional properties of NRCs. (Study I) 
 
2. Generate a disease model of CPVT patients carrying a RyR2 mutation with iPSC-
derived CMs and clarify the cellular level pathomechanisms of the disease by studying 
electrophysiology and intracellular Ca2+ cycling of these cells. (Studies II-III) 
 
3. Characterize mutation-specific differences of iPSC-derived CPVT CMs and study the 
antiarrhythmic potential of dantrolene in the treatment of CPVT by assessing the effica-
cy of intravenously administered dantrolene in patients carrying various RyR2 muta-
tions and compare these effects to in vitro studies using iPSC-derived CMs generated 
from the same patients. (Study III) 
 
4. To analyze Ca2+ cycling of iPSC-derived CPVT CMs and abnormal Ca2+ transients. 
(Studies II-IV) 
 
5. To develop and test an automatic Ca2+ cycling analysis software tool based on interac-
tive visualization and to compare the results with a visually performed manual analysis. 
(Study IV) 
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4 Materials and methods 
4.1  Stimulation experiments with neonatal rat cardiomyocytes (I) 
4.1.1 Neonatal rat cardiomyocytes 
NRCs were harvested from the hearts of 2- to 5-day-old rats’ as described previously (Uusimaa 
et al., 1992). Briefly, the hearts were removed, enzymatically dissociated with collagenase type 
II and seeded at a cell density of 282 000 cells/cm2 onto collagen gel or 0.1% gelatin-coated 
MEA plates. First, cells were cultured in Culture Medium I [CMI, Dulbecco’s modified Eagle’s 
medium/Ham’s Nutrient Mixture F12 (DMEM/F-12, Sigma-Aldrich, Germany), 10% fetal bo-
vine serum (FBS, Gibco, Finland), 100 IU/ml penicillin/0.1 mg/ml streptomycin (P/S, Gambrex, 
Belgium), and 2.56 mM L-glutamine (Sigma-Aldrich, Germany)]. After the first day, the cells 
were precultured in 1 ml of complete serum-free medium [CSFM, DMEM/F-12, 10% bovine 
serum albumin (BSA, Sigma-Aldrich, Germany), 2.8 mM sodium pyruvate (Cambrex, Belgium), 
2.56 mM L-glutamine, insulin-transferrin-sodium selenite media supplement (ITS, Cambrex, 
Belgium; 1 µM insulin, 5.64 µg/ml transferrin, 32 nM selenium), 100 IU/ml P/0.1 mg/ml S, 0.1 
nM 3,3’,5-triiodo-L-thyronine sodium salt (T3, Sigma-Aldrich, Germany)] in a 37 °C/5% CO2 
to allow the cells to attach to MEA chambers. The animals were sacrificed according to the 
guidelines of the Animal Unit, Medical School, University of Tampere, and the Ethical Com-
mittee of the Animal Unit has accepted the method to obtain the cells. 
4.1.2 Collagen gel  
The collagen was isolated from adult Sprague-Dawley rat tails as described previously (Eschen-
hagen et al., 2002) with some modifications. Briefly, tails were cut into pieces, and the collagen 
fibers were pulled out and dissolved into 0.1% acetic acid. Then, collagen was precipitated us-
ing 25 v-% sodium chloride, the solution was centrifuged, and the collagen pellet was dissolved 
again in 0.1% acetic acid. The solution was dialyzed at 4 °C to balance the salinity. The concen-
tration of the collagen solution was determined using a Pierce® BCA Protein Assay kit (Thermo 
Scientific, USA) using BSA as a standard. The gelation of the collagen was performed as de-
scribed previously (Mather and Roberts, 1998), with two different neutralizing buffers, 12 
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mg/ml NaHCO3 (Sigma-Aldrich, Germany) in 0.1 N NaOH (Merck, Germany) and 1.3 M NaCl 
(Baker, The Netherlands) in 0.2 M Na2HPO4 (Baker, The Netherlands). The solution was incu-
bated at 37 °C for 30 minutes to allow the gel to form. 
4.1.3 Stimulation setup 
The stimulation system consisted of electronics for stimulation waveform generation and ampli-
fication, a MEA plate container with electrodes, and stimulation software running on a PC lap-
top. The container was manufactured from polymethyl methacrylate and designed to house six 
MEA plates. For each MEA plate, stainless steel plate electrodes were placed to generate a ho-
mogeneous field for stimulation. The container also included air exchange and water pools to 
counteract evaporation.  
The stimulation system was USB powered, and the electronics of the system were able to 
create a field strength of at least 5 V/cm with an output frequency ranging from 0.5 to 40 Hz. 
The shortest pulses capable of being produced were 2 ms wide. The electronics consisted of a 
single-sided supply operational amplifier circuit, which amplified the signal created by a PC-
controlled National Instruments USB-6008 Data Acquisition device and produced voltage-based 
stimulus. The stimulation voltage and waveforms, frequency, total stimulation time, pulse dura-
tion and delays between pulses could be operated by the user. The electrical output of the stimu-
lator was verified with an oscilloscope. In long-term stimulation testing, the effect of the EFS on 
pH levels of cell culture medium was also studied. 
4.1.4 Stimulation protocols 
First, cells on gelatin-coated MEA chambers were paced with both monophasic and biphasic 
pulses at 2.5 and 5 V/cm and frequencies of 1, 2 and 3 Hz with pulse durations of 2 ms, 4 ms 
and 10 ms to visually confirm the effect of EFS on the cell culture and beating frequency. For 
long-term stimulation, the cells were precultivated for 48 to 72 h to allow the cells to attach to 
MEA plates. This precultivation was followed by EFS for an additional 48 to 72 h using either 
monophasic or biphasic pulses at 5 V/cm or 5.3 V/cm, 2 ms, 4 ms or 200 ms pulse duration and 
a frequency of 1 Hz. Cell samples cultured without EFS were used as controls. Different stimu-
lation parameters were tested in four different stimulation experiments (n=3-6 per experiment).  
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4.1.5 Characterization of stimulated cells 
Total RNA was isolated from the stimulated cells using a NucleoSpin® RNA II kit (Machery-
Nagel, Duren, Germany) and transcribed to cDNA using a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). The expression levels of β-actin, MYH-6, MYH-7 and Cx-
43 were evaluated by PCR. Quantitative RT-PCR (qPCR) was performed according to the 
standard protocols on an Abi Prism 7300 instrument (Applied Biosystems, Foster City, CA, 
USA) with the above-mentioned primers.  
Stimulated cells were fixed in 4% paraformaldehyde (PFA), stained with the primary anti-
bodies anti-troponin I (Santa Cruz) (1:500) and anti-cardiac troponin T (Abcam) (1:1500) and 
mounted with Vectashield (Vector Laboratories, USA) containing 4',6-diamidino-2-
phenylindole (DAPI) for staining nuclei. Live/dead staining of CMs was performed using a 
LIVE/DEAD® Viability/Cytotoxity Kit for mammalian cells (Molecular Probes, Inc, Invitrogen) 
with 0.1 µM calcein AM and 0.5 µM ethidium homodimer-1.  
The electrical activity of stimulated and control NRCs was monitored using the MEA sys-
tem (Multi Channel Systems MCS GmbH, Reutlingen, Germany) before and after the stimula-
tion. The sampling frequency of the MEA measurements was 20 kHz. Measurements were 
made at 37 °C, and signals were recorded for two minutes via every microelectrode. A Park 
Systems XE-100 AFM was used to study the surface and electrode wires of the MEA plates. 
4.2  Human induced pluripotent stem cell-derived cardiomyocytes (II-
IV) 
4.2.1 Generation of patient-specific iPSCs (II-IV) 
The iPSC study was approved by the ethical committee of Pirkanmaa Hospital District 
(R08070). Primary fibroblasts for iPSC induction were harvested from skin biopsies of pa-
tients and healthy volunteers. The research protocol was approved by the Ethics Committee 
of the Pirkanmaa Hospital District. All study subjects provided written informed consent. 
Table 2 summarizes the studied cell lines. 
 
  
46 
 
Table 2. iPSC-derived CPVT cell lines used in Studies II-IV; see Figure 10 for RyR2 clus-
ters. *Cell lines generated from the same patient. 
 
Cell line Mutation RyR2 cluster Study 
UTA.04602.WT WT - II-IV 
UTA.00112.HFF WT - II 
UTA.05605.CPVT exon 3 deletion 1 III, IV 
UTA.05203.CPVT* P2328S 2 II-IV 
UTA.05208.CPVT* P2328S 2 II-IV 
UTA.07001.CPVT T2538R between 2-3 III, IV 
UTA.03701.CPVT L4115F 3 III, IV 
UTA.05503.CPVT Q4201R 3 III, IV 
UTA.05404.CPVT V4653F 4 III, IV 
 
Patient-specific iPSC lines were established as described previously (Takahashi et al., 
2007). Culture medium for primary fibroblasts was composed of DMEM (Lonza, Switzer-
land) supplemented with 10% FBS (Lonza), 2 mM L-glutamine, and 50 U/mL penicil-
lin/streptomycin. To generate iPSC lines, primary fibroblasts were infected with lentiviruses 
followed by retroviral infection using 293FT and Platinum-E (Plat-E) cells as packaging 
cells along with the following plasmids and reagents: pLenti6/UbC/mSlc7a1-vector 
(Addgene, Cambridge, MA, USA), ViraPower packaging mix (Invitrogen), Lipofectamine 
2000 (Invitrogen), pMX retroviral vector (with hOCT3/4/3, hSOX2, hKLF4, or hc-MYC; 
Addgene), and Fugene (Roche Diagnostics, Mannheim, Germany). The medium for 293FT 
cells (Invitrogen, Carlsbad, CA, USA) was additionally supplemented with 1% non-essential 
amino acids (NEAA, Cambrex, NJ, USA). Mouse embryonic fibroblasts (MEFs, Millipore, 
MA, USA) and Plat-E cells were cultured without penicillin/streptomycin. 
4.2.2 Characterization of iPSC lines (II, III) 
All the CPVT-iPSC lines were characterized for their karyotypes, mutations, pluripotency, 
and immunocytochemistry as well as EB and teratoma formation. RT-PCR was used to de-
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termine endogenous and exogenous gene expression of the iPSC lines. To study endogenous 
pluripotency markers at the protein level, 4% PFA fixed iPSCs were stained with at least 
four primary antibodies directed against the following proteins or antigens: SOX2, NANOG, 
OCT3/4, stage-specific embryonic antigen (SSEA-4), and tumor-related antigens TRA-1-60 
and TRA-1-81. 
The presence of heterozygous RyR2 mutations in the CPVT iPSC lines was studied by 
sequencing or direct RyR2 exon sequencing of PCR-amplified DNA. DNA was isolated 
using a DNA Tissue XS kit (Macherey-Nagel GmbH & Co., Düren, Germany). The genomic 
region containing the expected mutation was amplified using PCR. Each PCR product was 
directly sequenced in both directions using BigDye Terminator v3.1 and an ABI 3730xl 
DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA). In addition to direct sequencing, 
exon 3 deletion (1128 nucleotides) was also confirmed using PCR and agarose gel electro-
phoresis.  
Karyotypes of the cell lines were determined using either standard G-banding chromo-
some analysis (Medix Laboratories, Espoo, Finland) or KaryoLite™ BoBs™ assay (Perkin 
Elmer) based on BACs-on-Beads™ technology (Molecular and Systems Immunology and 
Stem Cell Biology, Turku Centre for Biotechnology, University of Turku, Finland).  
The expression of markers characteristic of the development of the three embryonic 
germ layers, ectoderm (Nestin or SOX-1), endoderm (α-fetoprotein AFP or SOX-17), and 
mesoderm (VEGF-R2), were studied from EBs maintained in EB medium (knockout (KO)-
DMEM with 20% FBS, NEAA, L-glutamine and penicillin/streptomycin) for 5 weeks. The 
teratoma study was approved by ELLA-Animal Experiment Board of Regional State Admin-
istrative Agency for Southern Finland (ESAVI/6543/04.10.03/2011). Nude mice were inject-
ed with iPSCs under the testis capsule, and tumor samples were collected eight weeks later, 
followed by fixation and staining with hematoxylin and eosin. 
4.2.3 Differentiation and characterization of cardiomyocytes (II-IV) 
iPSC differentiation into CMs was performed by co-culture with END-2 cells. Briefly, undiffer-
entiated iPSC colonies were dissected mechanically into small aggregates and plated on mito-
mycin C-treated END-2 cells in hESC medium without serum (Mummery et al., 2003; Passier 
et al., 2005). Differentiation medium was changed on days 5, 8, and 12, and after two weeks, 
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10% serum was added to the medium. END-2 cells were cultured as described previously 
(Mummery et al., 1991). 
For single cell CM characterization, beating cell colonies were excised mechanically and 
dissociated with collagenase. RNA from CMs was isolated and used to study the expression of 
troponin T, RyR2, SERCA2a, LTCC, PLB, and NCX (Study II). In addition, CMs were stained 
with antibodies for the cardiac markers troponin T and Cx-43 (Studies II and III). 
4.2.4 Calcium imaging (II-IV) 
Dissociated CMs were loaded with 4 µmol/L Fura-2 AM (Life Technologies, Molecular Probes) 
for 30 minutes in HEPES-based medium. The cells were perfused with pre-heated extracellular 
solution consisting of 137 mM NaCl, 5 mM KCl, 0.44 mM KH2PO4, 20 mM HEPES, 4.2 mM 
NaHCO3, 5 mM D-glucose, 2 mM CaCl2, 1.2 mM MgCl2 and 1 mM Na-pyruvate. The pH was 
adjusted to 7.4 with NaOH. Ca2+ cycling measurements were conducted on an inverted IX70 
microscope (Olympus Corporation, Hamburg, Germany) with a UApo/340 x20 air objective 
(Olympus) and an ANDOR iXon 885 CCD camera (Andor Technology, Belfast, Northern Ire-
land). Fura-2 AM was excited at 340 nm and 380 nm light with a Polychrome V light source, 
and the emission recorded at 505 nm with TILLvisION or LiveAcquisition software (TILL Pho-
tonics, Munich, Germany). For Ca2+ analysis, regions of interests were selected for spontane-
ously beating cells, and background noise was subtracted before further analysis. The Ca2+ lev-
els are presented as fura-2 ratio units F340/F380 or as ΔF/F0.  
Ca2+ cycling was measured during spontaneous baseline beating (Studies II-IV), and beating 
rhythm was induced with EFS (DS3 Constant Current/Voltage Isolated Stimulators, Digitimer 
LTD, USA) (Study II) and/or 1 μM adrenaline (Sigma-Aldrich) (Studies II-III) and with 1 µM 
adrenaline together with 10 µM dantrolene (Sigma) (Study III). The SR Ca2+ content was esti-
mated by releasing SR Ca2+ instantaneously with 40 mM caffeine (Sigma-Aldrich) (Study II). 
Data analysis was performed with Clampfit software (Molecular Devices, USA) (Studies II, III). 
Ca2+ signals were also analyzed manually with visual recognition by dividing the signals as 
normal or abnormal (Studies II-IV), and Ca2+ cycling patterns were categorized into different 
subgroups (Studies II, IV). Ca2+ cycling patterns were also analyzed with AnomalyExplorer 
software (see below, Study IV). Drug responses of dantrolene were categorized depending on 
the effect of dantrolene on Ca2+ abnormalities, and differences in responders, semi-responders 
and non-responders were compared between in vivo and in vitro studies (Study III). 
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4.2.5 Ca2+ abnormality analysis software (IV) 
In Study IV, AnomalyExplorer, an interactive Ca2+ abnormality analysis software, was used to 
assist in visual classification of Ca2+ signals. AnomalyExplorer was designed to detect the ab-
normalities in the same fashion as a human observer, i.e., to define whether the signal is normal, 
and to further analyze the quality and distribution of detected Ca2+ abnormalities. In Study IV, 
in addition to visual manual analysis, Ca2+ signals were analyzed with AnomalyExplorer where 
suitable user-defined percentage limits for each abnormality type were selected for two record-
ing software (TillVision and LiveAcquisition, referred to as recording software 1 and 2, respec-
tively) data groups. 
AnomalyExplorer exploits the height of the Ca2+ signals as well as sections and regression 
lines, which act as points of reference for the rules defining the Ca2+ abnormality types. A sec-
tion reflects the Ca2+ rise or decay and allows a small amount of noise in the signal. The noise 
threshold determines how much the signal may exhibit direction changes without regarding it as 
a change in monotonous movement. The regression lines are needed as references for the ab-
normalities if the amplitude of a Ca2+ signal fades over time. Abnormalities are detected by pre-
defined and user-defined limits that can be manipulated via the user interface to correspond to 
Ca2+ measurement settings such as the frame rate of the recordings. 
AnomalyExplorer detects six abnormality types. The low peak or middle peak abnormalities 
are detected if the amplitude of the Ca2+ signal does not reach the normal Ca2+ signal amplitude 
level. Oscillation of the Ca2+ signal is detected if the signal does not descend low enough before 
ascending to the next peak for at least three peaks. A double peak is detected if the signal does 
not descend low enough before ascending to the next peak. An irregular phase is detected if the 
distances of peaks differ from a user-defined percentage for the median peak distances. Plateau 
abnormality is detected if the signal changes its rise or decay rate more than a user-defined per-
centage within a section.  
4.2.6 Patch-clamp measurements (II) 
APs were recorded in current-clamp mode using amphotericin B with the perforated patch tech-
nique. Extracellular perfusate consisted of 143 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 1.2 mM 
MgCl2, 5 mM glucose, and 10 mM HEPES, and the pH was adjusted to 7.4 with NaOH. The 
osmolarity set to 300±2 mOsm (Gonotec, Osmomat 030, Labo Line Oy, Helsinki, Finland) with 
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sucrose. The intracellular solution included 122 mM KMeSO4, 30 mM KCl, 1 mM MgCl2, and 
10 mM HEPES; the pH was adjusted to 7.15 with KOH; and the osmolarity set to 295 ±2 mOsm. 
Spontaneously beating CMs were patched under similar conditions as during Ca2+ imaging. 
Patch pipettes (model PG150T, Harvard Apparatus, UK) were pulled and flame polished 
(Narishige, UK) to a resistance of 2.0-2.5 MΩ. APs were recorded in gab-free mode with 
pClamp 10.2 software. Current-clamp recordings were digitally sampled at 20 kHz and filtered 
at 5 kHz with a lowpass Bessel filter. AP durations at 50% and 90% of repolarization (APD50 
and APD90), AP amplitude (APA), maximum diastolic potential (MDP) and beats per minute 
(BPM) were analyzed from AP recordings with Microcal OriginTM 8.6. 
4.3  Clinical data (II, III) 
4.3.1 Monophasic action potential and 24-h-ECG recordings (II) 
Monophasic action potentials (MAPs) were previously recorded from CPVT patients and 
healthy controls as reported (Paavola et al., 2007). The data were recorded during sinus rhythm 
and atrial pacing at a constant cycle length of 600 ms during both baseline and adrenaline infu-
sion. Analysis was performed with custom-made software. EADs were defined as low-
amplitude depolarizations during phase 2 or 3 of the AP, with an amplitude of ≥3% of the pre-
ceding AP. DADs were defined as low-amplitude depolarizations after completion of repolari-
zation and had an amplitude of ≥3% of the preceding AP. (Vos et al., 2000) 
Twenty-four-hour ECGs were previously recorded from CPVT patients and healthy controls 
with commercial tape recorders (model 8500; Marquette Electronics Inc., Milwaukee, WI, 
USA). The data were initially analyzed with a Marquette 8000 Holter Analysis system. T1-, T2-, 
and U-waves were defined as previously reported (Viitasalo et al., 2006; Viitasalo et al., 2008). 
4.3.2 Exercise-stress test and dantrolene infusion (III) 
In Study III, the antiarrhythmic potential of dantrolene was studied in the treatment of CPVT 
with both patients and iPSC-derived CMs generated from the same individuals. The clinical 
tests and the iPSC studies were performed separately and blinded.  
The study was approved by the Ethical Review Committee of the Helsinki University Hos-
pital (HUS 396/13/03/01/12) and was performed in accordance with the institutional guidelines 
  
51 
 
and the Declaration of Helsinki. Written informed consent was obtained from all patients. The 
clinical trial was registered with EudraCT (2012-005292-14). The follow-up time of the patients 
was three days after the dantrolene infusion.  
Six patients (mean age 50±10 years, range 37–59 years, 5 females) with exon 3 deletion, 
P2328S, T2538R, L4115F, Q4201R or V4653F RyR2 mutations (same as in Table 2) causing 
CPVT were associated with exercise-induced ventricular arrhythmias and syncopal spells. Pa-
tients used a beta-adrenergic blocking agent during all study phases and no other medications 
were in use. Patients underwent the exercise stress test with a bicycle ergometer three times with 
an initial load of 30 W, followed by load increases of 15 W each minute. In the latter phases of 
the study, the workload target was equal to that achieved in the first study. The first baseline 
study was carried out in the morning, and later in the afternoon after intravenous infusion of 
dantrolene sodium (Dantrium®, 1.5 mg per kg of body weight), the second exercise test was 
repeated. The third exercise test was carried out on the second day to study the effects after dan-
trolene washout. ECG was recorded continuously throughout the exercise test and the first 8 
minutes after the test. Numbers of PVCs and the maximum number of consecutive PVCs during 
exercise and at the recovery phase were calculated. 
4.4  Statistical analysis (I-III) 
In Study I, at least two replicates from both stimulated and control groups from each qPCR 
experiment were analyzed as triplicates. The relative quantification was defined using the 2-
ΔΔ Cτ -method (Livak and Schmittgen, 2001). The data were normalized to the expression of 
the housekeeping gene β-actin, and the unstimulated sample for each test series was used as 
the calibrator. The statistical significance for each EFS experimental group was determined 
with the t-test.  
In Studies II and III, the significance of in vitro differences between two groups was 
evaluated with the unpaired Student’s t-test. The significance of changes within a group was 
evaluated with the paired Student’s t-test. The data are expressed as the average±S.E.M.; n 
refers to the number of cells or experiments. 
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Statistical analysis of in vivo studies (Study III) was performed using SPSS 21.0 statisti-
cal software package (SPSS, Chicago, IL). The data are presented as the average+1 SD. 
Comparisons between phases were performed by the non-parametric Wilcoxon test. 
  
53 
 
5 Results 
5.1  The effect of electrical stimulation on primary cardiomyocytes (I) 
5.1.1 The effect of stimulator on cardiomyocytes 
The difference in medium pH levels in control and stimulated medium samples after long-term 
stimulation was 0.10%, suggesting that stimulation had no effect on the pH levels. Different 
stimulation protocols did not cause degradation of the electrodes or any gas formation. The ef-
fect of the EFS on cell beating was characterized visually by a pacing experiment with varying 
parameters. Stimulation paced the beating rhythm, which returned to its spontaneous frequency 
after the stimulation. 
5.1.2 Cell viability, morphology and functionality 
NRC viability was determined with live/dead staining, which revealed no observable differ-
ences in cell viability between the stimulated and control samples; approximately 50% of the 
cells were viable in both groups. However, the number of NRCs decreased similarly during the 
culture in both the control and stimulated samples. Stimulation did not change the morphology 
of NRCs, and EFS did not elongate or orientate the cells. Instead, the orientation of the NRCs 
was observed to be parallel to the MEA plate electrode wires in both the control and stimulation 
samples where cells were cultured on gelatin (Figure 13). To estimate the effect of MEA surface 
abrasions on the orientation of cells, the height of the electrode wires was measured with AFM 
to be 600 nm.  
The spontaneous beating rate of NRCs was measured with MEA and was found to vary be-
tween 0.5 and 2 Hz, although it was commonly 1.0 Hz. The culturing time decreased the beating 
rate, which also became irregular during the experiment. This phenomenon was evident in both 
stimulation and control samples. MEA measurements could not be carried out on NRCs on col-
lagen gel due to the thickness of the gel. However, microscopy revealed that the culturing time 
also affected the number of beating areas in these samples, and the beating frequency of stimu-
lation and control samples decreased. 
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5.1.3 Gene and protein expressions 
RT-PCR showed that the MYH-7 mRNA levels were higher in the 3-day stimulation experi-
ments than in the control samples and that Cx-43 expression levels were slightly elevated. qPCR 
analysis confirmed that stimulation increased MYH-7 and Cx-43 expression levels in two ex-
periments (p<0.05) when compared to controls (Figure 13). In two other experiments, MYH-7 
and Cx-43 expression levels had slightly higher expression, but these levels did not reach statis-
tical significance. 
The stimulated cells stained positive for troponin T or I similar to the controls. Stimulation 
caused no visible changes in the sarcomeric structure of the NRCs. 
 
 
 
Figure 13. A) Expression levels of Cx-43, MYH-6, and MYH-7 after different stimulation ex-
periments at the end of culturing. Error bars are SD. * indicates statistical significance of p<0.05. 
B) The orientation of NRCs parallel to the electrode lines of the MEA plate was evident in the 
live/dead stainings. 
5.2  Characterization of iPSC and iPSC-derived cardiomyocytes (II, 
III) 
The iPSC lines generated from a CPVT patient and from healthy control subjects were morpho-
logically and karyotypically normal (Figure 14). Retrovirally encoded reprogramming factors 
were silenced, and endogenous pluripotency genes were turned on and expressed at the protein 
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level (Figure 14). The pluripotency of the cell lines was further confirmed with in vivo teratoma 
formation and with in vitro EB formation as well as with the expression of all three germ layers. 
The presence of the RyR2 mutations was verified for all the CPVT-iPSC lines by DNA se-
quence analysis (Figure 14) or by PCR.  
iPSC lines were differentiated into spontaneously beating CMs that expressed troponin T 
and Cx-43 cardiac markers at the protein level. In Study II, expression of troponin T, RyR2, 
SERCA2a, LTCC, PLB and NCX were confirmed by RT-PCR. No differences in the studied 
gene or protein expression levels were observed between control and CPVT CMs.  
 
 
 
Figure 14. Characterization of CPVT iPSCs. A) Morphology of an iPSC colony. B) Normal 
karyotype. C) Expression of pluripotency markers at the protein level. Scale bars 200 µm. (E) 
Sequencing analysis confirming the correct RyR2 mutation of the CPVT iPSC line.  
5.3  Functionality of iPSC-derived CMs (II-IV) 
5.3.1 Ca2+ cycling (II, III) 
Ca2+ cycling properties of spontaneously beating CPVT-P2328S and control CMs were com-
pared in Study II. The beating rhythm of the cells was induced with electrical pacing and adren-
aline perfusion, and the effect of a high-dose caffeine puff was studied. Ca2+ transients were 
categorized into four different categories, with abnormal Ca2+ cycling in three of the categories 
based on irregularity of the rhythm and/or transient amplitude. In spontaneously beating CPVT-
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P2328S CMs, 14% of cells showed abnormal Ca2+ cycling, which was slightly diminished to 
10% during electrical pacing. When beating rhythm was induced with adrenaline (Figure 15), 
abnormalities increased to 29% and to 32% together with electrical pacing. In control CMs, 
spontaneously beating cells had only 8% abnormalities, and adrenaline increased the amount to 
11%. Electrical pacing completely abolished abnormal Ca2+ cycling in control cells. During 
spontaneous baseline beating and electrical pacing, CPVT-P2328S and control CMs had similar 
diastolic intracellular Ca2+ levels. Adrenaline and electrical pacing induced the intracellular Ca2+ 
to significantly higher levels in CPVT-P2328S cells compared to controls. The SR Ca2+ load 
was measured as the transient amplitude of high-dose caffeine-induced Ca2+ release, which was 
significantly lower in CPVT-P2328S CMs at baseline and in the presence of adrenaline pacing 
compared to controls. Fractional Ca2+ release indicated the amount of Ca2+ released from the SR 
during normal beating in proportion to the total SR Ca2+ store. Fractional SR Ca2+ release was 
significantly higher in CPVT CMs during spontaneous beating and during electrical pacing with 
and without adrenaline perfusion compared to controls.  
In Study III, Ca2+ cycling of CMs from six different RyR2 mutations were compared to con-
trol cell lines. Generally, Ca2+ transient abnormalities such as multiple peaks/double peaks (Fig-
ure 15) composed of two peaks, irregular phases, oscillations (Figure 15), and varying ampli-
tude manifested as low peaks were more incommon in CPVT CMs than in control CMs at base-
line and in response to adrenaline (Figure 15). Although these abnormalities were common with 
all six mutations examined, some differences between RyR2 mutations were also observed. 
Accordingly, Ca2+ transient abnormalities were somewhat more common in the cluster 4 muta-
tion than in cluster 1, 2 and 3 mutations. Adrenaline increased the beating frequency of each cell 
line studied. All RyR2-mutated CMs had lower beating frequencies at baseline and during 
adrenaline perfusion than control CMs. Adrenaline produced significantly elevated diastolic 
Ca2+ levels only in P2328S CMs, while diastolic Ca2+ levels were lower or similar in other mu-
tant CMs compared to control CMs. Exon 3 deletion CMs had both lower beating frequency and 
diastolic Ca2+ levels compared to other mutations. 
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Figure 15. Ca2+ cycling transients of control and CPVT CMs during the spontaneous baseline 
beating and after adrenaline perfusion, which provoked double peaks and oscillating Ca2+ ab-
normalities in CPVT CMs. 
5.3.2 Analysis of Ca2+ cycling abnormalities (IV) 
In Study IV, AnomalyExplorer software was developed and used to analyze visual patterns of 
Ca2+ cycling data independent of observers. The data were generated with two different Ca2+ 
signal recording software. Signals generated with recording software 1 had frequencies from 9 
to 10 Hz and signals generated recording software 2 had frequencies from 23 to 26 Hz. This 
affected the noise level of the recordings; therefore, optimal user-defined parameter settings 
were selected for both recording software data groups. 
Each Ca2+ signal was analyzed manually with visual recognition and compared with the re-
sults obtained from AnomalyExplorer. With recording software 1 signals, there was 2% incon-
sistency between manual and AnomalyExplorer analyses, and these were specified as false ab-
normal (false positive) stating that they were categorized as normal manually but the software 
categorized them as abnormal. With recording software 2 signals, there was 9% inconsistency 
with the manual analysis where 4% were false abnormal and 5% were false normal (false nega-
tive) stating that they were categorized manually as abnormal but the software categorized them 
as normal.  
The majority of the spontaneously beating CMs were categorized as normal in the manual 
and AnomalyExplorer analyses. Table 3 shows the percentage of abnormally categorized signals 
and the percentage of detected abnormality patterns of the data generated with both recording 
software and with both manual and AnomalyExplorer analyses. Comparison of the analyses and 
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the consistency of the manual and AnomalyExplorer analysis of different RyR2 mutated CPVT 
cell lines revealed mutation-specific differences in the Ca2+ transient abnormalities with both 
analysis methods (Table 4). 
 
Table 3. Comparison of detected Ca2+ cycling abnormalities analyzed manually and with 
AnomalyExplorer software in Study IV.  
 
 Recording software 1 Recording software 2 
 Manual analysis,  
abnormalities 
(n=171) 
AnomalyExplorer 
analysis, abnor-
malities (n=157) 
Manual analysis,  
abnormalities 
(n=301) 
AnomalyExplorer, 
analysis abnor-
malities (n=284) 
Double peaks 29% 30% 33% 34% 
Low peaks 20% 15% 15% 6% 
Middle peaks 5% 6% 9% 9% 
Oscillations 26% 30% 26% 28% 
Plateau abn. 6% 6% 7% 15% 
Irregular phase 14% 13% 13% 8% 
Signals catego-
rized as  
abnormal 
34% 
(n=132) 
36% 
(n=132) 
43% 
(n=212) 
42% 
(n=212) 
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Table 4. Comparison of AnomalyExplorer and manual Ca2+ signal analysis of the different 
RyR2-mutated CPVT cell lines. AE denotes AnomalyExplorer analyzed data, and M denotes 
manually analyzed data. Replicates of the analyzed data: exon 3 del, n=46; P2328S, n=32; 
T2538R, n=51; L4115F, n=106; Q4291R, n=57; V4653F, n=29. 
5.3.3 Electrophysiology (II) 
In Study II, CPVT-P2328S and control CMs showed similar AP characteristics, and adrenaline 
caused a similar increase in the beating rate and decreases in APD50 and APD90. Three of 16 
control cells showed random single DADs at baseline, but no DADs were observed during 
adrenaline perfusion in five measured control cells. Six of 14 CPVT-P2328S cells showed ran-
dom DADs at baseline. Eleven CPVT-P2328S cells were exposed to adrenaline, and five of 
them showed DADs (Figure 16) and a subsequent decrease in the beating rate. During sponta-
neous baseline beating, three CPVT-P2328S cells showed singular EADs (Figure 16), which 
were initiated above -25 mV, and the maximum EAD amplitude was 45 mV. One cell with 
EADs also showed DADs and a phase 3 burst episode. During the burst, the MDP was -50 mV 
 Oscillation Double 
peaks 
Low peaks Middle 
peaks 
Plateau abn. Irregular 
phase 
AE M AE M AE M AE M AE M AE M 
exon 3 
del 
19% 16% 38% 38% 0% 6% 3% 3% 37% 28% 3% 9% 
P2328S 16% 11% 45% 43% 16% 21% 9% 10% 8% 5% 6% 10% 
T2538R 52% 51% 31% 17% 0% 7% 4% 4% 2% 4% 11% 17% 
L4115F 29% 27% 35% 34% 11% 15% 7% 4% 5% 5% 13% 15% 
Q4201R 21% 17% 22% 29% 23% 38% 4% 1% 25% 7% 5% 8% 
V4653F 47% 44% 26% 21% 2% 17% 8% 11% 3% 3% 14% 4% 
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and the maximum upstroke amplitude 95 mV. No EADs or burst episodes were observed in 
control CMs. 
 
 
 
Figure 16. DADs and EADs in electrophysiological measurements of CPVT CMs and in clini-
cal patient recordings. A) In vitro patch clamp measurements showing DADs and EADs, and B) 
in vivo MAP recordings of the corresponding phenomena. 
5.3.4 Antiarrhythmic effect of dantrolene on Ca2+ cycling (III) 
Effects of dantrolene were divided into three groups based on their Ca2+ responses on iPSC-
derived CPVT CMs. In the “responder” group, dantrolene abolished all the Ca2+ cycling abnor-
malities (Figure 17); in the “semi-responder” group, dantrolene reduced them by more than 50%; 
and in the “non-responder” group, dantrolene reduced them by less than 50%. In CPVT CMs 
with the mutation in the N terminal or central region of the RyR2 protein (clusters 1-3), dantro-
lene abolished or reduced the majority of Ca2+ cycling abnormalities (Table 4). With exon 3 
deletion, P2328S, T2538R or L4115F, dantrolene abolished or reduced Ca2+ abnormalities by 
more than 50% in 65-97% of cells. With the mutation at the end of cluster 3 (Q4201R) or in the 
transmembrane region (V4653F), the effect of dantrolene was only minimal (Table 4). Dantro-
lene had no effect on the Ca2+ transients in control CMs. Dantrolene did not significantly affect 
the diastolic Ca2+ levels of CMs in which Ca2+ transient abnormalities were abolished, which 
were significantly increased in control and Q4201R CMs where Ca2+ transients were unaltered 
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by the drug. No correlation between the antiarrhythmic effect of dantrolene and its effect on 
beating frequency was observed. 
 
 
 
Figure 17. Representative Ca2+ transients of CPVT CMs, where dantrolene abolishes adrena-
line-induced Ca2+ cycling abnormalities. 
5.4  Clinical features of CPVT (II, III) 
5.4.1 MAP and ECG (II) 
In Study II, MAP recordings of CPVT patient demonstrated DADs and occasional EADs (Fig-
ure 16), which were absent in MAP recordings of healthy controls. Additionally, 24-h ECGs of 
19 CPVT patients and 19 matched healthy controls showed occasional simultaneous T1-, T2- 
(corresponding to EAD) and U-waves (corresponding to DAD) only in CPVT patients. 
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5.4.2 Antiarrhythmic effects of dantrolene in patients (III) 
In the baseline study, exercise bicycle testing induced polymorphic PVCs in all patients and 
non-sustained ventricular tachycardia (NSVT, episodes of 3 to 4 consecutive PVCs) in three of 
them. The average threshold sinus rate for the appearance of PVCs was 105±9 min-1. The total 
count of PVCs during the workload was 172±119. 
All patients tolerated the intravenous infusion of dantrolene but reported considerable mus-
cle weakness as a side effect. Dantrolene abolished from 67% to 97% of PVCs in patients with 
the mutation in the N-terminal or central region of the RyR2 protein (exon 3 deletion, P2328S, 
T2538R and L4115F) (Table 4). In contrast, dantrolene abolished only 1 to 2% of PVCs in pa-
tients carrying the mutation closer to or within the transmembrane region (Q4201R and V4653F) 
(Table 5). iPSC-derived CMs markedly reproduced the varying individual clinical responses of 
dantrolene (Table 4). Dantrolene significantly increased the threshold at which the arrhythmias 
appeared in patients from 105±9 to 120±17 min-1. After the dantrolene was washed out, the 
prevalence of PVCs approached the baseline results. 
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Table 5. In vivo and in vitro effects of dantrolene corresponding with each RyR2 mutation. In 
vitro drug effects were categorized into three groups depending on how dantrolene affected the 
amount of Ca2+ abnormalities compared to the adrenaline responses. The in vivo responder 
group shows the percentage of the abolished PVCs compared to the baseline. Numbers of cells 
analyzed in exon 3 del, n=16; P2328S, n=32; T2538R, n=17; L4115F, n=36; Q4201R, n=22; 
V4653F, n=13. 
 
  Drug effects 
  Non-responder Semi-responder Responder 
exon 3 del. in vivo 3%  97% 
in vitro 19% - 81% 
P2328S in vivo 12%  88% 
in vitro 3% 28% 69% 
T2538R in vivo 33%  67% 
in vitro 35% 30% 35% 
L4115F in vivo 23%  77% 
in vitro 22% 25% 53% 
Q4201R in vivo 98%  2% 
in vitro 68% 18% 14% 
V4653F in vivo 99%  1% 
in vitro 77% 15% 8% 
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6 Discussion 
The main goal of this thesis was the development and functional characterization of cardiac cell 
models. NRCs were exposed to EFS with a novel device to study different stimulation protocols 
and their effects on morphological and functional properties of the cells. A disease model for 
CPVT was produced with hiPSC-derived CMs generated from CPVT patients carrying various 
RyR2 gene mutations to characterize and treat the arrhythmic events of these cells in vitro as 
well as to validate the results in the index patients in vivo. With these RyR2 gene-mutated CMs, 
the role- and mutation-specific differences in intracellular Ca2+ cycling were studied. Based on 
the findings showing abnormal Ca2+ transients in these CMs, a Ca2+ cycling analysis software 
tool based on interactive visualization was developed to facilitate and accelerate the analysis 
compared to manual analysis with visual recognition.  
The main findings of this work are summarized in Figure 18. Stimulation studies showed 
that EFS could be used to affect the gene expression of cardiac proteins and utilized as a tool for 
short-term pacing. CPVT studies indicated that molecular and cellular level research exploiting 
hiPSC-derived CMs correspond to the clinical phenotypes of the patients in studying both path-
ophysiological and drug responses of the disease and encourage the continuation of disease 
modeling utilizing iPSCs even in a mutation- or patient-specific manner. Impaired Ca2+ cycling 
was evident in CPVT-specific CMs and was shown as an essential mechanism of cardiac dys-
function in these patients. In future studies, these abnormal Ca2+ transients can be analyzed and 
categorized with the new Ca2+ cycling analysis software tool developed in this thesis. 
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Figure 18. Summary of the findings in Studies I-IV highlighting the correspondence of the 
CPVT disease model phenotype to the clinical phenotype. 
6.1  Electrical field stimulation (I, II) 
A novel platform for the EFS of cells was designed in Study I, which had a programmable stim-
ulation platform and the possibility of stimulating several cell culture plates for a long-term 
period on MEA plates as a benefit compared to other existing stimulation systems. The aim of 
this study was to determine whether EFS affects cell functionality, morphology and maturation 
when different stimulation parameters were applied to NRCs cultured on top of gelatin or colla-
gen gel.  
EFS and its duration seemed to affect the cardiac gene expression profile. The expression 
level of MYH-7 increased after three days of stimulation but not after two days stimulation. 
This increase in MYH-7 could indicate that most isolated and cultured NRCs were ventricular 
CMs (Asp et al., 2010; Sharma et al., 2003) or that mechanical stress caused by EFS induced a 
shift from α-MHC toward β-MHC composition (Krenz and Robbins, 2004), which can reduce 
the contractile efficiency of the CMs. However, EFS was previously shown to increase the ratio 
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of the sarcomeric proteins MYH-6 and MYH-7, which benefits cardiac contractility and indi-
cates the maturation of the CMs (Radisic et al., 2004). In our study, Cx-43 levels were signifi-
cantly higher in two stimulation experiments compared to the controls, which could indicate 
both electrical and metabolic coupling of CMs due to EFS. These results suggest that this stimu-
lation system may prove useful in the future to enhance the cardiac differentiation and matura-
tion of CMs. Because differentiation protocols are constantly improving and more mature and 
functional CMs are sought, stimulations have already been tested to enhance CM maturation 
with EFS mimicking the heart environmental stimuli. (Nunes et al., 2013) Electrical pacing has 
increased the maturation of Ca2+ cycling and contractile properties as well as the expression of 
Ca2+ cycling proteins and T-tubule proteins in hESC-derived CMs (Li et al., 2013; Liu et al., 
2007). 
Although previous studies have shown that EFS influences CM functionality (Chiu et al., 
2008; Radisic et al., 2004; Sathaye et al., 2006), and although stimulation increased Cx-43 ex-
pression, no long-term effects of EFS on the electrophysiological behavior of the CMs was ob-
served. Instead, the beating rate of the NRCs decreased in all samples and cells detached from 
the MEA plates, causing the loss of cell-to-cell contacts necessary for signal induction. Howev-
er, live/dead stainings revealed no significant differences in cell viability between the stimulated 
and control samples. This decrease in the beating rhythm could be due to the tendency of prima-
ry cells to dedifferentiate and eventually stop beating in culture (Montessuit et al., 2004). 
In earlier studies, the CMs have been shown to elongate and orientate parallel to the EFS 
(Au et al., 2007; Hedgepath et al., 1997; Radisic et al., 2004), which was not evident in Study I 
for this thesis. Instead, the surface topography of MEA electrode wires was a stronger determi-
nant of CM orientation than EFS in both the control and stimulation samples. Electrode wires of 
the MEA plates had a height of 600 nm, which was in line with previous studies, where topo-
graphical cues of a height of several hundred nanometers have been shown to induce cell orien-
tation (Au et al., 2007; Au et al., 2009; Kim et al., 2010a). Consequently, the surface topogra-
phy should be designed carefully when CM orientation is desired. 
Short-term stimulation experiments were able to pace the NRCs, and in the absence of 
stimulation, the beating returned to the spontaneous rhythm. This observation can be exploited 
in various cardiac-related studies requiring the electromechanical stimulation of CMs. Because 
of this phenomenon, iPSC-derived CMs were exposed to EFS in Study II to determine the effect 
of pacing on intracellular Ca2+ cycling. In this study, a commercial stimulation device and plat-
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form were used. Electrical pacing has also been exploited with disease modeling of iPSC-
derived CMs, e.g., for studying Ca2+ cycling of non-beating CPVT CMs (Jung et al., 2012), as 
well as for studying the effect of stimulation on nuclear senescence and cellular apoptosis of 
lamin A/C-related dilated cardiomyopathy (Siu et al., 2012). Stimulation has also been used for 
modeling atrial fibrillation with primary atrial myocytes (Ji et al., 2013). 
6.2  iPSC-differentiated cardiomyocytes in disease modeling (II-IV) 
In Studies II-IV, several iPSC lines carrying different RyR2 mutations were used. iPSC lines 
were established with an efficient and original technique utilizing lenti- and retroviruses 
(Takahashi et al., 2007). This method excluded the use of these cell lines for clinical purposes; 
however, for disease modeling studies, these cell lines were sufficient after their successful 
characterization. The characterization of the cell lines proved their pluripotency by the expres-
sion of certain pluripotency markers at the mRNA and protein levels as well as their ability to 
form three embryonic germ layers as shown by EB and in vivo teratoma forming assays. Most 
importantly, the iPSCs lines carried the same RyR2 mutations as the fibroblast donor patients.  
All the iPSC lines were able to differentiate into functional CMs. The electrophysiology of 
CPVT iPSC-CMs appeared fairly mature in Study II based on their AP characteristics, such as 
AP amplitude, APD90 and resting membrane potential. In addition, CMs expressed several key 
Ca2+ cycling proteins: troponin T, NCX, SERCA2a, RyR2, LTCC and PLB. In addition, in 
Studies II and III, Ca2+ cycling abnormalities were substantially more consistent in CPVT CMs 
than in control CMs, and drug responses corresponded to the clinical phenotype. This finding 
indicated that Ca2+ cycling of the iPSC-derived CMs was mature based on the differences be-
tween control and CPVT cells and similarities between the cell and patient phenotypes. CMs 
also expressed troponin T and Cx-43 at the protein level, and some cells were multinucleated, 
which corresponded to the adult CM morphology. However, the round shape of the CMs indi-
cated immature morphological properties. Stem cell-differentiated CMs have been considered 
immature because of their Ca2+ cycling (Fu et al., 2010; Liu et al., 2007; Liu et al., 2009) and 
electrical properties (Moore et al., 2005; Cao et al., 2008) and because they resemble neonatal 
CMs with their small cell size and lack of clear T-tubules (Lundy et al., 2013). However, slow 
maturation does occur with these cells during prolonged culture (Acimovic et al., 2014; Lundy 
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et al., 2013). The immaturity of iPSC-derived CMs may complicate the analysis of these cells or 
even cause incorrect phenotypes of the cells. Therefore, comparing results between similarly 
produced iPSCs and having valid control cells for these studies are important.  
Despite the large usage of control iPSCs lines generated from healthy individuals, those 
lines have been occasionally criticized due to possible genetic variations between diseased and 
control iPSCs, which can cause false conclusions regarding the underlying mechanisms of the 
disease (Kim et al., 2014). Disease-causing mutations of the iPSCs can be corrected by genera-
tion of genetically identical (isogenic) sibling iPSC lines where nucleotides causing the muta-
tion are altered. These isogenic corrected cell lines have been thought to be optimal controls for 
in vitro disease modeling as they represent the same genetic background except for the mutation. 
Methods based on zinc finger nucleases (ZFNs) (Soldner et al., 2011), transcription activator-
like effector nucleases (TALENs) (Ding et al., 2013) or clustered regularly interspaced short 
palindromic repeats (CRISPRs) (Li et al., 2015) have been utilized with iPSCs; however, the 
generation of corrected isogenic iPSC lines is laborious (Kim et al., 2014). In the work for this 
thesis, control iPSC lines were generated from healthy individuals and compared to the results 
of disease-specific iPSC-derived CMs, and some clear differences were observed. The benefit of 
Studies II and III were that the in vitro results were also compared and confirmed in the index 
patients in vivo. 
6.3  Modeling of CPVT with iPSCs and comparison of the results to 
the clinical phenotype (II-IV) 
6.3.1 Functional properties of iPSC-derived CPVT cardiomyocytes (II, III) 
After the discovery of iPSCs, disease modeling with CPVT patient-specific cells has been wide-
ly studied. Several groups have reported the generation of CPVT specific CMs from individuals 
carrying a CASQ2 mutation (Novak et al., 2012; Novak et al., 2015) and RyR2 mutations (Fat-
ima et al., 2011; Jung et al., 2012; Itzhaki et al., 2012; Zhang et al., 2013; Di Pasquale et al., 
2013; Novak et al., 2015). In Studies II-IV, iPSC disease models from CPVT patients were gen-
erated, and the benefit of these studies was that various RyR2 gene mutations were characterized, 
and the results were compared to the clinical phenotype of the patients.  
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6.3.1.1 Defects in Ca2+ cycling and electrophysiology in vitro and corre-
spondence with the clinical phenotype (II) 
In Study II, an iPSC line from CPVT-P2328S mutation was generated, and the results were 
compared to iPSC lines generated from healthy controls and to clinical data of the same CPVT-
P2328S mutation-carrying patient. No changes were observed between control and P2328S 
CMs in the morphology or in the expression of cardiac markers in the immunocytochemical 
stainings. This observation seems natural because CPVT is a disease with a structurally normal 
heart (Swan et al., 1999). However, in the literature, immature ultrastructures with a disor-
ganized contractile apparatus have been reported with iPSC-derived CMs with CASQ2-D307H 
mutation (Novak et al., 2012), which was contradictory to the normal heart morphology ob-
served in CPVT mouse models (Faggioni et al., 2012) and in CPVT patients (Leenhardt et al., 
1995; Swan et al., 1999). 
The new finding of Study II was the identification of EADs in CPVT-P2328S CMs as a 
novel mechanistic insight in CPVT, and this finding was validated in the clinical data of the 
index patient. DADs, which can give rise to the polymorphic VT in CPVT, were identified in 
patch clamp studies of P2328S CMs. Corresponding electrical instability manifested as EADs 
and DADs were detected in clinical MAP and ECG recordings, which highlight the clinically 
correct phenotype of the CPVT-P2328S iPSC model. In control CMs, rare single DADs, but no 
EADs, were detected. Both EADs and DADs were absent in clinical MAP recordings of control 
patients. 
At baseline, Ca2+ transients were similar in control and P2328S CMs. Defective intracellular 
Ca2+ release with Ca2+ cycling abnormalities were observed in CPVT-P2328S cells in response 
to catecholaminergic stimulation with adrenaline. These observations correlate with the clinical 
phenotype of CPVT where arrhythmias and VT are detectable under conditions of physical or 
mental stress (Swan et al., 1999). Adrenaline produced significantly elevated diastolic Ca2+ lev-
els, increased the amplitude of Ca2+ transients, decreased the SR Ca2+ content and increased 
fractional SR Ca2+ release in P2328S CMs compared to control CMs. Taken together, these 
results demonstrate that catecholaminergic stimulation caused increased sensitivity of Ca2+ re-
lease from SR in the CPVT-P2328S CMs. This increased diastolic SR Ca2+ leak may lead to 
DADs and to the generation of triggered arrhythmias (Schlotthauer and Bers, 2000) and ex-
plains the aforementioned results of patch clamp and clinical studies. Surprisingly, stimulation 
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with adrenaline caused occasionally slowing in the beating rate of CMs. Nevertheless, this find-
ing was in line with a previous study (Novak et al., 2012) and was thought to be a cause of 
adrenaline-induced frequent DADs, which can suppress the following AP and therefore prevent 
the increase in the beating rate. Interestingly, electrical pacing did not increase the arrhythmo-
genicity of the P2328S CMs. At baseline, pacing stabilized Ca2+ cycling in both control and 
CPVT CMs and adrenaline together with electrical pacing did not increase Ca2+ abnormalities. 
This result is opposite of previous findings of some other CPVT iPSC studies (Novak et al., 
2012; Jung et al., 2012) and could suggest mutation-specific differences in CPVT disease.  
The Ca2+ cycling results of Study II suggest Ca2+ mediated mechanisms behind EAD-
formation. EADs have been thought to result from spontaneous reactivation of LTCCs under 
conditions of APD prolongation, when LTCCs recover from inactivation but reactivate while 
the membrane is still depolarized (January and Moscucci, 1992). However, later, the roles of 
cytoplasmic Ca2+ overload and spontaneous Ca2+ release were thought to be the triggers behind 
EAD formation (Volders et al., 2000; Xie and Weiss, 2009). This phenomenon is a result of 
NCX activation due to spontaneous release of Ca2+ from the SR, which causes a depolarizing 
current that reactivates the LTCC and leads to an EAD. EADs arising from membrane potentials 
that are more negative than the threshold potential of LTCC have been shown to be NCX-
mediated and to share similar properties with DADs (Patterson et al., 1990; Spencer and Sham, 
2003; Xu et al., 1996). These mechanistic explanations indicate that EADs and DADs some-
what resemble each other; therefore, the observation of both afterdepolarization types in CPVT-
P2328S CMs was not contradictory to the previous hypothesis. In addition, the possibility of 
EAD-mediated triggered activity in CPVT patients has been suggested based on previous find-
ings in ECG recordings (Viitasalo et al., 2008).  
Compared to other CPVT disease modeling studies where RyR2 gene mutations have been 
studied with iPSC-derived CMs (Fatima et al., 2011; Jung et al., 2012; Itzhaki et al., 2012; 
Zhang et al., 2013; Di Pasquale et al., 2013; Novak et al., 2015), all of these studies have shown 
similar results, including abnormal Ca2+ cycling and DADs, and some of them have shown re-
duced SR Ca2+ content (Jung et al., 2012; Zhang et al., 2013). No clinical data were available in 
any of these studies to corroborate the validity of the iPSC-derived CM phenotype, and no other 
previous study suggested novel mechanistic insight regarding CPVT. Taken together, the results 
of the iPSC model of CPVT in Study II showed disturbances in intracellular Ca2+ cycling and 
recapitulated the arrhythmic changes observed clinically in patients with CPVT. Overall, this 
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study confirmed the usefulness of the CPVT model in pathophysiological studies and suggested 
its applicability to drug screening, which was studied and verified in Study III. 
Because Study II raised questions about mutation-specific differences between CPVT muta-
tions, six RyR2 gene mutations were investigated in Study III, and the results were compared to 
a healthy control cell line. RyR2 mutations are clustered in four hotspots, one-third of the re-
ported mutations can be found in clusters 1 and 2, and the rest can be found between clusters 3 
and 4. Only 10% of RyR2 mutations have been detected outside of these clusters. (Priori and 
Chen, 2011) 
6.3.1.2 RyR2 mutation-specific differences in the Ca2+ cycling in vitro (III, 
IV)  
In Study III, RyR2 mutations from all four mutation clusters were investigated, and both simi-
larities and differences in the CPVT in vitro phenotypes were observed depending on the nature 
of the mutation. All the CPVT CMs showed similar disturbances in intracellular Ca2+ cycling 
consisting of variable abnormality patterns, including multiple peaks/double peaks, oscillation, 
varying amplitude such as low peaks, irregular beating rhytmn and prolonged rise or decay time 
(plateau abnormality). These abnormalities were somewhat more common in the cluster 4 muta-
tion than in cluster 1, 2 and 3 mutations, and in all cases, were more common compared to con-
trol cells. Surprisingly, abnormalities were also observed in baseline recordings of the CPVT 
CMs, although arrhythmias in patients are usually provoked by catecholaminergic stimulation. 
When comparing the baseline Ca2+ transient abnormality patterns of different CPVT cell lines in 
Study IV, mutation-specific differences were shown. These types of differences could reflect the 
mutation-specific pathology of the disease and indicate that the location of the mutation could 
affect the disease phenotype. Further Ca2+ cycling experiments combined with electrophysiolog-
ical studies are needed to assess how different Ca2+ cycling abnormality patterns reflect the 
mechanism of the disease. In Study III, adrenaline did not increase the amount of Ca2+ cycling 
abnormalities significantly in all mutations because the amount of abnormalities was already 
high in the baseline. This phenomenon could be explained by the single-cell level Ca2+ cycling 
measurements, where the abnormalities might be more easily detected from single cells than 
from cell aggregates or the whole hearts, where the surrounding healthy CMs can pace the ab-
normally beating cells. In other CPVT iPSC studies, Ca2+ cycling abnormalities have already 
been detected at the baseline, and abnormalities have been somewhat exacerbated due to cate-
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cholaminergic stimulation (Itzhaki et al., 2012; Zhang et al., 2013; Di Pasquale et al., 2013). In 
addition, baseline conditions in HEK293 cells expressing RyR2 mutations showed frequent 
spontaneous Ca2+ oscillations (Jiang et al., 2002). Thus, the susceptibility of different RyR2 
mutations to Ca2+ cycling abnormalities can be mutation specific. 
The beating frequency of CPVT CMs was lower than that in control CMs in Study III. This 
finding was in line with CPVT patients (Postma et al., 2005; van der Werf and Wilde, 2013). A 
lower beating frequency could be a cause of Ca2+ cycling abnormalities detected in CPVT CMs, 
which decreases the amount of regular spiking and causes irregular and abnormal spiking. Exon 
3 deletion CMs differed from all the other mutated CMs by having lower diastolic Ca2+ levels 
and beating frequencies at baseline and in response to adrenaline. Exon 3 encodes secondary 
structure elements that are crucial for folding of the N-terminal domain. RyR2 with exon 3 dele-
tion may regulate Ca2+ release by altering the conformation of the domain (Lobo et al., 2011), 
which could explain the observed differences between this deletion and the point mutations.  
With the RyR2 point mutations presenting descending trends for the beating frequency and 
diastolic Ca2+ levels, increased Ca2+ abnormalities observed when moving from P2328S toward 
transmembrane area mutations. Mutations other than P2328S had lower or similar diastolic Ca2+ 
levels compared with control CMs. At the molecular level, different mechanisms explaining 
why RyR2 mutations lead to abnormal diastolic Ca2+ release have been hypothesized, which 
most likely could explain these mutation-specific phenotypes observed in basic Ca2+ cycling 
characterization and in drug response studies discussed in the next chapter. RyR2 sensitivity to 
low cytosolic Ca2+ concentrations and increased SR Ca2+ uptake, leading to SR Ca2+ overload 
and SOICR, (Jiang et al., 2002; Priori and Chen, 2011) could explain why diastolic Ca2+ levels 
were lower in some mutations and still cause abnormal Ca2+ release. Some RyR2 mutations 
change the receptor to be inappropriately activated at low diastolic levels of cytosolic Ca2+, 
thereby inducing a diastolic SR Ca2+ leak (Meli et al., 2011). Diastolic Ca2+ levels were not sig-
nificantly elevated with adrenaline in mutations other than P2328S, which could indicate that 
[Ca2+]i alone was unlikely to account for the increase in spontaneous Ca2+ release. Overall, fur-
ther conclusions regarding the mutation-specific mechanism behind abnormal Ca2+ release re-
quire further electrophysiological and Ca2+ cycling studies of these RyR2 mutations, including 
investigation of SR Ca2+ levels. 
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6.3.2 Pharmacological responses of dantrolene (III) 
Due to detected defective Ca2+ cycling of CPVT iPSC-derived CMs and similarities between the 
in vivo and in vitro phenotypes of CPVT observed in Study II, the goal in Study III was to test 
the antiarrhythmic effect of dantrolene on both patients and iPSC-derived CMs. Dantrolene is a 
muscle relaxant that can prevent or reduce severe high body temperature and is therefore a spe-
cific, and currently the only, effective treatment for malignant hyperthermia. Dantrolene reduces 
ECC in muscles by binding to ryanodine receptors and decreasing free [Ca2+]i. (Krause et al., 
2004) Dantrolene is also thought to inhibit Ca2+ leak from RyR2 because it has shown anti-
arrhythmic effects in experimental animal models of CPVT (Kobayashi et al., 2009; Kobayashi 
et al., 2010; Suetomi et al., 2011; Uchinoumi et al., 2010; Xu et al., 2010) and in iPSC-derived 
CMs (Jung et al., 2012).  
The location of the RyR2 mutation is thought to be critical for a favorable effect of dantro-
lene. The binding site for dantrolene has been localized to the N-terminus of RyR2 between 
amino acids 601 and 620 (Kobayashi et al., 2009; Paul-Pletzer et al., 2005), and this binding 
sequence is considered to constitute part of the domain switch region. Therefore, dantrolene 
may participate in the correction of defective unzipping and allosteric stabilization of inter-
domain interactions between the N-terminal and central regions of RyR2 by restoring inter-
domain interactions critical for the closed state of the RyR2 Ca2+ channel, which causes the 
inhibition of Ca2+ leak from RyR2 (Kobayashi et al., 2005; Suetomi et al., 2011; Wang et al., 
2011). This hypothesis has been demonstrated in previous studies (Kobayashi et al., 2005; Ko-
bayashi et al., 2009; Paul-Pletzer et al., 2005). 
6.3.2.1 Antiarrhythmic effects of dantrolene in vitro and in vivo  
In Study III, the antiarrhythmic effect of dantrolene was shown only with RyR2 mutations of 
exon 3 deletion, P2328S, T2538R and L4115F located in the N-terminal or central regions of 
the RyR2 protein (clusters 1-3). This effect was evident both in vivo and in vitro and could indi-
cate that a defective inter-domain interaction within RyR2 could be the underlying arrhythmo-
genic mechanism for these mutations. In the case of the T2538R mutation, dantrolene did not 
suppress the arrhythmias to the same extent as in other central region mutations. This finding 
could be explained by differences in the mode of interdomain interaction in dantrolene binding 
regions, which could cause differences in its antiarrhythmic efficacy (Suetomi et al., 2011). 
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Furthermore, it is possible, that other additional dantrolene binding regions in the carboxyl-
terminal half or in the N-terminal area of the RyR2 exist (Kobayashi et al., 2009).  
Interestingly, minimal or no antiarrhythmic effect of dantrolene was observed in vivo or in 
vitro with mutations Q4201R or V4653F located at the end of cluster 3 or in the transmembrane 
region of cluster 4. Although the Q4201R mutation is located in the cytosolic portion of RyR2 
and in cluster 3, no antiarrhythmic effect of dantrolene was observed in its terminal part. This 
result suggests that the antiarrhythmic response of dantrolene is not necessarily cluster specific. 
Because the antiarrhythmic effect of dantrolene was evidently similar in vivo and in vitro, iPSC-
derived CMs can be used to model individual responses. Although a dose-dependent effect of 
dantrolene cannot be excluded for certain, the antiarrhythmic effect of dantrolene appeared to be 
mutation specific. Similar observations on mutation-specific drug responses have been obtained 
for other genetic disorders, including LQT3 (Ruan et al., 2007) and cystic fibrosis (O'Reilly and 
Elphick, 2013), as well as for certain neoplastic diseases (Willyard, 2011). In our work, the in 
vitro studies showed that dantrolene had no effect on normally beating control or CPVT CMs, 
which was in line with previous reports showing that dantrolene inhibits only abnormal Ca2+ 
release. This inhibition has been thought to be a cause of the native conformation of RyR2, 
which may restrict binding of the drug. Alternatively, dantrolene binding to RyR2 may be de-
pendent on a specific conformational state present only in mutated cells. (Kobayashi et al., 2009; 
Paul-Pletzer et al., 2005) Dantrolene has also been shown to restore defective calmodulin bind-
ing caused by RyR2 domain unzipping (Ono et al., 2010; Xu et al., 2010), which could be the 
reason why dantrolene inhibits only abnormal Ca2+ releases. 
Overall, Study III showed the proof of principle that dantrolene suppresses ventricular ar-
rhythmias in various patients with RyR2-mutated CPVT and has clinical benefit. In addition, 
iPSC-derived patient-specific CMs correctly predicted the clinical response of the drug. In addi-
tion, both in vivo and in vitro results consistently showed that the location of the RyR2 mutation 
affects the antiarrhythmic effect of dantrolene in CPVT. The results of Study III indicate that 
iPSC-derived CMs could serve as a platform for drug development and for the design of per-
sonalized medication, which would allow an individual’s medication to be tailored in cell cul-
ture without predisposing the individual to the potentially serious side effects of a drug.  
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6.3.2.2 New insights into the treatment of CPVT 
At present, risk stratification for the occurrence of arrhythmic events in CPVT patients is poorly 
defined, and these patients are advised to abstain from competitive sports and not to swim unsu-
pervised (van der Werf and Wilde, 2013). Beta-antiadrenergic drugs are the first-line drug 
treatment for CPVT and have been shown to reduce the risk of arrhythmic events. Carvedilol, 
both α- and β-blocker, could be optimal choice due to its RyR2 blocking properties. (Hayashi et 
al., 2009; Hayashi et al., 2012) Flecainide together with β-blocker treatment has also been sug-
gested to be beneficial. Based on preclinical data, which has shown direct RyR2 blocking prop-
erties of flecainide (Watanabe et al., 2009), the use of flecainide in the treatment of CPVT pa-
tients has increased; however, its mechanism remains under debate (Hilliard et al., 2010). A 
placebo-controlled randomized, crossover trial (NCT01117454) of flecainide together with 
standard beta-blocker therapy in CPVT treatment is currently going on in Europe and the USA 
(van der Werf and Wilde, 2013). A RyR2-specific compound, S107 (Lehnart et al., 2008; 
Hwang et al., 2011), is currently in phase 2 trials for the treatment of ventricular arrhythmias in 
CPVT and HF (van der Werf and Wilde, 2013). The efficacy of verapamil in CPVT patients has 
also been studied, but its long-term efficacy has been disappointing (Rosso et al., 2007). Current 
therapeutic options for CPVT also include ICDs; however, several case reports have shown that 
they may be proarrhythmic in CPVT because ICD shocks and the subsequent catecholamine 
release may trigger ventricular storms (Mohamed et al., 2006). In some earlier iPSC studies, the 
phenotype of CPVT has also been rescued with drugs. Dantrolene was shown to restore normal 
Ca2+ spark properties and the arrhythmogenic phenotype of CMs carrying an N-terminal S406L 
mutation (Jung et al., 2012). Flecainide and thapsigargin have been shown to eliminate afterde-
polarizations, and beta-blockers have improved Ca2+ abnormalities worsened with adrenergic 
stimulation (Itzhaki et al., 2012). Treatment with KN-93, a methoxybenzenesulfonamide that is 
an effective inhibitor of CaMKII phosphorylating activity, has been shown to reduce DADs in 
CVPT-CMs (Di Pasquale et al., 2013). However, all of these studies were conducted only with 
iPSC-derived CMs; therefore, whether these findings will translate into a clinical benefit cannot 
be stated, although the drugs were found to be beneficial in the patient-derived iPSC differenti-
ated CMs. 
Our study suggests that at least a subset of patients would benefit from the antiarrhythmic 
potential of dantrolene. Intravenously administered dantrolene could be beneficial for CPVT 
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patients in emergencies such as incessant VT. However, further drug development is needed 
because dantrolene would not be suitable for long-term treatment of CPVT patients due to mus-
cle weakness as a side effect. Overall, in the case of further drug development, the recognition 
of potential mutation-specific responses will be important because our results indicate that one 
drug may not work for all patients even if the disease is the same. The existence of defective 
RyR2-mediated Ca2+ leak in patients with HF has been reported previously (George, 2008); 
therefore, the results of these findings could also be beneficial for these patients. 
6.3.3 Ca2+ cycling abnormalities and novel Ca2+-analysis software (II-IV) 
As shown in Studies II and III, RyR2-mutated iPSC-derived CMs show defective and abnormal 
Ca2+ cycling, which can be observed as variations in the beating rhythm and amplitude and 
manifested as multiple peaks/double peaks, oscillations, irregular rhythm and/or low amplitude 
peaks. As reviewed previously, Ca2+ cycling has a central role in CM ECC, and disturbances in 
this process can have fatal consequences. As shown in Study II, other studies have shown that 
disease-specific iPSC-derived CMs with Ca2+ cycling abnormalities also manifest arrhythmic 
features such as DADs in their AP (Fatima et al., 2011; Itzhaki et al., 2012; Jung et al., 2012; 
Lan et al., 2013; Novak et al., 2012; Yazawa et al., 2011). Simultaneous AP and Ca2+ recordings 
of LQT-specific CMs have revealed that abnormal Ca2+ cycling is involved in prolonging the 
AP duration as well as in forming EADs (Spencer et al., 2014). These results indicate that dis-
ease phenotype-specific changes in electrophysiology can be mirrored by changes in Ca2+ cy-
cling, highlighting the importance of Ca2+ cycling abnormality analysis. 
In Studies II and III as well as in other previous studies, the detection of Ca2+ signal abnor-
malities has been performed manually with visual recognition. This method is based on how the 
researchers categorize data based on an individual’s experience and observations, which makes 
the analysis highly subjective. Usually, the signal has been categorized as abnormal if at least 
one abnormality is detected and the absolute amount or Ca2+ abnormalities in one signal is not 
clarified (Yazawa et al., 2011; Fatima et al., 2011; Novak et al., 2012; Jung et al., 2012; Itzhaki 
et al., 2012; Lan et al., 2013; Novak et al., 2015). In some previous studies (Itzhaki et al., 2012; 
Jung et al., 2012) as well as in Studies II and III, Ca2+ abnormalities were divided into sub-
groups, which is challenging in some cases because one signal can express different abnormali-
ty patterns. Comparison of disease modeling between different studies is challenging for these 
aforementioned reasons and because no specific analysis criteria are determined for abnormali-
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ties and their definitions are not interchangeable. Unspecified criteria for Ca2+ abnormality anal-
ysis also complicate the comparison of Ca2+ cycling parameters between studies because it is 
unclear how Ca2+ cycling abnormalities have been considered in the numerical analysis of the 
data. In addition, analysis of drug responses, such as in Study III, would be more accurate with 
specified criteria for Ca2+ abnormality analysis. 
In Study IV, novel software for Ca2+ cycling abnormality analysis was developed. This 
AnomalyExplorer tool recognized and categorized abnormalities by the visual features alone, 
using interactive visualization in a manner similar to traditional manual analysis. However, 
compared to manual analysis made with visual recognition, AnomalyExplorer is fast, repeatable, 
person-independent, and capable of screening large datasets. In addition, specific criteria for 
different types of Ca2+ abnormalities can be determined. All of these reasons make the results 
more comparable between the different studies. 
In Study IV, AnomalyExplorer was tested with the Ca2+ cycling signals recorded from both 
CPVT and control iPSC-derived CMs. Data were generated with two different Ca2+ recording 
software programs to test the usability of the AnomalyExplorer with data consisting of varying 
sampling frequencies. Due to the ability of user-defined analysis criteria in the AnomalyExplor-
er software, optimal analysis parameters could be found for the data recorded with different 
software. This setting enables the universal use of software regardless of the recording software 
utilizes in Ca2+ cycling studies. When manual analysis of the test data was compared with 
AnomalyExplorer analysis, the detection of normal and abnormal signals was reasonably uni-
form, with inconsistency ranging from 2 to 9%. When the abnormalities were categorized into 
subgroups, the difference in the amount of different subgroup-specific abnormalities ranged 
from 0 to 5% between manual and AnomalyExplorer analysis, with the exception of two ab-
normality subgroups with 8 or 10% difference. The usefulness of AnomalyExplorer for detect-
ing cell line- and mutation-specific variability in the Ca2+ transient abnormality patterns was 
also shown in this study by showing mutation-specific differences in the CPVT cell line.  
The differences between manual and AnomalyExplorer analysis could be a cause of the 
background noise in the high sampling frequency measurements, thus complicating both manual 
and AnomalyExplorer analyses. In addition, the accuracy of the manual analysis made by visual 
recognition can vary and make the analysis non-repeatable. Challenges of Ca2+ imaging meth-
ods such as photobleaching as well as the toxicity of the Ca2+ indicator and UV light to CMs can 
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add interference and noise to the measurements, and these can complicate the analysis and cause 
differences between these two analysis methods. 
In future studies, this software and analysis method can be exploited for Ca2+ cycling analy-
sis to study not only basic disease pathology but also different drug responses. AnomalyExplor-
er does not exclude the need for the numerical analysis of different Ca2+ cycling parameters; 
however, it will clarify the analysis by defining how abnormalities should be considered in the 
numerical analysis, for example, when calculating the peak duration of multiple peaks/double 
peaks or oscillations. To understand the mechanism and severity of Ca2+ cycling abnormalities, 
combined electrophysiological measurements and Ca2+ imaging measurements are essential in 
the future. 
6.4  Limitations of the study 
In Study I, the problem with NRCs was their tendency to dedifferentiate during culture, which 
caused a lack of functionality and complicated the analysis of the effects of EFS. The amount of 
stimulated samples per one experiment was restricted due to our stimulation setup, and more 
replicates and repetition of stimulation protocols would be needed to compare results between 
different stimulation settings more thoroughly. In addition, comparing our results to those of 
other stimulation studies is difficult because the stimulation devices, stimulation parameters, 
and time in culture vary a lot greatly between studies. In the future, to enhance the positive ef-
fect of EFS, it would be important to understand the mechanism by which stimulation and dif-
ferent stimulation parameters influences cellular maturation and processes. In addition, more 
effective ways to quantify this phenomenon at the cellular level are needed. 
In Study II, iPSC-derived CMs from two CPVT and two control cell lines were studied, and 
both CPVT lines were from the same patient. Cell lines of CPVT patients behaved the same 
way; however, whether the results were typical to this mutation or only to this patient cannot be 
stated with certainty. Despite the very rare nature of CPVT disease, we were able to extend our 
research by examining in detail six different disease-causing RyR2 mutations in Study III. 
However, only one cell line per patient and control was studied, and the results could be cell 
line-specific. However because the in vitro dantrolene responses resembled the in vivo respons-
es, the phenotype of the iPSC-derived CMs was highly likely to be at least patient specific in 
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Study III. Only one fixed concentration of dantrolene was used in Study III, which is why the 
dose-responsive effect of dantrolene cannot be evaluated although positive effects of dantrolene 
were observed with four mutations with the same dantrolene concentration. Future studies of 
disease modeling and different mutations in multiple cell lines per patient as well as in muta-
tion-specific cell lines from several individuals are necessary.  
One challenge in disease modeling studies is proper controls for diseased cell lines. The 
problem with healthy controls is that they might differ from diseased cells lines with disease-
causing mutation and may contain several other mutations and polymorphisms that cause phe-
notypic differences. Therefore, the use of multiple different iPSC lines as controls would be 
optimal for disease modeling studies. One way to limit the variability between control and dis-
eased cell lines would be to derive control iPSC lines from close relatives of the patient who are 
not affected by the disease-causing mutation. However, even in studies in which healthy sib-
lings have been used as controls for disease patients, only ∼50% of the genome is shared be-
tween any siblings. Furthermore, phenotypic differences could be the result of DNA variants in 
the other ∼50% of the genome, rather than the disease-associated mutations. (Wang et al., 
2014b) In our study, we observed clear phenotypic differences between healthy control CMs 
and CPVT CMs. However, isogenic controls could more accurately depict non-diseased cellular 
phenotypes compared to healthy controls. With the help of isogenic controls, the effects of ge-
netic modifiers and epigenetic factors of CPVT disease progression between different individu-
als could be studied. Addressing whether healthy control cell lines are as suitable for controls in 
CPVT disease modeling as are isogenic gene-edited iPSC lines is important. However, the gen-
eration of isogenic cell lines also needs validation because they are subject to clonal variation. 
Abnormal Ca2+ cycling was observed in CPVT CMs but rarely in control CMs, which is 
why at least most of the abnormalities resembled the CPVT disease phenotype. Validation of 
the in vitro results with the patient data indicated the correct phenotype of our CPVT CMs. 
However, some abnormal Ca2+ cycling may still be a consequence of the immature CM gene 
expression levels or phosphorylating activity of the CMs because some iPSC-derived CMs lack 
of t-tubules and have low expression levels of the SR Ca2+ buffering protein CASQ2, which can 
disturb RyR2-dependent Ca2+ release (Knollmann, 2013). These possibilities, together with 
possible electrophysiological and structural CM immaturity, may interfere with the normal Ca2+ 
cycling of these cells. Nevertheless, earlier studies have shown that iPSC-CMs display func-
tional and loaded RyR-regulated intracellular Ca2+ stores, which can release Ca2+ via RyRs and 
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can reload their content through SR Ca2+ uptake. The immaturity of the CMs can be a problem 
in disease modeling. Their immature phenotype is due to current differentiation technologies, is 
dependent of culturing time, and can cause significant line-to-line and patient-to-patient varia-
bility. This variability complicates comparisons of results where CMs have been generated with 
different differentiation protocols. Otherwise, immaturity of iPSC-derived CM have been ob-
served as immature morphology, incomplete organization of the sarcomeric structure (Lieu et al., 
2009; Luna et al., 2011), changes in the expression of ion channels related to the cardiac AP 
(Sartiani et al., 2007), varying AP characteristics (Doss et al., 2012), and as a lack of clear t-
tubule structures (Lieu et al., 2009; Novak et al., 2012), which all may cause problems in Ca2+ 
cycling due to slower spread of electrical signals and have an effect on the phenotype of the 
CMs. Additionally, in earlier studies, significant heterogeneity in the subtypes of hiPSC-CMs, 
including atrial, nodal, and ventricular CMs, has been found with each round of differentiation 
(Moretti et al., 2010). While this characteristic can be considered an advantage due to the possi-
bility of assessing the physiological properties in all these cell types, the disadvantage is that 
changes that occur only in one subpopulation of cells cannot be specified when the readout is 
taken from all cells (Sinnecker et al., 2014). The various CM subtypes express differential sets 
of transcription factors, structural proteins and ion channels and have distinguishable AP pa-
rameters (David and Franz, 2012). Therefore, the arrhythmic events detected in these subtypes 
can also vary. The development of cardiac differentiation and maturation protocols will hopeful-
ly improve the homogeneity of iPSCs; however, clarifying the rules for what should be consid-
ered mature CMs and characterizing the effects of various cardiac subtypes with AP measure-
ments will be important. 
In Studies II-IV, the type of CMs (nodal, atrial, or ventricular) under investigation was un-
clear in the Ca2+ imaging studies because Ca2+ imaging method cannot be used to determine the 
CM type. The differences between the CM types can affect the Ca2+ cycling and future simulta-
neous recording of APs and Ca2+ would help to distinguish the CM type and provide mechanis-
tic information regarding the interplay between Ca2+ cycling and the membrane potential. Un-
derstanding the electrophysiological mechanism behind different Ca2+ cycling abnormalities 
will also be very important. In Studies III and IV, AP characteristics, SR Ca2+ storage or Ca2+ 
sparks indicating Ca2+ leak from SR were not studied between different mutations, which would 
allow more information regarding mutation-specific differences. These differences could be 
addressed in the future by patch clamp, Ca2+ imaging methods and computational models. 
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Because the nature of abnormal Ca2+ analysis has been visual inspection, this analysis was 
performed subjectively in Studies II-IV and may not be repeatable between two persons. How-
ever, this problem occurs for all manual data analyses. Consistent rules for the analysis of Ca2+ 
signal abnormalities are currently lacking, and AnomalyExplorer software was generated for 
this reason. Because this program does not consider the interplay between AP and Ca2+ or quan-
tify the Ca2+ cycling parameters, these abnormalities could be studied and improved in the fu-
ture. The user-defined analysis parameters in AnomalyExplorer might cause differences be-
tween two individuals performing the analysis, although those parameters are needed for anal-
yses performed with different software and/or with different sampling frequencies. In addition, 
AnomalyExplorer was designed and implemented for a specific use case and for specific digiti-
zation systems, which can be stated as a limitation of the current prototype. Therefore, some 
future improvement may be needed, for example, for analysis of high frequency Ca2+ signals. 
In clinical recordings in Study II, the noise and acquisition frequency of the ECG signal can 
be limiting factors in the 24-h recordings and affect the results of the recordings. One limitation 
of the MAP method used in Study II was that it records extracellular activity and can provide 
only limited information regarding events occurring across the cell membranes. In Study III, we 
were permitted to study only acute effects of intravenously administered dantrolene and, there-
fore, cannot state the long-term clinical effects of the drug. Additionally, although the dose of 
dantrolene was titrated according to the weights of the patients, serum levels of the drug were 
not measured and could have varied from patient to patient, resulting in concentration-
dependent variations in clinical responses.  
6.5  Future perspectives 
The advantages of iPSCs cannot be ignored in disease modeling, designing personalized medi-
cations for patients, preclinical drug testing and regenerative medicine in the future. iPSCs do 
not have ethical issues like ESCs, and compared to animal models, they mimic the physiological 
conditions more close to humans and have a possibility of providing consistent phenotypes of 
the diseases.  
Cardiac disease modeling with single-cell iPSC-CM technology is challenging because the 
CM monolayer environment lacks the cell–cell connections between both CMs and non-
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myocytes found in vivo, as well as the interactions with the ECM and mechanical forces that are 
important for maintaining morphology, maturity, and molecular composition. In addition, the 
CM monolayer does not mimic the native cardiac tissue because impulse propagation in the 
heart depends on not only the excitability of individual CMs but also impulse transmission be-
tween adjacent myocytes and the 3D arrangement of those cells (Smaill et al., 2013), thus con-
straining the modeling of cardiac diseases in monolayers. Therefore, future cardiac disease 
modeling, as well as the case of CPVT, could benefit from 3D culture models that resemble 
native cardiac tissue. For these models, cultures that include other cells should be developed 
because, for example, endothelial-CM contacts are known to be crucial for maintaining the 
rhythmic and synchronous contraction of CMs (Smaill et al., 2013). The development of 3D 
culture models would minimize the immaturity of cultures by enhancing the structural organiza-
tion of the cells and improving the contractile performance and Ca2+ cycling of CMs, which 
would benefit the disease and arrhythmia modeling of CPVT and the study of Ca2+ cycling 
propagation and abnormalities of these cells.  
As iPSCs eliminate the chances of immunorejection, they hold great importance in regen-
erative medicine and in gene therapy, with the possibility of using isogenic corrected cell lines 
in complete correction of a genetic deficiency. However, before future clinical applications, 
more comprehensive knowledge of the reprogramming process is needed. To reach the potential 
of iPSCs technology, many questions related to safety issues and to the method efficiency need 
to be solved. Optimal and efficient non-integrating reprogramming factors need to be found due 
to the problems with genomic integration of the viral transgenes, possible reactivation of even 
silenced reprogramming genes and the risk of tumorigenesis. Novel nonviral and non-genetic 
methods for reprogramming are improving quickly, and these methods may resolve these prob-
lems. For therapeutic purposes in the future, the culture conditions of iPSCs have to be xeno-
free, and genomic alterations and chromosomal abnormalities during reprogramming and cultur-
ing have to be avoided. Overall, methods to evaluate the safety of iPSCs in clinical applications 
must be clarified. Cardiac regenerative medicine holds its own challenges; for example, proper 
Ca2+- cycling and electrophysiological properties are also essential in these applications because 
transplantation of cells with improper characteristic could lead to potentially lethal arrhythmias, 
and proper integration of the transplanted cells into the recipient heart is essential. Derivation of 
iPSCs is rather slow, which may limit their use in the treatment of acute conditions such as my-
ocardial infarction (MI). One solution for this problem may be direct reprogramming of fibro-
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blasts into iCMs, which is already under investigation (Fu et al., 2013; Nam et al., 2013; Wada 
et al., 2013). Currently, iPSC technology is primarily utilized only with laboratory scale produc-
tion and testing assays, and its efficiency needs to be increased for the use of these cells in the 
larger scale in clinical applications. The economic issues related to iPSCs need to be considered 
because the generation of cell lines and a sufficient amount of CMs for each treatment or drug 
screening studies is costly. 
Currently, clinical cell therapy applications of patient- and disease-specific iPSC-derived 
CMs are not yet available due to various challenges. However, these cells have potential to be 
exploited for designing individualized medications and for the diagnostics of genetic cardiac 
diseases because they provide a great improvement compared to previous animal models and 
transfected non-cardiac cells (Savla et al., 2014; Sugiyama, 2008). Of course, for reliable studies 
regarding pathogenesis and for pharmacological testing related to cardiac diseases, the cardiac 
differentiation methods and maturation need to be improved. Large quantities of more homoge-
nous and adult-like mature populations of CMs are needed with sufficient quality for these ap-
plications. Overall, the requirements for the maturation state of the hPSC-derived CMs need to 
be investigated and determined, and maturation may need to be enhanced, with alterations in 
culture conditions, for example, with electrical or mechanical stimulation. Additionally, to de-
velop highly efficient differentiation protocols, purification and cell sorting of CMs from a het-
erogeneous cell population could be beneficial. 
The further validation of iPSCs as a drug discovery technology helps the pharmaceutical in-
dustry to avoid failed drug development programs and may lead to a new era where preclinical 
testing in non-predictive animal models can be reduced and where testing can proceed directly 
from in vitro trials to actual clinical trials in patients. As differentiation protocols and high-
throughput techniques improve, iPSC technology may play an integral role in developing new 
pharmacologic agents for genetically based diseases and in screening compounds for potential 
cardiotoxicity. In addition to identifying new compounds, iPSC-derived disease-specific CMs 
could be used to test drug responsiveness in vitro before administration of the drug to the patient. 
iPSC-derived cells could prevent drugs with severe cardiac side effects to enter the market. In 
addition, these cells could be used for screening against druggable targets in cells that recapitu-
late disease pathology or to determine whether a particular target contributes to the pathogenesis 
of a specific disease (Sterneckert et al., 2014).  
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In disease modeling, the combination of iPSC technology together with clinical experiments 
will help clarify the mechanisms behind the diseases and optimize treatment in a patient-specific 
manner. Thus, the iPSC disease model can be validated clinically and utilized increasingly in 
the future as a safe platform for studying therapeutic options for patients. iPSC technology is 
beneficial especially in diseases such as CPVT, which may arise from hundreds of different 
mutations, and optimal therapy is likely to be mutation or even patient specific. Therefore, stud-
ies of CPVT will likely shift from animal models to iPSC models combined with clinical trials. 
Of course, with regard to a disease with a high risk of SCD such as CPVT, arrhythmia risk pre-
diction and prevention are extremely crucial for these patients and for the pathophysiology of 
the disease, and new treatment options need to be studied further. 
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7 Conclusions and outlook 
The aim of this thesis was functional characterization of CMs and generation of a CPVT-disease 
model with iPSC-derived CMs to study, characterize and treat the arrhythmic events of these 
cells in vitro as well as to validate the results in patients in vivo. Based on the four studies pre-
sented, the following conclusions can be drawn: 
 EFS with a novel device did not enhance functional or morphological properties of 
NRCs. However, stimulation could be used for short-term pacing. Stimulation affected 
gene expression of some main cardiac proteins, suggesting that stimulation could be uti-
lized to enhance CM differentiation and maturation. 
 Using hiPSC technology, CPVT-specific iPSC lines carrying different RyR2 mutations 
could be established and differentiated into functional CPVT CMs recapitulating the 
disease phenotype observed in patients. 
 CPVT CMs carrying the P2328S mutation showed abnormalities in electrophysiology 
in the form of DADs and EADs. Novel mechanistic insight regarding EADs in CPVT 
was also evident in the index patient.  
 CPVT CMs showed defects and abnormalities in Ca2+ cycling in vitro, which in addi-
tion to drug responses, varied between different RyR2 mutations, suggesting patient- or 
mutation-specific differences in the mechanisms of arrhythmias. 
 Dantrolene showed mutation-specific antiarrhythmic effects in vivo in CPVT patients 
and iPSC-derived CPVT CMs generated from the same patients reproduced these drug 
responses. These findings illustrate the potential of iPSC models to serve as a platform 
for disease modeling and for design of personalized medication of inherited diseases.  
 A novel software for the classification of abnormal Ca2+ transient patterns detected in 
iPSC-derived CMs was developed. This tool, which was based on interactive visualiza-
tion, will facilitate and speed up the analysis of Ca2+ signals by making it more accurate 
and person-independent compared to traditional visual analysis. 
 
In conclusion, the findings in this thesis show that iPSC disease models can be used to clari-
fy the mechanisms behind the diseases and to optimize treatment in a mutation- or patient-
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specific manner. Translational studies provide important insight regarding how the iPSC-
derived CMs resemble and predict the clinical phenotype and outcomes of the patient, therefore 
helping to improve our understanding of CPVT. Most importantly, these findings give proof of 
concept about how insights gained in basic research can be translated into benefits for patients 
in clinical practice. Because the deficient Ca2+ cycling behavior in CPVT pathophysiology re-
sembles those observed in patients with HF, the results of these mechanistic findings could also 
be beneficial for patients other than those with CPVT. 
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AbstrAct
Electrical field stimulation has been shown to improve cardiac cell alignment and functional properties. 
In this study, neonatal rat cardiomyocytes were exposed to both long-term and short-term stimulation with 
the goal of investigating whether it is possible to achieve cell orientation and the maturation of cardiomyo-
cytes with a novel, microelectrode array (MEA)-compatible electrical stimulation platform. Cells were via-
ble after electrical stimulation, but no orientation or other morphological changes were observed. However, 
the electrode wires in MEA dishes affected the cell orientation. Cell contractions synchronized with pacing, 
but settled back to their original frequency in the absence of stimulation. The expression of genes encoding 
a gap junction protein connexin-43 (Cx-43), and contractile cardiac protein beta myosin heavy chain 7, was 
stronger in stimulated cells than in controls (p<0.05). In summary, the surface topography influenced to 
cardiomyocyte orientation, suggesting that the micro architecture of the biomaterials should be carefully 
designed for cell applications. However, as electrical stimulation and its duration affected gene expression of 
some main cardiac proteins, the stimulation system may prove useful to enhance the cardiac differentiation 
of stem cells. (Int J Biomed Sci 2012; 8 (2): 109-120)
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INtrODUctION
The ultimate goal in cardiac tissue engineering is to 
generate heart muscle with the morphological and func-
tional properties of natural myocardium. Pluripotent hu-
man embryonic stem cells (hESC) and human induced 
pluripotent stem cells (hiPS) can differentiate into cardio-
myocytes (CM) (14, 34), and with the help of stem cell 
technology, it could be possible to generate a tissue model 
for cardiac studies and eventually to create a graft to re-
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place damaged heart tissue. However, one major problem 
in culturing CMs has been the lack of cell orientation and 
immature phenotype.
Contractile and electrophysiological functionality as 
well as cell alignment, mechanical stability and the ex-
pression of cardiac cell markers are among the most im-
portant characteristics of engineered cardiac constructs. 
Electrical field stimulation has proposed to improve cell 
differentiation, alignment and functional properties, and is 
therefore considered a crucial parameter for the generation 
of synchronously contracting cardiac cells. Even though 
electrical field stimulation studies have been carried out 
mostly on neonatal rat CMs (NRCs), electrical fields have 
also served in the cardiac differentiation of mouse embry-
onic stem cells (27) and hESCs (28). Electrical stimulation 
has been shown to induce cell elongation (3-5, 9, 24) and 
alignment (3, 11, 24), both affecting cell functionality. In 
addition, reports indicate that electrically stimulated CMs 
have a preferred orientation in response to field stimula-
tion. Namely, it has been demonstrated that CMs are more 
excitable when the long axis of the cell is oriented parallel 
to the electrical field (30). Also, a marked level of ultra 
structural organization has been observed due to stimula-
tion by means of centrally positioned elongated nuclei and 
well-aligned registers of sarcomeres (24). As for function-
al properties, stimulation has induced regular excitation-
contraction coupling between electrical pacing signals 
and macroscopic contractions, which is necessary for the 
development of contractile behavior (9, 24). In addition, 
stimulation has induced other functional properties such 
as low excitation threshold (9), amplitude of synchronous 
contractions (24), stabilization of action potential dura-
tion (26) and an increase in the calcium current peak (6). 
Electrical stimulation has also led to enhanced calcium 
transients (12) and the development of more organized 
myofibrils (20), while stimulated CMs have demonstrated 
well-developed contractile apparatuses (3, 24). On the mo-
lecular level, electrical stimulation has induced a rise in 
myosin heavy chain (MHC) levels (24), which correlates 
with the contractile velocity of cardiac muscle (22). Elec-
trical stimulation has also increased the production of gap 
junction protein Connexin-43 (Cx-43) (4, 5, 9, 24) as well 
as expression of the cardiac genes of myosin light chain-2 
and atrial natriuretic factor (20).
Electrical stimulation has been studied with vari-
ous stimulation systems using current- or voltage-based 
stimulation. Optimization of the stimulation parameters is 
based on those found in both the developing and the na-
tive heart (i.e., in the hearts of one-week-old rats) (3, 9). 
The frequency of 1 Hz has been used because it is physi-
ological for humans and at the low end of the physiological 
regime for rats (3). In earlier studies, rat CMs have typi-
cally been stimulated with a field strength of around 5 V/
cm with monophasic or biphasic waveforms (3, 9, 12, 24). 
The main objective of this study was to investigate 
whether electrical field stimulation with our novel plat-
form could enhance CM orientation and maturation as 
well as improve functional properties. NRCs were cul-
tured as monolayers on collagen gel or gelatin-coated 
micro electrode array (MEA) chambers and stimulated. 
The cell viability, electrophysiological and morphological 
properties, as well as protein and gene expression of car-
diac cell markers were analyzed to determine the effect of 
this novel device on functional and molecular properties 
of NRCs.
MATERIALS AND METHODS
Cell culture
NRCs were chosen to this study because they are easy 
to obtain in large amounts and they provide a suited cell 
model of beating CMs. NRCs were harvested from the 
whole-hearts of two- to five-day-old rats as described 
earlier (31). The hearts were removed and enzymatically 
dissociated with collagenase type II solution and seeded 
as cell density of 282 000 cells/cm2 onto collagen gel or 
0.1% gelatin-coated MEA chambers in Culture Medium I 
[CMI, Dulbecco’s Modified Eagle’s Medium/Ham’s Nutri-
ent Mixture F12 (DMEM/F-12, Sigma-Aldrich, Germany), 
10% Fetal bovine serum (FBS, Gibco, Finland), 100 IU/
ml Penicillin/ 0.1 mg/ml Streptomycin (P/S, Gambrex, Bel-
gium), 2.56 mM L-glutamine (Sigma-Aldrich, Germany)]. 
After first day and thereafter cells were precultured in 1 ml 
of Complete Serum Free Medium [CSFM, DMEM/F-12, 
10% Bovine serum albumin (BSA, Sigma-Aldrich, Ger-
many), 2.8 mM Sodium Pyruvate (Cambrex, Belgium), 
2.56 mM L-glutamine, Insulin-transferrin-sodium selenite 
media supplement (ITS, Cambrex, Belgium; 1 µM insulin, 
5.64 µg/ml transferring, 32 nM selenium), 100 IU/ml P/ 0.1 
mg/ml S, 0.1 nM 3,3’,5-Triiodo-L-thyronine sodium salt 
(T3, Sigma-Aldrich, Germany)] in a 37°C/5% CO2 to allow 
the cells to attach to MEA chambers. Culture medium was 
changed every or every second day. Cells serving as con-
trols were cultured in the same way as electrically stimu-
lated cells were. The animals were sacrificed according to 
guidelines of the Animal Unit, Medical School, University 
of Tampere and the Ethical Committee of the Animal Unit 
has accepted the method to obtain the cells.
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Collagen gel
The collagen was isolated from adult Sprague Daw-
ley rat tails (10) and stored at -20°C. In brief, tails were 
thawed and cut into pieces, the skin was then removed, 
and the collagen fibers were pulled out and placed into 
0.1% acetic acid. The fibers were dissolved into acetic 
acid, and the collagen was precipitated with 25 v-% sodi-
um chloride. The solution was then centrifuged, and the 
collagen pellet was again dissolved in 0.1% acetic acid. 
To balance the salinity, the solution was dialyzed at 4°C. 
Finally, the concentration of the collagen was determined 
with a Pierce® BCA Protein Assay kit (Thermo Scien-
tific, USA) using BSA as the standard. The concentration 
was 1.043 mg/ml.
The gelation of the collagen (19) was performed as 
described earlier, with some modifications. At first the 
collagen solution was placed on ice, and two different 
neutralizing buffers [12 mg/ml NaHCO3 (Sigma-Al-
drich, Germany) in 0.1 N NaOH (Merck, Germany) and 
1.3 M NaCl (Baker, the Netherlands) in 0.2 M Na2HPO4 
(Baker, the Netherlands)] were added. The solution was 
then incubated at 37°C for 30 min to allow for gel for-
mation.
Electrical stimulation setup
The in-house designed and developed system com-
prised three parts: electronics for stimulation waveform 
generation and amplification, an MEA dish container with 
electrodes, and stimulation software running on a PC lap-
top (Figure 1A and 1D). The functionality of the system 
was tested electrically, and its effects on the cells were ob-
served with a microscope.
The electrode holder manufactured from polymethyl 
methacrylate also worked as a container and was designed 
to serve as a petri-dish as well. The container was de-
signed to house six MEA dishes. For each MEA dish, two 
10-mm-wide stainless steel plate electrodes were placed 5 
mm apart to create a homogeneous field for stimulation. 
The electrode setup and the stimulus field were simulated 
with the finite element method using Comsol Multiphysics 
software to assess the homogeneity of the field across the 
whole cell culture (Figure 1B and 1C). To ensure that the 
stimulation field is as uniform as possible, the electrodes 
were set to 0.5 mm from the bottom. Air exchange was 
enabled via a small space between the container and the 
lid, which was designed to feature a 10 mm protruding rim 
to keep the container closed. To counteract evaporation, 
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Figure 1. (A) The stimulation system. The stimulation sequence is designed with PC software that controls the NI USB-6008 DAQ 
device. The waveform that the device produces is amplified and delivered to the MEA container, where the cells reside on MEA dishes; 
(B, C) The simulated result of the electrical field on an MEA dish; (B) If the cells to be stimulated are placed on the MEA electrodes 
in the middle of the MEA dish, they will experience a fairly uniform 500 V/m electrical field. The image is plotted at the height of 0.1 
mm; (C) A lateral view from the center line shows that the electrical field diminishes at the bottom of the MEA close to the electrodes. 
The MEA dish has been included in the simulation as an insulator at the bottom; (D) The designed stimulation system, consisting of the 
stimulation electronics, PC, and the MEA dish container; the MEA dish container appears in detail on right, with an individual electrode 
shown in detail at the bottom.
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the bottom part of the container was designed to provide 
pools for sterile water. The lid and the bottom part fea-
tured small glass windows which allow the user to observe 
the cell cultures on the MEAs with a microscope.
The electronics of the system were designed to yield a 
field strength of at least 5 V/cm, as similar field strengths 
had proved effective (23). The electronics consisted of a 
single-sided supply operational amplifier circuit which 
amplifies the signal created by a PC-controlled National 
Instruments USB-6008 Data Acquisition (DAQ) device 
and produces a voltage-based stimulus. The system was 
designed to be USB powered. The user can set the stimula-
tion voltage, frequency, total stimulation time, pulse dura-
tion, and delays between pulses. The software allows users 
to design stimulation waveforms, thus enabling them to 
use uncommon pulse shapes. The system produces elec-
trical fields with a maximum of 5.3 V/cm and an output 
frequency ranging from 0.5 to 40 Hz. The shortest pulses 
produced were 2 ms wide. Two clips and wiring connected 
the electronics to the electrodes. Waveform production 
using the DAQ device was controlled with the software, 
which allows the user to adjust the required stimulation 
parameters and to queue different stimulation sequences. 
The electrical output of the stimulator, from both the 
stimulation electrodes and the MEA electrodes, was veri-
fied with an oscilloscope. In addition, the effect of stimu-
lation on medium pH levels was measured with pH elec-
trode (AMANI-1000, Innovative Instruments, Inc, Tampa, 
USA) from stimulated and control samples after a long-
term stimulation with the same parameters used in experi-
ment I (Table 1). 
Stimulation protocols
Pacing experiment. Delivery of the stimulation pulses 
to the cells and the effect of stimulation on the cell culture 
and beating frequency was tested by observing the behav-
ior of NRCs with a microscope (Olympus IX51, Olympus 
Corporation, Tokyo, Japan). The cells were seeded on gel-
atin-coated MEA chambers and paced for 20 s with both 
monophasic and biphasic pulses at 2.5 and 5 V/cm and a 
frequency of 1, 2, and 3 Hz with pulse durations of 2 ms, 
4 ms, and 10 ms.
Long-term stimulation. After preculture, MEA 
chambers were transferred to the stimulating chamber. 
The cells were cultivated for 48 to 72 h without electrical 
field stimulation in order to allow the cells to attach; elec-
trical field stimulation followed for an additional 48 to 72 
h using either monophasic or biphasic pulses at 5 V/cm or 
5.3 V/cm with 2 ms, 4 ms or 200 ms pulse durations and a 
frequency of 1 Hz (Figure 2). Constructs cultured without 
electrical stimulation served as controls. There were four 
independent experimental series and three to six samples 
in both the stimulation and control groups within each ex-
perimental series. Electrical field stimulation stopped on 
days 4 to 6, and cells were processed either for live/dead 
staining, immunocytochemistry, or for RNA isolation. 
More detailed information on each experimental series 
appears in Table 1.
Electrophysiology - microelectrode array (MEA)
The electrical activity of beating NRCs was monitored 
using the microelectrode array (MEA) system (Multi 
Channel Systems MCS GmbH, Reutlingen, Germany). 
Measurements were made of cells on gelatin coating at 
37°C, and signals were recorded for 2 min via every mi-
croelectrode. The sampling frequency was 20 kHz. Signals 
were measured before and after stimulation from the first, 
second, and third experimental samples, and in addition, 
signals from the second experimental samples were meas-
ured twice during the stimulation period. Signals from the 
control samples were measured at the same time points.
Cell stainings
Live/dead staining. CMs were live/dead stained using 
a LIVE/DEAD® Viability/Cytotoxity kit for mammalian 
cells (Molecular Probes, Inc., Invitrogen, USA). Staining 
Table 1. Experimental groups
Pulse form Pulse duration Electrical field Frequency Duration of stimulation Culture material na
Experiment I Biphasic 100 ms / 100 ms 5.3 V/cm 1 Hz 3 d 2D-coating 3/3
Experiment II Biphasic 2 ms / 2 ms 5.3 V/cm 1 Hz 2 d 2D-coating 3/5
Experiment III Monophasic 2 ms 5 V/cm 1 Hz 3 d 2D-coating 4/5
Experiment IV Monophasic 2 ms 5 V/cm 1 Hz 3 d collagen gel 6/6
aControl/stimulated samples.
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was carried out according to Molecular Probes’ instruc-
tions. 0.1 µM Calcein AM staining live cells green and 
being seen at wavelength of 488 nm and 0.5 µM Ethidium 
homodimer-1 staining dead cells red and being seen at 
wavelength of 568 nm were added to the culture medium 
and incubated at room temperature. The labeled cells were 
viewed and photographed with a Nikon Eclipse TE2000-S 
phase contrast microscope with fluorescence optics and a 
Nikon COOLPIX 5400 camera.
Immunocytochemistry. The cells were fixed in MEA 
chambers with 4% PFA in phosphate-buffered saline (PBS) 
(0.01 M, pH7.4) for 20 min at room temperature (RT), fol-
lowed by washing with PBS (2 × 5 min). The cells were 
then permeabilized and blocked with 0.1% Triton X-100, 
1% BSA (Sigma-Aldrich, Germany), and 10% normal don-
key serum (Sigma-Aldrich, Germany) in PBS for 45 min at 
RT. Primary antibodies anti-troponin I (Santa Cruz, USA) 
(1:500) and anti-cardiac troponin T (Abcam, UK) (1:1500) 
were incubated overnight at 4°C. Alexa Fluor 568-conjugat-
ed donkey anti-goat served as a secondary antibody (1:800) 
(Invitrogen, USA) and finally the cells were mounted with 
Vectashield (Vector Laboratories, USA) containing 4’,6-di-
amidino-2-phenylindole (DAPI) for staining nuclei. 
RT-PCR
Total RNA was isolated with a NucleoSpin® RNA II kit 
(Macherey-Nagel GmbH & Co., Germany). The concentra-
tion and quality of the RNA was monitored spectroscopical-
ly (Nanodrop, Wilmington, DE, USA) and 100 ng of total 
RNA was transcribed to cDNA in a total volume of 20 µl 
with a High Capacity cDNA Reverse Transcription kit (Ap-
plied Biosystems, USA). The PCR reaction consisted of 1 µl 
cDNA, 24 µl of 2 × PCR Mastermix (Applied Biosystems, 
USA), and 200 nM of each primer. The expressions of three 
cardiac markers were evaluated: alpha myosin heavy chain 
6 (MYH-6), beta myosin heavy chain 7 (MYH-7), and con-
nexin 43 (Cx-43). GAPDH served as a housekeeping gene 
and calibrator of all cells (Primers: Table 2).
Quantitative RT-PCR
Quantitative RT-PCR was performed according to the 
standard protocols on an Abi Prism 7300 instrument (Ap-
plied Biosystems, Foster City, CA, USA). Total RNA was 
isolated as described above. Complementary DNA was 
synthesized from 200 ng of total RNA in a total volume 
of 20 µl as described above. The PCR reaction consisted 
of 1 µl cDNA, 7.5 µl of 2 × Power SYBR green PCR mas-
Figure 2. Experimental design. (A) Experimental groups for long-term stimulation where NRCs were cultured either on gelatin coat-
ing (1-3) or on collagen gel (4). Parameters used for electrical stimulation were biphasic 100-ms square pulses at 5.3 V/cm and 1 Hz (1), 
biphasic 2-ms square pulses at 5.3 V/cm and 1 Hz (2), and monophasic 2-ms square pulses at 5 V/cm and 1 Hz (3 and 4). (B) Experimental 
timelines for each stimulation group. Control samples were cultured for the same amount of time, but without electrical stimulation. CS, 
cell seeding; EFS, electrical field stimulation initiation; END, experimental ends.
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termix (Applied Biosystems, Foster City, CA, USA), 5.3 
µl sterile water, and 400 nM of each primer, which were 
for the same markers as those in RT-PCR (Table 2). Each 
experiment group was analyzed separately and at least two 
replicates between both the stimulated and control groups 
were analyzed as triplicates. Cτ values were determined 
for every reaction, and the relative quantification was de-
fined with the 2-ΔΔCτ method (18). The data were normal-
ized to the expression of the housekeeping gene Beta actin 
(β-actin), and the unstimulated sample for each test series 
served as the calibrator. Statistical significance for each 
experiment group was determined with the t-test.
Atomic force microscopy
Atomic force microscope (AFM) (XE-100, Park Sys-
tems, Korea) with ACTA-50 probe was used in studying 
the surface of the MEA dish. AFM images of an empty 
MEA surface were obtained by moving the probe on the 
sample surface across the measurement area in one direc-
tion for each image line in order to create a topographical 
map of the sample (7).
RESULTS
Stimulator capabilities
The designed system, consisting of the MEA con-
tainer, stimulation electronics, and the controlling soft-
ware on a laptop computer, fulfilled the requirements set 
for the device. To our knowledge, the resulting system 
is among the first systems to enable the use of the MEA 
platform in long-term electrical stimulation with homo-
geneous fields.
The difference of medium pH levels in control and stim-
ulated samples after long term stimulation was 0.10% sug-
gesting stimulation had no effect on pH levels. There were 
either seen no degradation of the electrodes or any possible 
gas formation during the different stimulation protocols.
Cardiomyocyte function in a short-term pacing experiment
The effect of short-term stimulation on cell beating 
was characterized by a pacing experiment in which dif-
ferent stimulation parameters were applied and the pacing 
of the cells observed visually with a microscope. Initially, 
the beating rate was about 60 per minute. As the stimula-
tion stopped, beating returned to its original, spontaneous 
frequency, so the cells did not remain in the paced rhythm 
after stimulation (data not shown). Visually, the pulse du-
ration or pulse form had no effect on cell beating. When 
the electrical field was 5 V/cm, the beating was stronger 
than with the smaller 2.5 V/cm field. 
Cell morphology
In the long-term stimulation, cells in experiments I, II, 
and III (Table 1) were electrically stimulated on gelatin-
coated MEA chambers with different parameters (Figure 
2). Different parameters based on earlier publications (3, 
9, 24) were tested to try to find the optimal parameters for 
NRC stimulation. The morphology of NRCs was the same 
during stimulation, and both stimulated and control cells 
exhibited similar morphological features throughout the ex-
Table 2. Primer sequences
Gene Forward Primer Reverse Primer Size (bp)
RT-PCR
GAPDHa TGGAAAGCTGTGGCGTGATG TCCACCACCCTGTTGCTGTAGC 380
MYH6a (alpha myosin heavy chain 6) GGAAGAGCGAGCGGCGCATCAAGG CTGCTGGACAGGTTATTCCTCA 304
MYH7a (beta myosin heavy chain 7) GCCAACACCAACCTGTCCAAGTTC TCAAAGGCTCCAGGTCTCAGGGC 201
Cx-43a (connexin 43) CATTGGGGGGAAGGCGTGAGG AGCGCACGTGAGAGATGGGGAAG 401
Q-PCR
β-actinb (beta actin) TAAAGACCTCTATGCCAACAC GATAGAGCCACCAATCCAC 166
MYH6c (alpha myosin heavy chain 6) TTCCGCAAGGTGCAGCACGAG TCCTCATCGTGCATTTTCTGCTTGG 125
MYH7c (beta myosin heavy chain 7) TTCCGCAAGGTGCAGCACGAG TACTCTTCATTCAGGCCCTTGGCGC 122
Cx-43b (connexin 43) GTTCTATGTGATGAGGAAGG ACTTCTTGATTTCAATCTGC 116
a, bPrimers have been described earlier (24), (9), respectively;  cPrimers have been made with Primer-BLAST of NCBI.
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perimental period. The cells were not elongated or oriented 
parallel to the electrical field. Instead, the orientation of the 
cells was seen parallel to the MEA electrode wires in both 
the control and stimulation samples (Figures 3A and 3B). 
An equal number of cells were plated on each well, and the 
number of cells decreased similarly during the culture in 
both the control and stimulated samples. The time in culture 
also affected the beating frequency, which was evident both 
microscopically and in MEA measurements as a decrease 
in the beating rate (Figures 4A and 4B).
In experiment series IV, CMs were cultured on collagen 
gel (Figures 3C and 3D). The cells contracted nicely and 
were well spread over the surface of the gel. After three 
days of stimulation, cell orientation appeared unaltered. 
Microscope analysis revealed that cells in the control and 
stimulation samples were similarly shaped. In both the 
control and stimulated samples, long tube-like structures 
(Figure 3C and 3D) were observed on the collagen gel in 
addition to cardiac cells.
Electrophysiology
We monitored the electrical activity of both stimulated 
and control NRCs with MEA. The spontaneous beating rate 
varied between 0.5 and 2 Hz, and was usually 1.0 Hz (Fig-
ures 4A and 4B). After stimulation, the cells either stopped 
beating or the beating rate was more irregular than before 
stimulation; this was also evident in the controls after exper-
iment. In experiment II, the signals were measured before 
stimulation and 5, 24, and 48 hours after stimulation. The 
control samples were measured at the same time points. The 
beating rate decreased both in stimulated and control groups 
(Figure 4A and B), but less radically than in experiments I, 
III and IV. The beating was more irregular in the end of the 
experiment than in the beginning (Figure 4A and 4B).
Figure 3. Cell viability. In addition to cell viability, the ori-
entation of NRCs on gelatin coating parallel to the electrode 
lines of the MEA chambers is evident in the live/dead stainings 
(live cells green, dead cells red) in both control (A) and stimu-
lated (B) samples. The tube formation of cells on collagen gel 
in experiment IV is clearly evident from the live/dead stainings 
in both control (c) and stimulated (D) samples. Arrows denote 
tube-like structures, which were observed in both stimulated 
and control samples. The direction of the electrical field is hori-
zontal in the pictures. Scale bars are 200 µm.
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Figure 4. Functional properties of long-term stimulated NRCs. 
Electrical activity of control NRCs (A) and stimulated samples 
(B) in experiment II before stimulation (1) and after 5 hours 
(2), 24 hours (3), and 48 hours (4) of stimulation. (C) Cx-43, 
MYH-6, and MYH-7 expressions from each experiment deter-
mined by qPCR at the end of culturing. Statistical significance 
is marked with (*p<0.05). Number of control vs stimulated 
samples analyzed as triplicates: Exp. I n=2 vs n=3, Exp. II n=3 
vs n=4, Exp. III n=2 vs n=2, Exp. IV n=3 vs n=3. Error bars are 
SD. (D) Gene expressions from each experiment determined 
by RT-PCR at the end of culturing. S, electrically stimulated 
samples; C, control samples.
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MEA measurements could not be carried out on cells 
on collagen gel due to the thickness of the gel, so the beat-
ing was observed only visually with a microscope. Before 
stimulation, the beating rate of the cells on the gel was 
regular, contractions were clearly observed, and the gel 
adjusted to the beating. Although the size of the beating 
area differed between replicates, overall the beating was 
the same when compared to the samples on gelatin coat-
ing. After stimulation, beating areas were fewer in num-
ber and smaller in size, and the beating frequency in both 
sample groups decreased. 
Cell viability
Cell viability was determined after each experimental 
series. Live/dead staining indicated that there were no dif-
ferences in cell viability between the stimulated and con-
trol samples (Figures 3A, 3B, 3C, and 3D) and roughly 50 
% of the cells were alive in both conditions. In addition, 
cell alignment and elongation was more distinguishable 
with the help of live/dead staining, but we observed no 
changes due to stimulation. Instead, the orientation of the 
cells on gelatin coating was parallel to the MEA chamber 
electrode wires in both the control and stimulation sam-
ples (Figures 3A and 3B). The orientation was very clear in 
experiment II, and cell alignment was precisely paralleled 
the direction of the electrode wires.
With the help of live/dead staining, we observed the 
tube-like structures from the collagen gel samples. Tubes 
were present in every collagen gel sample (Figures 3C and 
3D) and showed no orientation in any specific direction.
Gene expression
According to the RT-PCR results, the MYH-7 mRNA 
level was higher in the 3-day stimulation experiments (I, 
III, and IV) than in the control samples. Cx-43 expres-
sion levels were also slightly elevated in these stimulated 
samples, but in other genes no differences were evident 
(Figure 4D).
To ensure the difference in gene expression levels, 
quantitative RT-PCR was carried out for the same samples 
as used in RT-PCR. Stimulation increased MYH-7 and 
Cx-43 expression levels in experiments I and IV (p<0.05) 
when compared to controls (Figure 4C). In experiments II 
and III, MYH-7 and Cx-43 expression levels had a trend 
towards higher expression, but it did not reach statistical 
significance. No significant difference in MYH-6 expres-
sion between the control and stimulated samples was ob-
served in any experiment.
Protein expression
Immunocytochemistry served to identify CM struc-
tures. The stimulated cells stained positively with troponin 
T or I similarly to the controls (Figure 5). The stimulated 
CMs revealed no visible changes in sarcomeric structure. 
In experiment IV, narrow and long tube-like struc-
tures formed during culture on collagen gel. The tubes 
were analyzed with antibodies against Vimentin (mesen-
chymal origin: fibroblasts, endothelial, smooth muscle), 
α-AS (myotubes in skeletal and cardiac muscles), α-SMA 
(smooth muscle), VWf1 (endothelial), VWf2 (endothelial), 
Pax-6 (neural) and MAP-2 (neural), however, no positive 
staining with any antibodies used was seen (13). Since 
the origin of tubes were not neural, vascular or muscle-
derived the nature of the tubes remains unknown. 
Surface measurement using AFM
To estimate the effect of surface abrasions on the ori-
entation of cells, AFM served to measure the height of the 
Figure 5. Expression of troponin T (red) in control (A) and in stimulated (b) samples; blue 
indicates cell nuclei (scale bars 200 µm).
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electrode wires on an MEA dish. The results revealed that 
the electrode wires on the MEA had a height of 600 nm 
(Figure 6).
DIscUssION
A novel platform for the electrical stimulation of cells 
was designed in this study. When compared with other 
existing systems for cell culture stimulation, the designed 
system provides several possibilities which to our knowl-
edge can not all be found in other stimulation platforms: 
the possibility to stimulate several cell cultures, homoge-
neous long term electrical field stimulation on MEAs and 
programmable stimulation platform. In some earlier stud-
ies MEAs have been used (8, 16), which have the capabil-
ity of localized electrical stimuli. However in studies with 
goal of creating a uniform field, carbon rod electrodes have 
been more widely used (3, 12, 24) together with commer-
cial cell containers like plates, wells and dishes (3, 12, 24). 
In waveform creation commercial stimulators are used in 
several studies (3, 11, 24). 
The main objective was to examine whether electrical 
field stimulation affects synchronous cell contractions 
and cell alignment, the maturation or functional assem-
bly of CMs. In the present study, stimulation was initi-
ated on either the second or third day after plating. This 
arrangement was based on previous findings (24), which 
indicate that if applied on the first day in vitro, electrical 
stimulation yields poor contractile behavior. In contrast, 
if stimulation was applied on day five, fewer contractile 
proteins were found in the cells (24). This timing also 
ensured that the cells had enough time to recover from 
the cell isolation procedure and to attach properly to the 
MEA chambers prior to stimulation. In the present study 
both monophasic and symmetric biphasic square pulses 
were used. A previous study has reported that the use 
of biphasic pulses in applications of electrical stimula-
tion maintains biocompatibility better by avoiding tissue 
injury or electrode damage (25). Biphasic pulses mini-
mize the damage caused by electrodes as a result of the 
redox reaction on the electrodes, which leads to tissue 
damage due to pH and metal salts released in the process 
(25). Biphasic pulses have also been reported to enhance 
the positive effects of electrical stimulation with regard 
to functional and structural properties (9). However, we 
saw no differences between biphasic and monophasic 
pulses in our set-up.
In the pacing experiments the stimulator served to 
pace NRCs and in the absence of stimulation the beat-
ing returned back to spontaneous rhythm. When the 
field strength was 2.5 V/cm, the cells failed to contract as 
uniformly as with the higher 5 V/cm fields, thus demon-
strating the efficacy of the system. Previous studies have 
shown that the higher the field strength, the more likely the 
cell will reach the depolarization threshold and contract in 
response to the stimulus (3).
Figure 6. An AFM surface scan of the MEA electrode wiring. The scan shows the height of the electrode wirings to be approximately 
600 nm. The height was determined by averaging the height profile from an 8-µm-long wiring track.
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The benefit of the new stimulation system is its poten-
tial to stimulate cells in MEA chambers and measure the 
electrical activity of cells both before and after stimula-
tion. In the long-term experiments, the beating rate de-
creased in all samples. The detachment of the cells affect-
ed negatively on the spontaneous beating rate which might 
be due to the loss of the cell-to-cell contacts necessary for 
signal induction. CMs isolated from the heart and cultured 
in vitro are known to dedifferentiate and eventually stop 
beating (21). They also lose many of their surface channels 
and receptors (2), myofilament equipment, and acquire a 
round shape (35). All these factors may lower the beating 
rate, which was evident in the MEA measurements. Pre-
vious studies indicate that the number of spontaneously 
beating cells decreased to 8% after eight days in vitro and 
no spontaneous beating was observed in the stimulated 
samples, but the beating could be triggered by external 
stimulus (26). 
Live/dead staining revealed that there were no signifi-
cant differences in cell viability between the stimulated 
and control samples. In earlier studies, the cells were shown 
to elongate, couple, and orientate parallel to the electrical 
field (3, 11, 24) using either a direct (3) or an alternating 
current field (11). In the present study no such morpho-
logical changes in the cells were observed. However, no 
changes in cell morphology during electrical stimulation 
has also reported earlier (26). Collagen gel could also pro-
vide a more elastic surface to enable cell orientation. How-
ever, we found no improvement in the stimulation results, 
but the cells spread nicely and migrated within the gel, and 
the gel allowed the cell beating. 
In the present study, cells were oriented parallel to the 
MEA chamber electrode wires in both the control and 
stimulation samples, so the topography of the cell culture 
surface was a determinant of cell orientation. The AFM 
results showed that the electrode wires on the MEA have a 
height of 600 nm. Previous studies have shown that topo-
graphical cues of a height of several hundred nanometers 
are sufficient to induce cell orientation (3, 4, 15). Au et 
al. used topographical cues from 140 to 700 nm of height 
(3) as well as microgrooves of 400 nm (4) which were all 
capable of inducing cellular orientation. Kim et al. used 
nanoscale cues from 200 to 500 nm in height, and these 
affected the structure and function of cardiac tissue con-
structs (15). Our findings support those earlier observa-
tions that the surface topography is a stronger factor than 
the electrical field with regards to cell orientation; once 
cells have orientated towards topographical shapes, they 
cannot re-orient with electrical stimulation (3, 4). We can 
therefore conclude that when aiming at cell orientation, it 
is more worthwhile to model and improve the topography 
of the cell substrate than to use electrical field stimulation.
Previous studies have shown that electrical field 
stimulation influences CM functionality (9, 24, 26). Cx-
43 molecules form gap junctions, which are intercellular 
channels located in the intercalated disc and provide both 
electrical and metabolic coupling for CMs (33). Cx-43 is 
expressed in virtually all myocytes of the atrial- and ven-
tricular mammalian myocardium regardless of the stage 
of development (33). According to the qPCR analysis in 
our study, the expression level of Cx-43 was significantly 
higher in two stimulation experiments when compared 
to the controls. This is in line with earlier studies where 
the expression of Cx-43 increased on both the gene and 
protein levels due to electrical field stimulation (3, 9, 24). 
MHC is the major contractile protein of cardiac mus-
cle cells and the primary determinant of the efficiency 
of muscle contraction (32). MHC genes exist in cardiac 
cells in two isoforms: α-MHC encoded by the MYH-6 
gene, which is upregulated during adult cardiac devel-
opment, and β-MHC by the MYH-7 gene, which is up-
regulated during fetal cardiac development (22). In this 
study, the gene expression level of MYH-7 increased af-
ter three days of stimulation, which suggests an increase 
in the fetal type of cardiac cells due to electrical stimula-
tion. Stimulating the CMs for two days instead of three 
showed no differences in MYH-7 expression, which may 
indicate that stimulation should last at least three days to 
ensure perceptivity of the effects of stimulation. These 
results are in line with previous studies where the ex-
pression of sarcomeric proteins MYH-6 and MYH-7 
increased due to electrical stimulation and its duration. 
However, in the earlier reports the ratio of these two 
isoforms has changed indicating maturation of the CMs 
(24). We did not observe this in our study. Other stud-
ies have shown that the mRNA level of MYH-7 in CMs 
derived from hESCs is substantially higher in ventricular 
tissue (1) which has also been observed in rat hearts (29). 
This could indicate that most isolated and cultured NRCs 
were ventricular, and therefore only MYH-7 expression 
increased. One reason for the increase in MYH-7 expres-
sion could be the mechanical stress, in this case due to 
electrical stimulation, which in earlier studies induced a 
shift from α-MHC toward β-MHC composition in mice 
hearts (17). This shift could reduce contractile efficiency, 
and therefore be one reason for the lower beating rate ob-
served in this study.
As a conclusion our data suggest that surface topog-
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raphy was a stronger determinant of CM orientation than 
electrical field stimulation; consequently, the micro ar-
chitecture of the materials should be examined carefully 
when cell orientation is desired. Electrical stimulation and 
its duration seem to affect gene expression profile, and 
this stimulation system may prove useful in the future, for 
example, to enhance cardiac differentiation of stem cells. 
Our stimulation platform proved capable of pacing cul-
tured cells, and this property can be exploited in various 
cardiac-related studies requiring the electromechanical 
stimulation of cardiac cells. However, we did not detect 
any long-term effects of electrical stimulation on the elec-
trophysiological behavior of the cells even though stimula-
tion increased Cx-43 expression. In the future, it would 
be important to optimize the stimulation parameters to 
improve the maturation process and to understand the ef-
fect of these parameters at the cellular level. It would also 
be important to understand better the mechanism of how 
electrical stimulation influences cell differentiation and 
maturation and to discover effective ways to quantify this 
phenomenon at the cellular level.
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Abstract
Background: Induced pluripotent stem cells (iPSC) provide means to study the pathophysiology of genetic disorders.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a malignant inherited ion channel disorder predominantly
caused by mutations in the cardiac ryanodine receptor (RyR2). In this study the cellular characteristics of CPVT are
investigated and whether the electrophysiological features of this mutation can be mimicked using iPSC -derived
cardiomyocytes (CM).
Methodology/Principal Findings: Spontaneously beating CMs were differentiated from iPSCs derived from a CPVT patient
carrying a P2328S mutation in RyR2 and from two healthy controls. Calcium (Ca2+) cycling and electrophysiological
properties were studied by Ca2+ imaging and patch-clamp techniques. Monophasic action potential (MAP) recordings and
24h-ECGs of CPVT-P2328S patients were analyzed for the presence of afterdepolarizations. We found defects in Ca2+ cycling
and electrophysiology in CPVT CMs, reflecting the cardiac phenotype observed in the patients. Catecholaminergic stress led
to abnormal Ca2+ signaling and induced arrhythmias in CPVT CMs. CPVT CMs also displayed reduced sarcoplasmic reticulum
(SR) Ca2+ content, indicating leakage of Ca2+ from the SR. Patch-clamp recordings of CPVT CMs revealed both delayed
afterdepolarizations (DADs) during spontaneous beating and in response to adrenaline and also early afterdepolarizations
(EADs) during spontaneous beating, recapitulating the changes seen in MAP and 24h-ECG recordings of patients carrying
the same mutation.
Conclusions/Significance: This cell model shows aberrant Ca2+ cycling characteristic of CPVT and in addition to DADs it
displays EADs. This cell model for CPVT provides a platform to study basic pathology, to screen drugs, and to optimize drug
therapy.
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Introduction
Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is a severe inherited cardiac disorder characterized by
stress-induced polymorphic ventricular tachycardia in a structur-
ally normal heart. Approximately 30% of CPVT patients have
symptoms before the age of 10 and the mortality rate is 30–35%
by the age of 30. b-blockers are recommended for CPVT, but this
treatment often fails to prevent even fatal arrhythmias [1].
CPVT is caused by mutations in the cardiac ryanodine receptor
(RyR2) or calsequestrin (CASQ2) gene. RyR2 is involved in the
release of calcium (Ca2+) from the sarcoplasmic reticulum (SR) and
thus plays a key role in excitation-contraction coupling. Calse-
questrin is a regulatory calcium-buffering protein associated with
RyR2 in the SR. RyR2 mutations can be detected in about 70% of
patients with CPVT. These mutations are thought to result in
increased release, or leak, of Ca2+ from the SR potentially leading
to diastolic oscillations of intracellular Ca2+, delayed afterdepolar-
izations (DAD), and polymorphic ventricular tachycardia [1].
However, our understanding of the detailed pathophysiology
behind CPVT remains incomplete.
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e44660
Although the pathomechanisms have been clinically studied in
CPVT patients with exercise stress tests, genetically engineered
mouse models have been significant to the understanding of
CPVT. Most of the CPVT-studies related to RyR2 mutations have
been performed in autosomal dominant transgenic knock-in
mouse models expressing mutations which have shown Ca2+ -
mediated arrhythmogenesis [2].
Induced pluripotent stem cell (iPSC) technology where plurip-
otent stem cells are generated by reprogramming differentiated
cells into a pluripotent state provides a way to study the
pathophysiology of various disorders in human cells. iPSCs can
be differentiated into the desired cell type, retaining the original
genotype. Recently CPVT-specific iPSCs -derived cardiomyocytes
(CMs) from individuals carrying RyR2 mutations [3,4] have
demonstrated DADs as the electrical abnormalities.
The P2328S mutation in RyR2 has been found in families with
CPVT. Here we introduce a functional cell model for CPVT
caused by this mutation. We investigated the mechanistic
characteristics of this disease in vitro using iPSC –derived CMs.
Importantly, we demonstrate the presence of EADs in addition to
DADs as a pathophysiological mechanism of CPVT.
Methods
Generation of Patient-Specific iPSCs
The study was approved by the ethical committee of Pirkanmaa
Hospital District (R08070) and written informed consent was
obtained from all the participants. Patient-specific iPSC lines were
established as described earlier [5]. Two CPVT-specific iPSC lines
(UTA.05203.CPVT and UTA.05208.CPVT) were generated
from a 25-year-old male carrying a RyR2-P2328S mutation. iPSC
lines UTA.00112.hFF (derived from foreskin fibroblasts) and
UTA.04602.WT (from skin fibroblasts of a healthy 55-year-old
female) were used as controls.
Characterization of iPSC Lines
Genotyping. The RyR2-P2328S mutation was assayed with
PCR amplification of genomic DNA with primers for RyR2 exon
46 (forward: ttt gtt tac tta tct tcc cca ttc, reverse: tat gga tca ctc gtg
agg gt) and HaeIII digestion (New England Biolabs, Ipswich, MA,
USA). DNA for wild type was 170 and 87 and for P2328S
heterozygote 257, 170 and 87 base pairs long. For confirmation of
the mutation by direct sequencing, the RyR2 exon 46 PCR
products were sequenced with BigDye Terminator v3.1 and ABI
3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA).
Karyotype analysis. Karyotypes of the cell lines were
determined using standard G-banding chromosome analysis
(Medix laboratories, Espoo, Finland).
Reverse transcription polymerase chain reaction (RT-
PCR). Endogenous and exogenous gene expressions were
studied from iPSCs by RT-PCR. The PCR reaction consisted of
1 ml cDNA and 500 nmol/L of each primer. PCR primers for
iPSC characterization and detailed reaction conditions have been
described earlier [5]. b-actin served as a housekeeping gene.
Immunocytochemistry. The iPSCs were fixed with 4%
paraformaldehyde (Sigma-Aldrich, Saint Louis, USA). Primary
antibodies anti-SOX2, anti-NANOG, anti-stage-specific embry-
onic antigen (SSEA)4, and anti-tumour-related antigen (TRA)1–
81 (all 1:200, from Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-OCT3/4 (1:400, R&D Systems) and anti-TRA1–60
(1:200, Millipore) were used. Cells were mounted with Vectashield
(Vector Laboratories, USA) containing 49, 6-diamidino-2-pheny-
lindole (DAPI) for staining nuclei.
Embryoid body (EB) formation. EBs were maintained in
EB-medium (KO-DMEM with 20% FBS, NEAA, L-glutamine
and penicillin/streptomycin) for 5 weeks. The expression of
markers characteristic of ectoderm (Nestin), endoderm (AFP), and
mesoderm (a-cardiactin) development in EBs were studied (primers
in Table 1).
Teratoma formation. The study was approved by ELLA-
Animal Experiment Board of Regional State Administrative
Agency for Southern Finland (ESAVI/6543/04.10.03/2011).
iPSCs were injected into nude mice under the testis capsule and
tumor samples collected 8 weeks after injection. This was followed
by fixation with 4% paraformaldehyde and staining of the sections
with haematoxylin and eosin.
Cardiomyocyte Differentiation and Characterization
Differentiation into cardiomyocytes (CMs) was carried out by
co-culturing iPSCs with murine visceral endoderm-like (END-2)
Table 1. Primer sequences for RT-PCR.
Gene Forward Primer Reverse Primer GenBank ID
Endodermal
AFP AGAACCTGTCACAAGCTGTG GACAGCAAGCTGAGGATGTC 174
Ectodermal
Nestin CAGCTGGCGCACCTCAAGATG AGGGAAGTTGGGCTCAGGACTGG 10763
Mesodermal
a-cardiactin GGAGTTATGGTGGGTATGGGTC AGTGGTGACAAAGGAGTAGCCA 70
Ca2+ cycling
RyR2 TAGATTTATAAGGGGCCTTG GATTCTTCAGGGCTCGTAGT 6262
Cav1.2 TGACATCGAGGGAGAAAACT ACATTAGACTTGACTGCGGC 775
Serca2a GAGAACGCGCACACCAAGA TTGGAGCCCCATCTCTCCTT 488
Phospholamban CTGCCAAGGCTACCTAAAAG AGCTGAGCGAGTGAGGTATT 5350
NCX TTCCAGAATGATGAAATTGTGAAGAT TCCTCAAGCACAAGGGAGAAAC 6546
TNTT2 ATCCCCGATGGAGAGAGAGT TCTTCTTCTTTTCCCGCTCA 7139
GAPDH AGCCACATCGCTCAGACACC GTACTCAGCGGCCAGCATCG 2597
doi:10.1371/journal.pone.0044660.t001
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cells (Humbrecht Institute, Utrecht, The Netherlands) as described
earlier [6]. The beating areas of the cell colonies were
mechanically excised and treated with collagenase A (Roche
Diagnostics) [6].
Immunocytochemistry. Single beating CMs were immuno-
stained with anti-cardiac-troponin-T (1:1500, Abcam, Cambridge,
MA, USA), anti-a-actinin (1:1500, Sigma-Aldrich) and anti-
connexin-43 (1:1000, Sigma-Aldrich).
RT-PCR for cardiac Ca2+-cycling protein analysis. RNA
was isolated from iPSC-derived CMs. The expression of troponin
T (TNTT2), RyR2, SR Ca2+ ATPase (SERCA2a), L-type Ca2+
channel (Cav1.2), phospholamban (PLN) and sodium-calcium
exchanger (NCX) were assessed. Primer sequences are listed in
Table 1. GAPDH served as a housekeeping gene.
Ca2+ imaging. Dissociated CMs on a coverslip were loaded
with 4 mmol/L Fura-2 AM (Invitrogen, Molecular Probes) for 30
minutes in HEPES based medium, followed by a 30-minute de-
esterification. The coverslip was then transferred to an RC-27NE
or an RC-25 recording chamber (Warner Instruments Inc., CT,
USA) and continuously perfused with 37uC HEPES based
perfusate. The perfusate was preheated by an SH-27B inline-
heater controlled by a TC-324B unit (Warner Instruments Inc.,
USA) and consisted of (in mmol/L): 137 NaCl, 5 KCl, 0.44
KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-glucose, 2 CaCl2, 1.2
MgCl2 and 1 Na-puryvate (pH was adjusted to 7.4 with NaOH).
Ca2+ measurements were conducted on an inverted IX70
microscope (Olympus Corporation, Hamburg, Germany) where
spontaneously beating CMs were visualized with a UApo/340 x20
air objective (Olympus). Images were acquired with an ANDOR
Figure 1. Characterization of CPVT-iPSCs. A, Mutation analysis confirming the RyR2-P2328S mutation with altered DNA cleavage (arrow). B,
Morphology of an iPSC colony. Scale bar 200 mm. C, Normal karyotype. D, Expression of pluripotency markers at passage 4 shown by RT-PCR, b-actin
serving as a housekeeping gene. All studied endogenous pluripotency genes are turned on. None of the exogenous genes are expressed at passage
4. E, Immunocytochemical staining showing expression of pluripotency markers. Scale bars 1000 mm. F, Teratomas made from a CPVT-iPSC line
further confirms pluripotency. G, EBs express markers from all the three embryonic germ layers.
doi:10.1371/journal.pone.0044660.g001
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iXon 885 CCD camera (Andor Technology, Belfast, Northern
Ireland) synchronized with a Polychrome V light source by a real
time DSP control unit and TILLvisION software (TILL Photon-
ics, Munich, Germany). Fura-2 in CMs was excited at 340 nm and
380 nm light and the emission was recorded at 505 nm. For Ca2+
analysis, regions of interests were selected for spontaneously
beating cells and background noise was subtracted before further
processing. The Ca2+ levels are presented as ratiometric values of
F340/F380 or as DF/F0.
CMs were paced with 10–50 ms pulses (27–32 mA) (DS3
Constant Current/Voltage Isolated Stimulators, Digitimer LTD,
USA) at a frequency of 0.1–0.3 Hz higher than the spontaneous
beating rate. The changes in Ca2+ were recorded during
spontaneous baseline beating, electrical pacing, spontaneous
beating during 1 mmol/L adrenaline (Sigma-Aldrich) perfusion
and electrical pacing during adrenaline perfusion. The SR Ca2+
content was measured by releasing all the SR Ca2+ with
instantaneous and high concentration (40 mmol/L) caffeine
(Sigma-Aldrich) puffs after each measurement, after which the
relative amplitude change in calcium release in CPVT versus
control CMs was quantified. Viability of CMs was confirmed
after the experimental protocol. Amplitudes, beating frequency
and caffeine induced Ca2+ peaks were analyzed with Clampfit
version 9.2 (Molecular devices, USA). Analysis was performed
blinded to genotype of CMs.
Measurement of action potentials. Action potentials (APs)
were recorded in current-clamp mode using the standard patch-
clamp technique in the perforated patch configuration [7]. The
HEPES based extracellular perfusate for current-clamp recordings
consisted of (in mmol/L): 143 NaCl, 5 KCl, 1.8 CaCl2, 1.2 MgCl2,
5 glucose, 10 HEPES, pH was adjusted to 7.4 with NaOH and the
osmolarity set to 30062 mOsm (Gonotec, Osmomat 030, Labo
Line Oy, Helsinki, Finland). The intracellular solution consisted of
(in mmol/L): 122 KMeSO4, 30 KCl, 1 MgCl2, 10 HEPES. KOH
was used to set pH to 7.15 and the osmolarity was set to 29562
mOsm. Amphotericin B (Sigma-Aldrich) was used as membrane
perforation agent and dissolved in DMSO to a final concentration
in the patch pipette of 0.24 mg/ml. Spontaneously beating CMs
were patched in same bath conditions as in Ca2+ imaging. Patch
pipettes (model PG150T, Harvard Apparatus, UK) were pulled
with a PC-10 puller and flame polished with Microforge MF-900
(Narishige, UK) to a resistance of 2.0–2.5 MV measured in the
bath perfusate. APs were recorded in gab-free mode with pClamp
10.2 using the Axopatch 200B patch-clamp amplifier connected to
Figure 2. Characterization of iPSC-derived CPVT CMs. A, Immunocytochemical staining of cardiac markers, blue represents DAPI-staining for
nuclei. Scale bars 100 mm. B, The expression of Ca2+ cycling genes in differentiated CMs shown by RT-PCR. GAPDH is used as a housekeeping gene.
doi:10.1371/journal.pone.0044660.g002
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an acquisition computer via AD/DA Digidata 1440 (Molecular
devices, USA). Current-clamp recordings were digitally sampled at
20 kHz and filtered at 5 kHz using the lowpass Bessel filter on the
recording amplifier. AP duration at 50% and 90% of repolariza-
tion (ADP50 and ADP90), AP amplitude (APA), maximum diastolic
potential (MDP) and beats per minute (BPM) were extracted from
AP recordings using an automated script in Microcal OriginTM
8.6.
Monophasic Action Potential Recordings
Monophasic action potentials (MAPs) were previously recorded
from CPVT patients and healthy controls as reported [8]. Briefly,
MAPs were recorded from the right ventricular septum with a
bipolar silver-silver chloride catheter (model 006248, Bard Inc.,
Lowell, MA, USA). Data were recorded during sinus rhythm and
atrial pacing at a constant cycle length of 600 ms, both during
baseline and adrenaline infusion (maximum rate 0.05 mg/kg/min).
Custom-made software was used for analysis.
Definition of DADs and EADs
EADs were defined as low-amplitude depolarizations that occur
during phase 2 or 3 of the AP, before completion of repolarization,
and have an amplitude of $3% of the preceding AP. DADs were
defined as low-amplitude depolarizations that occur after comple-
tion of repolarization, and have an amplitude of $3% of the
preceding AP [9].
24h-ECG Recordings
24h-ECGs were previously recorded from CPVT patients and
healthy controls as reported [10]. Briefly, 24-h ECGs were
recorded using commercial tape recorders (model 8500; Mar-
quette Electronics Inc., Milwaukee, WI, USA). The tapes were
initially analyzed with a Marquette 8000 Holter Analysis system
(version 5.8 software) to label the QRS complexes to normal,
ventricular extrasystoles, or aberrant complexes.
Definition of T1-, T2-, and U-waves
The first peak during repolarization was considered as a T1-
wave. The second peak was considered as a T2-wave if it
occasionally merged with the T1-wave, or as a U-wave if it never
merged with the T1-wave. The third peak, which never merged
with the T1-wave, was also considered as a U-wave [10,11,12].
Statistical Analysis
The significance of differences between two groups was
evaluated with the unpaired Student’s t-test. The significance of
changes within a group was evaluated with the paired Student’s t-
test. P,0.05 was considered statistically significant, where (*)
represents P,0.05 and (**) P,0.01. Data are expressed as means
6 S.E.M. and n (where indicated) refers to the number of cells or
experiments.
Figure 3. Intracellular Ca2+ cycling and analysis of rhythm. A, representative traces of the four different rhythm categories. Regular rhythm of
calcium release with stable amplitude R, regular rhythm with varying amplitude Ra, irregular rhythm with stable amplitude I, irregular rhythm with
varying amplitude Ia. B, doughnut charts indicating the percentage of CPVT and control CMs under each rhythm category.
doi:10.1371/journal.pone.0044660.g003
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Results
Characterization of iPSC Lines Confirms Pluripotent Stem
Cell Characteristics
The presence of the P2328S mutation was confirmed in the two
CPVT-P2328S iPSC lines (Figure 1A). The iPSC colonies were
morphologically round-shaped and the iPSC lines had normal
karyotype (Figure 1B–C). All studied endogenous pluripotency
genes were turned on and expression of retrovirally encoded
reprogramming factors was silenced (Figure 1D). iPSC lines
expressed endogenous pluripotent markers at the protein level
(Figure 1E). Pluripotency was confirmed by teratoma formation
and with in vitro embryoid body (EB) formation expressing all three
germ layers (Figure 1F–G).
iPSC-derived CMs Express Cardiac Markers
iPSCs were differentiated into spontaneously beating cells and
the differentiated CMs expressed cardiac markers at the protein
level (Figure 2A). RT-PCR was performed to confirm the
expression of genes related to Ca2+ cycling (Figure 2B).
CPVT-P2328S CMs Display Aberrant Ca2+ Cycling
Ca2+ cycling properties of CPVT and control CMs were
compared in four conditions: spontaneous baseline beating,
pacing, spontaneous beating during adrenaline perfusion, and
pacing during adrenaline perfusion. Ca2+ cycling was categorized
into four different rhythm categories in which three of them the
Ca2+ cycling was characterized abnormal due to varying
amplitude and/or irregular rhythm (Figure 3A). Ca2+ cycling
abnormalities were more common in CPVT CMs than in control
CMs in each studied condition (Figure 3B). At baseline a higher
percentage of CPVT CMs (14%) showed abnormal Ca2+ cycling
when compared to control CMs (8%). Pacing stabilized Ca2+
cycling partially in CPVT CMs and completely in control CMs.
Adrenaline increased Ca2+ cycling abnormalities to 30% of the
CPVT CMs. In control CMs adrenaline had no effect on Ca2+
cycling. Pacing with adrenaline abolished all Ca2+ cycling
abnormalities in controls but did not have an effect in CPVT
CMs.
Under baseline and electrical pacing conditions, CPVT and
control CMs presented similar diastolic Ca2+ levels (Figure 4B).
However, adrenaline with and without pacing produced signifi-
cantly more elevated diastolic Ca2+ levels in CPVT CMs.
In CPVT CMs significantly lower SR Ca2+ load was seen at
baseline and in the presence of pacing during adrenaline
(Figure 4C). Caffeine-induced Ca2+ release via RyR2 was studied
under the four different aforementioned conditions (Figure 4A).
To determine the fractional Ca2+ release, the amplitude of the
Ca2+ transients were divided by the amplitude of the following
caffeine-induced Ca2+ transient. Fractional SR Ca2+ release was
significantly higher in CPVT CMs during spontaneous beating
Figure 4. Intracellular Ca2+ cycling and SR Ca2+ stores. A, representative traces from a single CPVT cell demonstrating the experimental
protocol. Bl; spontaneous baseline beating, Adr; adrenaline perfusion. Caffeine was added following 10 spontaneous or paced beats. B, diastolic level
of intracellular Ca2+. C, amplitude of caffeine-induced Ca2+ transients. D, amplitude of Ca2+ transients divided by amplitude of caffeine-induced Ca2+
transient, indicating fractional SR Ca2+ release. Units in A and B are Fura-2 ratio units, in C DF/F0. Numbers of control vs CPVT CMs analyzed: Bl n = 54
vs n = 90, Bl+paced n= 25 vs n = 50, Adr n= 27 vs 47, Adr+paced n=19 vs n= 35, respectively. Error bars, SEM. *P,0.05, **P,0.01, with student’s t-
test.
doi:10.1371/journal.pone.0044660.g004
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and during electrical pacing with and without adrenaline perfusion
(Figure 4D).
Current-clamp Reveals DADs and EADs in CPVT-P2328S
CMs
Using the perforated patch technique in current-clamp mode
APs of 16/18 control and 14/14 CPVT CMs were ventricular-
like. The basic AP characteristics were similar in control and
CPVT CMs (Table 2). Eleven CPVT and five control CMs were
exposed to adrenaline and a similar increase in beating rate and
decrease in APD50 and APD90 were observed in all of them. In
general, control CMs had robust synchronized beating throughout
the recordings, but in 3/16 CMs (19%) DADs were randomly
observed during baseline recordings (1–2 DADs/60 APs). At
baseline DADs were observed in 6/14 (42%) of CPVT CMs. In 6/
11 CPVT CMs exposed to adrenaline, wash-out recovered the
beating rate to normal as in control CMs. However, in the
remaining 5/11 CPVT CMs, adrenaline subsequently evoked
DADs and resulted in decreased beating rate (Figure 5A and 5B).
In three other CPVT CMs spontaneous EADs were seen at
baseline (Figure 5C and 5D). Additionally phase 3 burst episodes
were seen in one cell showing EADs and DADs (Figure 5C). All
solitary EAD upstrokes were seen above 225 mV. The MDP of
the burst was 250 mV. The maximum upstroke amplitude for
solitary EADs was 45 mV and during the bursts 95 mV. No EADs
or spontaneous bursting were observed in control CMs.
MAP Recordings of CPVT-P2328S Patients Reveal EADs
and DADs, ECGs Show Simultaneous T2 and U-waves
We examined MAP recordings for EADs and DADs and 24h-
ECGs for their ECG counterparts, T2 and U-waves. MAP
recordings demonstrated DADs (Figure 6A) and EADs (Figure 6B).
24h-ECGs showed occasional simultaneous T1, T2, and U-waves
(Figure 6C). These changes were observed repeatedly, and no
similar changes were seen in healthy controls.
Discussion
We report, for the first time, that in addition to DADs, CPVT
patient-specific iPSC-derived CMs display EADs, providing novel
insight into the arrhythmogenic mechanisms in CPVT. Our
findings demonstrate the applicability of iPSC-derived CMs in
studying the pathophysiology of CPVT-causing RyR2 mutations.
CPVT CMs show disturbances in intracellular Ca2+ cycling in
response to catecholaminergic stimulation with adrenaline. These
changes in Ca2+ cycling indicate increased diastolic SR Ca2+ leak,
which may lead to DADs and the generation of triggered
arrhythmias [13]. In accordance with a previous report [14],
upon perfusion with adrenaline, CPVT CMs develop frequent
DADs, which occasionally suppress the following AP, preventing
the increase in the beating frequency.
Adrenaline produced significantly more elevated diastolic Ca2+
levels in CPVT CMs. Adrenaline also failed to increase caffeine-
induced Ca2+ release and fractional Ca2+ release compared to
control cells. The Ca2+ measurements with adrenaline were
recorded after 3 minutes of perfusion with the drug. During this
time Ca2+ leaked from the SR to the cytosol in the CPVT CMs, as
indicated by the elevated diastolic Ca2+ levels in the cytosol and
the reduced caffeine-induced SR Ca2+ release.
Fractional SR Ca2+ release increases steeply with elevation of
SR calcium. [15,16]. Therefore, it is expected that continuous
adrenaline perfusion without pacing will only transiently increase
fractional SR Ca2+ release in the RyR2 mutant CMs, which will
soon find a new equilibrium, balanced by increased sensitivity to
SR Ca2+ and decreased SR Ca2+ stores. On the other hand,
transient pacing (10 beats) increases SR Ca2+ load. When the
fractional SR Ca2+ release is measured immediately after the
pacing, increased values are observed. As expected, in this case the
fractional SR Ca2+ release is greater in the RyR2 mutant CMs,
which are more sensitive to luminal SR Ca2+ release.
Traditionally, EADs have been thought to result from
spontaneous reactivation of the L-type Ca2+ channel (LTCC)
during conditions of prolonged APD, such as LQT2 [17].
However, recent understanding highlights the role of Ca2+
overload and spontaneous Ca2+ release as the main triggers
behind EADs [18,19]. Conditions leading to Ca2+ overload
include heart failure, digitalis toxicity, and CPVT. Under
conditions of SR Ca2+ overload or leaky RyR2s, spontaneous
release of Ca2+ from the SR leads to activation of the sodium-
calcium-exchanger (NCX), which results in a depolarizing current
that reactivates the LTCC, leading to an EAD. It has been shown
that early Ca2+ aftertransients are the primary events that induce
EADs, and not vice versa [20,21]. In addition to early EADs, late
EADs arising from membrane potentials more negative than the
threshold potential of LTCC (235 mV), are reported to be NCX-
mediated and share similar properties with DADs [22–24].
Further support for the role of cytosolic calcium in EAD induction
comes from recent findings that despite prolonging APD,
ranolazine suppresses EADs by stabilizing RyR2 [25]. However,
ranolazine’s ability to prevent EADs is also likely to be mediated
by late sodium current inhibition, which decreases cytosolic Ca2+
by reducing NCX-mediated Ca2+ influx [26,27]. Lower cytosolic
Ca2+ will less likely cause SR Ca2+ leak, which would lead to
forward-mode NCX activation and afterdepolarizations. Accord-
ingly, we must acknowledge the potential role of the late sodium
current in EAD provocation.
Table 2. Characteristics of spontaneous ventricular-like APs in control and CVPT-CMs during regular beating.
Baseline BPM APD50 (ms) APD90 (ms) APA (mV) MDP (mV)
control (n = 16) 4166 204.4620.3 329.7622.4 117.8562.61 268.3561.87
CPVT (n = 14) 4365 238.6622.4 305.4625.7 114.8062.70 267.5561.51
Adrenaline BPM
% increase
APD50
% decrease
APD90
% decrease
APA
DmV
MDP
DmV
control (n = 5) 23.260.9 18.461.8 16.862.1 25.8261.17 +2.5560.61
CPVT (n = 11) 16.0612.3 21.565.5 24.063.5 28.2562.15 +4.5960.82
doi:10.1371/journal.pone.0044660.t002
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Figure 5. CPVT-P2328S CMs display DADs and EADs. A, Time course of APD50 (empty squares) and APD90 (filled squares) Adr indicates
perfusion with adrenaline. B, bars 1–3 are 9 sec time courses enlarged from A. (1) baseline with DADs, (2) DADs in the presence of adrenaline, (3)
DADs continue after adrenaline perfusion. MDP270 mV. Arrows indicate DADs. C, A CPVT-P2328S CM showing an EAD (grey arrow) and a DAD (black
arrow) followed by a spontaneous burst episode (MDP250 mV, maximum upstroke amplitude 45 mV). D, Current clamp recording of a CPVT-P2328S
CM showing occasional EADs (arrows). MDP 270 mV. Dashed lines indicate the zero reference potential.
doi:10.1371/journal.pone.0044660.g005
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Our results support this emerging consensus on the role of
NCX-mediated generation of EADs. We found that CPVT CMs
display irregular spontaneous calcium release events, DADs, and
EADs. Furthermore, MAP recordings in CPVT-P2328S patients
show both DADs and EADs. Although not experimentally shown,
it has previously been suggested that CPVT patients with RyR2
mutations are susceptible to both EAD and DAD-mediated
arrhythmia mechanisms [10]. As shown here, these patients show
both T2 and U-waves, the ECG equivalents of EADs and DADs,
respectively [10].
We could not demonstrate increased arrhythmogenicity with
pacing. At baseline, pacing stabilized beating in both control and
CPVT CMs. When arrhythmias were provoked in CPVT CMs
with adrenaline, pacing on top of that did not have any affect on
the recorded arrhythmias. This is contrary to previous CPVT
reports using either spontaneously beating CMs with a CASQ2
mutation [14] or resting CMs with a RyR2 mutation [4]. This
observation suggests that there are mutation-specific differences.
Our P2328S-RyR2 mutation presents arrhythmias only in the
presence of catecholaminergic stimulation, but not if increased
beating rate is generated by pacing.
Our findings demonstrate that in addition to DADs, CPVT-
P2328S CMs display EADs which may be involved in arrhythmo-
genesis in these patients. This broadens the mechanistic under-
standing of arrhythmias linked to RyR2 mutations and helps to
direct efforts to optimize therapy in these patients. Our iPSC-
derived CM model offers a promising platform for further research
into the pathophysiological mechanisms of CPVT, as well as a safe
tool for screening and optimizing drug therapy with patient-
specific CMs.
Study Limitations
We studied iPSC-derived CMs from two CPVT and two
control iPS cell lines. However, both CPVT lines were from the
same patient. The control lines were from two healthy controls. It
is therefore unclear whether the changes we saw are typical of all
CPVT patients, of this specific mutation, or only this specific
patient. In the future we need to extend our studies, looking at
various RyR2 mutations and several cell lines from multiple
patients harboring a specific mutation.
The type of CM (nodal, atrial, or ventricular) under investiga-
tion was unclear in the Ca2+ imaging studies. Part of the variability
in the results may stem from differences between the CM types. To
address this in the future, simultaneous recording of APs and
intracellular Ca2+ will help to distinguish cell type and additionally
give temporally synchronized info on the interplay between Ca2+
handling and APs.
Additionally, further development of cardiac differentiation and
maturation procedures will hopefully improve the homogeneity of
iPS cell lines.
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Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly malignant inher-
ited arrhythmogenic disorder. Type 1 CPVT (CPVT1) is caused by cardiac ryanodine recep-
tor (RyR2) gene mutations resulting in abnormal calcium release from sarcoplasmic
reticulum. Dantrolene, an inhibitor of sarcoplasmic Ca2+ release, has been shown to rescue
this abnormal Ca2+ release in vitro. We assessed the antiarrhythmic efficacy of dantrolene
in six patients carrying various RyR2mutations causing CPVT. The patients underwent ex-
ercise stress test before and after dantrolene infusion. Dantrolene reduced the number of
premature ventricular complexes (PVCs) on average by 74% (range 33-97) in four patients
with N-terminal or central mutations in the cytosolic region of the RyR2 protein, while dantro-
lene had no effect in two patients with mutations in or near the transmembrane domain. In-
duced pluripotent stem cells (iPSCs) were generated from all the patients and differentiated
into spontaneously beating cardiomyocytes (CMs). The antiarrhythmic effect of dantrolene
was studied in CMs after adrenaline stimulation by Ca2+ imaging. In iPSC derived CMs with
RyR2mutations in the N-terminal or central region, dantrolene suppressed the Ca2+ cycling
abnormalities in 80% (range 65-97) of cells while with mutations in or near the transmem-
brane domain only in 23 or 32% of cells. In conclusion, we demonstrate that dantrolene
given intravenously shows antiarrhythmic effects in a portion of CPVT1 patients and that
iPSC derived CMmodels replicate these individual drug responses. These findings illus-
trate the potential of iPSC models to individualize drug therapy of inherited diseases.
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Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of the most malignant
inherited arrhythmogenic disorders. It manifests with exercise-induced premature ventricular
complexes (PVCs), polymorphic or bidirectional ventricular tachycardia, or sudden death, usu-
ally associated with vigorous physical exercise or mental stress.[1–3] Current therapeutic op-
tions include beta-antiadrenergic drugs, flecainide, implantable cardioverter-defibrillators
(ICD) [4–6] and left cardiac sympathetic denervation.[7,8] Better antiarrhythmic medication is
still needed to minimize the need for ICD shock therapies. The most common subtype, type 1
of CPVT (CPVT1) is a dominantly inherited disease caused by mutations in the cardiac ryano-
dine receptor (RyR2) gene.[9,10] The gain-of-function mutations of RyR2 cause increased cal-
cium (Ca2+) sensitivity which can lead to spontaneous Ca2+ release from sarcoplasmic
reticulum, generation of afterdepolarizations, and triggered activity.[4,5,11]
The ryanodine receptor isoform RyR1 is the skeletal muscle counterpart in the gene family.
Mutations of RyR1 result in malignant hyperthermia, a rare but life-threatening complication
of general anesthesia occurring upon administration of volatile anesthetics or depolarizing
muscle relaxants. Dantrolene is a specific and currently the only effective treatment for malig-
nant hyperthermia.[12] Interestingly, dantrolene has also shown to exert antiarrhythmic effects
in animal models of CPVT1.[13–15] Dantrolene has been proposed to act through binding to
the N-terminal parts of RyR1 and RyR2 and restoring inter-domain interactions critical for the
closed state of the RyR2 Ca2+ channel.[16]
Several studies using induced pluripotent stem cell (iPSC) technology [17] have indicated
the ability of CPVT1 patient-specific iPSC derived cardiomyocytes (CMs) to replicate the dis-
ease phenotype in cell culture.[18–24] Dantrolene was reported to rescue the disease phenotype
in iPSCs derived CMs from a single RyR2mutation carrier [20] but no in vivo data exists on its
effects on CPVT1 patients.
In the present study, we report the proof of principle of the antiarrhythmic activity of dan-
trolene in a cohort of CPVT1 patients. In addition, we demonstrate that the in vivo drug effects
are closely reproduced in iPSC-derived patient-specific CMs, and provide evidence for muta-
tion-specific effects of dantrolene in CPVT1.
Materials and Methods
The protocol for this trial is available as supporting information; see S1 Protocol and S2
Protocol.
Clinical Study Scheme
The study was approved by the Ethical Review Committee of the Helsinki University Hospital
(HUS 396/13/03/01/12) and was in accordance with the institutional guidelines and the Decla-
ration of Helsinki. A written informed consent was obtained from all patients. Clinical trial
was registered with EudraCT (2012-005292-14). Participants were recruited between 1st March
2013 and 29th May 2014. Follow up time of the patients was three days after the dantrolene in-
fusion. Four patients participated the study at the Helsinki University Hospital and two at the
Tampere University Hospital, Heart Center. The authors confirm that all ongoing and related
trials for this drug are registered.
Patients
The study group consisted of 6 individuals (mean age 50±10 years, range 37–59 years, 5 fe-
males), who were molecularly defined heterozygous carriers of different gain-of-function RyR2
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mutations causing CPVT1. CPVT1 patients carried the following mutations: c.168-301_c.273+
722del1128mutation (later called as exon 3 deletion) or point mutations p.P2328S
(c.6982C>T), p.T2538R (c.7613C>G), p.L4115F (c.12343C>T), p.Q4201R (c.12602A>G) or p.
V4653F (c.13957G>T). Mutation nomenclature was based on RyR2 reference sequence
NM_001035.2. The mutations were located in the four mutation hotspot clusters of the RyR2
gene (Fig 1).[11] Patients and families carrying mutations P2328S [3,10,25], exon 3 deletion
[3,26], Q4201R [10,25] and V4653F [10,25] have been described in detail earlier.
All mutations were associated with exercise-induced ventricular arrhythmias and syncopal
spells. All except L4115F were associated with one or more cases of sudden death at young age
in the family. An ICD had been implanted in five of them; one has received an adequate shock
therapy. Five out of the six patients had a history of syncopal spells upon a frightening situation
or physical exercise, and they all used a beta-adrenergic blocking agent (daily dose of 160 mg of
propranolol, 7, 5 to 10 mg of bisoprolol or 95 mg of metoprolol) during all study phases. No
other medications were in use. The patients were otherwise healthy without hypertension, dia-
betes, or evidence of other heart disease. None of them had bundle branch block.
In cardiac ultrasonography, left ventricular end diastolic dimension and systolic function
were normal in all patients (data not shown). Basic laboratory parameters including hemoglo-
bin, white blood cell count, plasma sodium, potassium, and creatinine concentrations were an-
alyzed prior to administration of the drug and they were all within the normal range in every
study patient (data not shown). Two of the patients with ICD showed atrial pacing at rest prior
to exercise; all others had sinus rhythm. Electrocardiographic parameters are presented in
Table 1.
Clinical Exercise Stress Test
All RyR2 patients underwent the exercise stress test three times. On the first morning a baseline
study was carried out. The test was repeated in the afternoon of the first day after intravenous
infusion of dantrolene sodium (Dantrium, 1.5 mg per kg of body weight). The third exercise
test was performed on the second day to assess the effects after dantrolene sodium washout
and to demonstrate the reproducibility of the basic exercise test.
Exercise tests were performed with a bicycle ergometer. The initial load was 30 W, followed
by increments of the load by 15 W each minute. In the baseline study, the patient was
Fig 1. RyR2 protein, mutations studied in the present study andmutation clusters 1–4.Mutations in this
study (arrows) are located in different parts of the RyR2 protein and mutation clusters. Clusters are
represented as black lines numbered from 1 to 4. Cluster 1 comprises of amino acids (AA) 44–466, cluster 2
AA 2246–2534 and cluster 3 AA 3778–4201 and these three clusters are located in the N-terminal and
central regions of the protein and form the cytoplasmic domain. Cluster 4 comprises of AA 4497–4959 and
forms the transmembrane domain, which is located in the C-terminal region. The figure is modified from [11].
doi:10.1371/journal.pone.0125366.g001
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instructed to target to a submaximal workload in order to be able to repeat the exercise stress
test. In the consecutive phases of the study, the workload target was the same as that achieved
in the first study. A twelve-lead electrocardiogram (ECG) was recorded continuously at paper
speed 25 or 50 mms-1 and amplification of 0.1 mV/mm throughout the exercise test. After ces-
sation of exercise, ECG was recorded continuously for the first 8 minutes. Both the maximum
workload achieved and the heart rate at which ventricular bigeminy first appeared were re-
corded whenever applicable. Numbers of PVCs during exercise and at recovery phase as well as
the maximum number of consecutive PVCs were counted. Plasma creatinine, sodium, potassi-
um and calcium were measured at rest before the first exercise test. The exercise tests and the
iPSC studies were done separately and blinded.
Characterization of iPSC Lines
The iPSC study was approved by the ethical committee of Pirkanmaa Hospital District
(R08070) and written informed consent was obtained from all the participants. Patient-specific
iPSC lines were established as described earlier.[17] Studied iPSC lines were UTA.05605.CPVT
generated from patient with RyR2 exon 3 deletion, UTA.05208.CPVT from patient with muta-
tion P2328S, UTA.07001.CPVT from patient with mutation T2538R, UTA.03701.CPVT from
patient with mutation L4115F, UTA.05503.CPVT from patient with mutation Q4201R,
UTA.05404.CPVT from patient with mutation V4653F and UTA.04602.WT from a healthy
control individual.
All the CPVT-iPSC lines were characterized for their karyotypes, mutations, pluripotency,
immunocytochemistry, embryoid body (EB) and teratoma formation. Endogenous and exoge-
nous gene expressions were examined by RT-PCR using 1 μl cDNA and 500 nmol/L of each
primer in one PCR reaction. β-actin and GAPDH served as the housekeeping genes. Detailed
reaction conditions and PCR primers for iPSC characterization have been described earlier.
[27] Endogenous pluripotency markers at the protein level were studied with immunocyto-
chemistry. The iPSCs were fixed with 4% paraformaldehyde (PFA, Sigma-Aldrich, Saint Louis,
USA). Primary antibodies anti-SOX2, anti-NANOG and anti-tumor-related antigen (TRA)1-
81 (all 1:200, from Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-OCT3/4 (1:400,
R&D Systems) were used. Cells were mounted with Vectashield (Vector Laboratories, USA)
containing DAPI for staining nuclei. To confirm the mutations of the CPVT iPSC lines with se-
quencing the DNA was isolated using DNA Tissue XS-kit (Macherey-Nagel GmbH & Co.,
Düren, Germany). The genomic region containing the expected mutation was amplified using
PCR. Each PCR product was directly sequenced in both directions using BigDye Terminator
v3.1 and ABI 3730xl DNA Analyzer (Applied Biosystems, Carlsbad, CA, USA). In addition to
Table 1. Electrocardiographic parameters.
Before dantrolene (n = 6) After dantrolene (n = 6) p-value
Heart rate (min-1) 61±5 60±5 NS
P (ms) 109±14 110±14 NS
PQ (ms) 154±31 163±34 NS
QRS (ms) 86±8 87±5 NS
QT (ms) 419±22 407±18 NS
QTc (ms) 418±35 409±35 NS
Comparison of electrocardiographic parameters of all patients before and after the dantrolene infusion. NS
indicates no signiﬁcant.
doi:10.1371/journal.pone.0125366.t001
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direct sequencing, exon 3 deletion (1128 nucleotides) was also confirmed using PCR and aga-
rose gel electrophoresis. Karyotypes of the cell lines were determined using either standard G-
banding chromosome analysis (Medix laboratories, Espoo, Finland) or KaryoLite BoBs assay
(Perkin Elmer) based on BACs-on-Beads technology (Molecular and Systems Immunology
and Stem Cell Biology, Turku Centre for Biotechnology, University of Turku, Finland). The ex-
pression of markers characteristic of ectoderm (Nestin or SOX-1), endoderm (AFP or SOX-17),
and mesoderm (VEGF-R2) development were studied from EBs maintained in EB-medium
(KO-DMEM with 20% FBS, Non-Essential Amino Acid (NEAA), L-glutamine and penicillin/
streptomycin) for 5 weeks. EB RT-PCR primers can be seen in S1 Table. The teratoma study
was approved by ELLA- Animal Experiment Board of Regional State Administrative Agency
for Southern Finland (ESAVI/6543/04.10.03/2011). IPSCs were injected into nude mice under
the testis capsule and tumor samples collected 8 weeks after injection, followed by fixation with
4% PFA and staining of the sections with hematoxylin and eosin.
Cardiomyocyte Differentiation and Characterization
iPSCs were co-cultured with murine visceral endoderm-like (END-2) cells (Humbrecht Insti-
tute, Utrecht, The Netherlands) to differentiate them into spontaneously beating CMs. The
beating areas of the cell colonies were mechanically excised and treated with collagenase A
(Roche Diagnostics).[28] Single CMs were immunostained with anti-cardiac-troponin-T
(1:1500, Abcam, Cambridge, MA, USA), anti-α-actinin (1:1500, Sigma) and anti-connexin-43
(1:1000, Sigma).
Ca2+ Imaging
Dissociated spontaneously beating CMs on a coverslip were loaded with 4 μmol/L Fura 2-AM
(Life Technologies, Molecular Probes). CMs were continuously perfused with 37°C HEPES
based perfusate during measurements and the perfusate consisted of (in mmol/L): 137 NaCl,
5 KCl, 0.44 KH2PO4, 20 HEPES, 4.2 NaHCO3, 5 D-glucose, 2 CaCl2, 1.2 MgCl2 and 1 Na-pury-
vate (pH was adjusted to 7.4 with NaOH). Ca2+ measurements were conducted on an inverted
IX70 microscope (Olympus Corporation, Hamburg, Germany) and cells were visualized with
UApo/340 x20 air objective (Olympus). Images were acquired with an ANDOR iXon 885 CCD
camera (Andor Technology, Belfast, Northern Ireland) synchronized with a Polychrome V
light source by a real time DSP control unit and TILLvisION or Live Acquisition software
(TILL Photonics, Munich, Germany). Fura 2-AM in CMs was excited at 340 nm and 380 nm
light and the emission was recorded at 505 nm. For Ca2+ analysis, regions of interest were se-
lected for spontaneously beating cells and background noise was subtracted before further data
processing. The Ca2+ levels are presented as fura ratio units of F340/F380. Ca2+ peaks were ana-
lyzed with Clampfit version 10.2 (Molecular Devices, USA).
The percentage of abnormal Ca2+ transients, such as multiple peaks comprising of two
peaks, irregular phases, oscillations, and varying amplitude manifested as low peaks, were
calculated from each studied cell line. Beating frequency and diastolic Ca2+ levels of CMs were
analyzed during spontaneous baseline beating, and during adrenaline perfusion. These param-
eters were compared between mutated and control cell lines and also between each mutated
cell line. Some results of Ca2+ cycling of CPVT-P2328S and control cell lines have been pub-
lished before [21] and parts of these results have been included here.
For dantrolene studies, the changes in Ca2+ were recorded during spontaneous baseline
beating, spontaneous beating during 1 μM adrenaline perfusion and spontaneous beating
during 1 μM adrenaline together with 10 μM dantrolene (Sigma) perfusion. If a CM displayed
Ca2+ transient abnormalities during adrenaline perfusion, it was exposed to dantrolene. Drug
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effects of dantrolene were categorized into three groups. In “responder” group dantrolene abol-
ished virtually all the Ca2+ handling abnormalities, in “semi-responder” group dantrolene re-
duced them by more than 50%, in “non-responder” group dantrolene reduced them by less
than 50%. Diastolic Ca2+ levels and beating frequency were compared between adrenaline and
dantrolene responses of responder CMs (exon 3 del, P2328S, T2538R, L4115F) and non-re-
sponder CMs (Q4201R, V4653F, controls). For this, adrenaline response values were divided
by dantrolene response values, separately for each cell.
Statistical Analysis
Statistical analysis of in vivo studies was made with SPSS 21.0 statistical software package
(SPSS, Chicago, IL). Data are presented as average + 1 SD. Comparisons between phases were
performed by the non-parametric Wilcoxon test. The significance of in vitro differences be-
tween two groups was evaluated with the unpaired Student’s t-test. The significance of
changes within a group was evaluated with the paired Student’s t-test. Data are expressed as
average ± S.E.M. and n refers to the number of cells. P<0.05 was considered statistically signifi-
cant in both in vivo and in vitro.
Results
Antiarrhythmic Effects of Dantrolene in Cpvt1 Patients
In the baseline study, patients exercised on an average 8±2 minutes reaching a maximum heart
rate of 134±17 min-1. Exercise bicycle testing induced polymorphic PVCs in all patients and
non-sustained ventricular tachycardia (NSVT, episodes of 3 to 4 consecutive PVCs) in three of
them. The average threshold sinus rate for the appearance of PVCs was 105±9 min-1. The total
count of PVCs during the workload was 172±119 (range 43–391).
All six patients tolerated the target dose 1.5 mg/kg of intravenous infusion of dantrolene but
reported considerable muscle weakness as a side-effect. Dantrolene did not affect atrioventricu-
lar conduction or the QT interval (Table 1). Dantrolene decreased the prevalence of PVCs in
four patients, whereas in two patients the number of PVCs remained virtually the same (Fig 2).
Dantrolene seemed to reduce arrhythmias in patients with the mutation in the N-terminal or
central region of the RyR2 protein (Figs 1 and 2). Thus, dantrolene abolished 97% of PVCs in
the patient with exon 3 deletion (cluster 1), 88% of PVCs in the patient with P2328Smutation
(cluster 2), 33% of PVSc in the patient with T2538Rmutation (right after cluster 2) and 77% of
PVCs in the patient with L4115Fmutation (cluster 3). In contrast, dantrolene abolished only 1
to 2% of PVCs in patients carrying mutation closer to (Q4201R, end of cluster 3) or within the
transmembrane region (V4653F, cluster 4).
Fig 3 illustrates an example of the PVCs and NSVT episodes during the baseline study and
after dantrolene. Dantrolene increased significantly the threshold at which the arrhythmias ap-
peared from 105±9 to 120±17 min-1. The duration of the exercise phase and the maximal
heart rate achieved during the exercise were similar to those in the baseline study. On day 2,
after wash-out of dantrolene, the prevalence of PVCs was approaching that in the first
baseline test.
Characterization of iPSC Lines Confirms Pluripotent Stem Cell
Characteristics
iPSC lines from six CPVT1 patients with above-mentioned RyR2mutations were generated.
Results of the P2328S and control iPSC line characterizations have been published before.
[21,27] All studied endogenous pluripotency genes (Nanog, Rex1, Oct 3/4 and Sox2) were
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turned on and the expression of retrovirally encoded reprogramming factors c-Myc, Klf4, Sox2
and Oct 3/4 was silenced (Fig 4A and 4B). CPVT1 iPSC lines expressed endogenous pluripo-
tent markers Nanog, Oct3/4, TRA 1–81 and SOX2 also at the protein level (Fig 4D). Pluripo-
tency was further confirmed by teratoma formation and with in vitro embryoid body (EB)
formation expressing all three germ layers (Figs 4C and 5G). The presence of the RyR2muta-
tions was confirmed from all the CPVT1 iPSC lines with DNA sequence analysis (Fig 4E). All
the iPSC lines had a normal karyotype (Fig 4F). In addition to sequencing, the presence of the
exon 3 deletion was confirmed with PCR (S1 Fig).
iPSC Derived Cms Display Abnormal Ca2+ Cycling
iPSCs were differentiated into spontaneously beating CMs (Fig 5A). When compared to CMs
derived from the healthy individual, CPVT1 CMs demonstrated marked Ca2+ transient abnor-
malities such as multiple peaks comprising of two peaks, irregular phases, oscillations, and
varying amplitude manifested as low peaks (Fig 5B) both in baseline and in response to adrena-
line. Although these abnormalities were common with all six mutations examined, some differ-
ences between RyR2mutations were also observed. Accordingly, Ca2+ transient abnormalities
were somewhat more common in the cluster 4 mutation than in cluster 1, 2 and 3 mutations
(Fig 5C).
Adrenaline increased the beating frequency of each cell line studied (Fig 5D). All RyR2mu-
tated CMs had lower beating frequency both at baseline and during adrenaline perfusion than
control CMs. Adrenaline produced significantly elevated diastolic Ca2+ levels only in P2328S
CMs, while diastolic Ca2+ levels were lower or similar in other mutant CMs compared to con-
trol CMs (Fig 5E). Exon 3 deletion CMs had both lower beating frequency and diastolic Ca2+
level when compared to other mutations (Fig 5 and S2 Table).
Fig 2. Features of the PVCs.Number of PVCs in exercise stress test before and after administration of intravenous dantrolene and 24 hours after
dantrolene wash out.
doi:10.1371/journal.pone.0125366.g002
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iPSC Derived Cpvt1 Cms Reproduced the Clinical Antiarrhythmic
Responses to Dantrolene
Effects of dantrolene were divided into three groups based on their Ca2+ responses. In “re-
sponder” group dantrolene abolished all the Ca2+ handling abnormalities, in “semi-responder”
group dantrolene reduced them by more than 50% and in “non-responder” group dantrolene
reduced them by less than 50%. iPSC derived CMs were found to markedly reproduce the vary-
ing individual clinical responses of dantrolene (Fig 6). In cell lines with the mutation in the N
terminal or central region of the RyR2 protein dantrolene abolished or reduced the majority of
Ca2+ transient abnormalities (Fig 6). These mutations were within or in close proximity of clus-
ters 1, 2 or 3 (Fig 1). A detailed analysis indicated that in CMs with exon 3 deletion, P2328S,
T2538R or L4115F, dantrolene abolished or reduced by more than 50% of Ca2+ abnormalities
in 65–97% of cells (Fig 6).
In striking contrast, the effect of dantrolene was only minimal in CMs carrying a mutation
at the end of cluster 3 (Q4201R) or in the transmembrane region (cluster 4, mutation V4653F)
(Fig 6), in accordance with the in vivo dantrolene infusion data. Dantrolene had no effect on
the Ca2+ transients in control CMs. Dantrolene did not significantly affect the diastolic Ca2+
levels of CMs in which Ca2+ transient abnormalities were abolished (S2 Fig). Dantrolene in-
creased significantly the diastolic Ca2+ levels of control and Q4201R CMs where Ca2+ transients
were unaltered by the drug. There was no correlation between the antiarrhythmic effect of dan-
trolene and its effect on beating frequency (S2 Fig).
Discussion
We have studied the antiarrhythmic potential of dantrolene in the treatment of CPVT1. To
this end, we assessed the efficacy of intravenously administered dantrolene in patients carrying
various RyR2mutations and compared these effects to in vitro studies using iPSC derived CMs
generated from the same patients. Our findings demonstrate that intravenous dantrolene, a
drug used to treat another ryanodine receptor disorder, malignant hyperthermia, abolished or
markedly reduced arrhythmias in a subgroup of CPVT1 patients with specific RyR2mutations.
By combining evidence from in vivo and in vitro studies, we propose that the location of the
RyR2mutation affects the antiarrhythmic effect of dantrolene in CPVT1.
Previously dantrolene has been shown to have beneficial effects on cardiac function in ex-
perimental animal models of CPVT1 [13–15,29,30] and in iPSC derived CMs from a CPVT1
patient with an N-terminal S406Lmutation [20], but no studies in patients have so far been re-
ported. It is also important to take into consideration that even if a drug is found to be benefi-
cial in the patient-derived iPSC-CMs, it cannot be automatically concluded that this will
translate into a clinical benefit. Here we show that dantrolene given intravenously has an anti-
arrhythmic effect also in some but not in all patients with CPVT1. This antiarrhythmic effect
was observed only in patients with RyR2mutations in the N-terminal or central regions of
RyR2 protein (clusters 1–3), whereas virtually no effect was seen in patients carrying mutations
at the end of cluster 3 or in the transmembrane region (cluster 4). Although a dose-dependent
effect cannot be excluded, similar observations on mutation-specific drug responses have been
obtained in some other genetic disorders including long QT syndrome type 3 [31], cystic fibro-
sis [32], as well as in certain neoplastic diseases.[33] Recognition of potential mutation-specific
Fig 3. ECG examples of a 38-year-old patient carrying the RyR2 P2328Smutation. (A) Resting ECG showing sinus rhythm and normal QRS
morphology. (B) Exercise ECG at the highest work load of 105W in the baseline study before dantrolene. PVCs include couplets and polymorphic NSVTs.
(C) Disappearance of ventricular arrhythmias after administration of dantrolene (work load 105W). (D) Exercise test on day two after 20-hours wash-out of
dantrolene showing return of PVCs (work load 105W).
doi:10.1371/journal.pone.0125366.g003
Antiarrhythmic Effect of Dantrolene with CPVT
PLOSONE | DOI:10.1371/journal.pone.0125366 May 8, 2015 9 / 17
Antiarrhythmic Effect of Dantrolene with CPVT
PLOSONE | DOI:10.1371/journal.pone.0125366 May 8, 2015 10 / 17
responses will be important for future drug development: one drug may not work for all pa-
tients even if the phenotype is the same.
Currently, beta-antiadrenergic medication is the first line antiarrhythmic treatment for all
CPVT patients. Flecainide has also shown beneficial effects.[34,35] ICDs are used if severe ar-
rhythmic events occur despite optimal beta-blocking treatment. However, use of ICDs is not
without risk since ICD-shocks may further aggravate catecholamine release and initiate an un-
controlled electric storm. Very recent data suggest that left cardiac sympatectomy may be high-
ly effective in patients refractory to medical therapy.[7,36] Although dantrolene as such would
not be suitable for long-term treatment of CPVT1 due to its side effects, and although only a
subset of patients would benefit from it, our data shows its antiarrhythmic potential. It also
suggest that it could be administered by intravenously to CPVT1 patients in emergencies such
as incessant ventricular tachycardia.
Fig 4. Characterization of CPVT1 iPSCs. (A) Expression of pluripotency markers shown by RT-PCR, β-actin or GAPDH serving as a housekeeping gene.
(B) None of the exogenous genes are expressed in CPVT1 cell lines. (C) EBs express markers from all the three embryonic germ layers. (D)
Immunocytochemical stainings and expression of pluripotency markers. Scale bar 200 μm. (E) Sequencing analysis confirmed the RyR2mutation in each
cell line. (F) All the cell lines had normal karyotype, example picture fromQ4201R cell line. (G) Teratomas made from a CPVT-iPSC line further confirms
pluripotency, example pictures from L4115F cell line.
doi:10.1371/journal.pone.0125366.g004
Fig 5. Characterization of CPVT-iPSCs derived CMs. (A) Immunocytochemical stainings of cardiac markers where red represents troponin T, green
connexin-43 and blue DAPI-staining for nuclei. Scale bars 200 μm. (B) Representative traces of a control CM showing normal regular Ca2+ transients and
CPVT1 CMs showing abnormalities like multiple peaks, low peaks, irregular phases and oscillations in Ca2+ handling. (C) Quantification of percentage of
CPVT1 and control iPSC CMs exhibiting abnormal Ca2+ transients at baseline (bl) and during adrenaline perfusion (adr). (D) Frequency and (E) Diastolic
level of intracellular Ca2+ of all CPVT1 and control CMs. Numbers of cells analyzed in C, D, and E, exon 3 del n = 48, P2328S n = 72, T2538R n = 52, L4115F
n = 110,Q4201R n = 63, V4653F n = 29, Controls (WT) n = 28. As an exception, number of WT cells analyzed in D, and E, in bl n = 54 and adr n = 27 and
number of P2328S cells in bl n = 90 and adr n = 47. Grey bars indicate cells at baseline and black bars during adrenaline perfusion. Error bars, SEM. *P<0.05
CPVT1 versus control, with Student’s t-test. Significance’s of mutation specific differences, see S2 Table.
doi:10.1371/journal.pone.0125366.g005
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Fig 6. iPSC derived CMs reproduced the clinical responses of dantrolene. (A) In vivo and in vitro effects of dantrolene correspond within each RyR2
mutation. In vitro drug effects were categorized into three groups (responders, semi-responders and non-responders) depending on how dantrolene affected
to the amount of Ca2+ abnormalities when compared to adrenaline response. In vivo responder group show the percentage of the abolished PVCs when
compared to the baseline. Numbers of cells analyzed in exon 3 del n = 16, P2328S n = 32, T2538R n = 17, L4115F n = 36,Q4201R n = 22, V4653F n = 13. (B)
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More than 150 mutations in RyR2 gene have been reported so far and they are clustered in
four hotspots.[11] One third of the reported mutations are in clusters 1 and 2 and the rest are
equally distributed between clusters 3 and 4. Only 10% of RyR2mutations have been found
outside these clusters.[11] The location of the RyR2mutation appears to be critical for a favor-
able effect of dantrolene. The binding site for dantrolene is localized in the N-terminus of RyR2
between amino acid 601 and 620.[13,37] The dantrolene-binding sequence is considered to
constitute part of the domain switch region, suggesting that dantrolene is involved in the cor-
rection of defective unzipping and allosteric stabilization of interdomain interactions between
the N- terminal and central regions of RyR2, resulting in inhibition of Ca2+ leak [16,30,38] and
in fact, this has been demonstrated in previous studies.[13,16,37] Also our data demonstrate
that dantrolene abolished arrhythmias in CPVT1 patients with mutations of N terminal or cen-
tral domain, suggesting that a defective inter-domain interaction within the RyR2 could be the
underlying arrhythmogenic mechanism in the exon 3 deletion, P2328S, T2538R and L4115F.
However, dantrolene did not suppress T2538R-related arrhythmias to the same extent as ar-
rhythmias caused by other central region mutations. It has been speculated that differences in
the mode of interdomain interaction in dantrolene binding regions may result in differences in
its antiarrhythmic efficacy.[30] Furthermore, other drug-binding regions in the carboxyl-ter-
minal half of the RyR2 or additional low affinity drug binding sites in the N-terminal area
could exist.[13] No previous studies on the effects of dantrolene on RyR2mutations in or close
to the transmembrane are available; here we show that dantrolene has no or only minimal ef-
fect on arrhythmias if mutations are located in these areas. It is interesting that the patient with
Q4201Rmutation did not respond to dantrolene even though this mutation is located in cyto-
solic portion of RyR2 and in cluster 3 although in its terminal part. This finding indicates that
the location of the mutation in certain mutation cluster does not necessarily determine the an-
tiarrhythmic response, and highlights the utility of the iPSC model for individual functional
analysis.
Our data showing similar patient-to-patient variation in dantrolene effects in the clinical
setting and corresponding iPSC-CMmodels suggest that, at least in theory, it may be possible
to tailor an individual's medication in cell culture without predisposing the individual to the
potentially serious side-effects of a drug. Dantrolene did not affect normally beating CMs. This
is consistent with previous reports showing that dantrolene inhibits only abnormal Ca2+ release
and has no effect on the normal Ca2+ transients, suggesting that the native conformation of
RyR2may restrict binding of the drug and that dantrolene binding to RyR2might be dependent
on a specific conformational state present only in mutated cells.[13,37] Defective calmodulin
binding caused by RyR2 domain unzipping has also been shown to be restored by dantrolene
[29,39] which may as well explain why dantrolene exerts effects on diseased but not healthy
hearts.
Besides differences in drug responses, we also saw both similarities and differences in the
CPVT1 in vitro phenotypes depending on the nature of the mutation. The beating frequency of
CPVT1 CMs was lower than that in control CMs. This is in line what has been reported also
with CPVT1 patients.[5,40] All the CPVT1 CMs showed similar disturbances in intracellular
Ca2+ cycling. Ca2+ transient abnormalities were somewhat more common in the cluster 4 mu-
tation than in cluster 1, 2 and 3 mutations. Exon 3 deletion differed from all the other muta-
tions by having lower diastolic Ca2+ levels and beating frequency both at baseline and during
Representative traces of dantrolene responder in vitro in an L4115Fmutated CM. Adrenaline causes Ca2+ cycling abnormalities and dantrolene abolishes all
the abnormalities. (C) Representative traces of semi-responder in vitro in a P2328Smutated CM. The cell has abnormal Ca2+ cycling at baseline and during
adrenaline perfusion and dantrolene reduces the abnormalities by abolishing the oscillation but leaving some low peak Ca2+ spiking.
doi:10.1371/journal.pone.0125366.g006
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adrenaline perfusion. Exon 3 encodes secondary structure elements that are crucial for folding
of the N-terminal domain. It has been proposed that RyR2 with exon 3 deletion has evolved ad-
ditional means to regulate Ca2+ release, by altering the conformation of the domain [41], which
may result in the observed differences in Ca2+ transients.
There are certain limitations in our study. First, only six CPVT1 patients and their iPSC cell
lines were studied; however, we emphasize that despite the very rare nature of this disease we
were able to examine in detail six different disease-causing mutations. Second, under the condi-
tions of the study design we were permitted to study only acute effects of intravenously admin-
istered dantrolene. Third, although we titrated the dose of dantrolene according to the weights
of the patients, serum levels of the drug were not measured and could have varied from patient
to patient, resulting in concentration-dependent variation in clinical responses. Fourth, we
used only a fixed concentration of dantrolene, selected on the basis of the work by Jung et al.
[20], in our iPSC studies. Fifth, immature phenotype of the iPSC-CMs may produce variation
in arrhythmias. However, in our previous study [21] the electrophysiology of CPVT1
iPSC-CMs appeared fairly mature. We have also shown here and in our previous study [21]
that arrhythmias are substantially more consistent in CPVT1 CMs than in control CMs.
In conclusion, we have shown here the proof of principle that intravenously administered
dantrolene suppresses ventricular arrhythmias in the congenital RyR2 defect and that the loca-
tion of the RyR2mutation may affect the antiarrhythmic effect of this drug. We also demon-
strate that iPSC derived patient-specific CMs correctly predict the clinical response to
dantrolene in CPVT1 patients with varying RyR2mutations. Our data support the notion that
iPSC-derived CMs could serve as a platform for drug development and for design of
personalized medication.
Supporting Information
S1 Fig. Confirmation of exon 3 deletion. Exon 3 deletion of 05605. CPVT cell line was also
confirmed with PCR and agarose gel electrophoresis.
(TIF)
S2 Fig. Ca2+ transient parameters as a response to dantrolene. (A) Diastolic Ca2+ level and
(B) beating frequency in responder and non-responder CMs. Values during adrenaline perfu-
sion were divided by values during dantrolene perfusion, separately for each cell. Green bars in-
dicate responder CMs and purple bars non-responder CMs. Error bars, SEM.  indicates
significant difference between adrenaline versus dantrolene within a group, P<0.05. Numbers
of cells analyzed in exon 3 del n = 13, P2328S n = 29, T2538R n = 11, L4115F n = 28, Q4201R
n = 15, V4653F n = 10, Control (WT) n = 20.
(TIF)
S1 Protocol. English translated trial study protocol.
(DOCX)
S2 Protocol. Trial study protocol in the original language (Finnish).
(DOC)
S1 Table. Primer sequences for EB RT-PCR.
(DOCX)
S2 Table. Differences between RyR2 mutations in their Ca2+ transient properties during
baseline and adrenaline perfusion. CL indicates cluster numbers. Upward pointing arrow in-
dicates significantly (p<0.05) higher and downward pointing arrow significantly lower diastol-
ic Ca2+ level or beating frequency of the first mentioned mutation when compared to the
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second mentioned mutation. NS indicates that there was no statistical significance between
mutations. As parallel pointing arrows between comparison groups indicate, the average of the
beating frequency and diastolic Ca2+ level inside one mutation group corresponded and the av-
erage of these parameters decrease when moving from P2328S towards transmembrane
area mutations.
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CORRECTION
Correction: Antiarrhythmic Effects of
Dantrolene in Patients with
Catecholaminergic Polymorphic Ventricular
Tachycardia and Replication of the
Responses Using iPSC Models
Kirsi Penttinen, Heikki Swan, Sari Vanninen, Jere Paavola, Annukka M. Lahtinen,
Kimmo Kontula, Katriina Aalto-Setälä
There are errors in Fig 2, “Features of the PVCs,” and its caption. Please see the corrected Fig 2
and its caption here.
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SUPPORTING INFORMATION 
STUDY III 
 
 
S1 Fig. Confirmation of exon 3 deletion. Exon 3 deletion of 05605.CPVT cell line was also 
confirmed with PCR and agarose gel electrophoresis.  
  
  
 
 
 
  
S2 Fig. Ca2+ transient parameters as a response to dantrolene. (A) Diastolic Ca2+ level and (B) 
beating frequency in responder and non-responder CMs. Values during adrenaline perfusion were 
divided by values during dantrolene perfusion, separately for each cell. Green bars indicate 
responder CMs and purple bars non-responder CMs. Error bars, SEM. * indicates significant 
difference between adrenaline versus dantrolene within a group, *P<0.05. Numbers of cells 
analyzed in exon 3 del n= 13, P2328S n=29, T2538R n=11, L4115F n=28, Q4201R n=15, V4653F 
n=10, Control (WT) n=20.  
  
S1 Protocol. English translated trial study protocol.  
 
Study protocol  
Study title: Dantrolene in CPVT 
The purpose of the study is to study whether  
1. dantrolene has an effect on ventricular arrhythmias  induced during stress exercise test in patient carrying 
different mutations for CPVT 
2. dantrolene has an effect on baseline beating rate, conduction or QTc in patient carrying different mutations for 
CPVT  
 
The following parameters are monitored: 
- sinus rhythm at baseline 
- the amount of ventricular extrasystole at baseline during 5 minutes  
- beating rate, where ventricular ext rasystole start to appear during stress exercise test 
- The amount of ventricular extrasystole /min during each ramp  
- The longest ventricular tachycardia event during each ramp 
- QTc interval is measured during baseline, during exercise test and during recovery  
- the duration of the exercise test is measured (minutes) 
- the beating rate (sinus rhythm) is measured at the end of each ramp 
- the maximal beating rate is monitored (sinus rhythm) 
 
Patients to be recruited 
 
For this study 5-6 CPVT patients with a sequenced RyR2 mutation are recruited. Patients to be included have already 
earlier donated a skin biopsy for iPS cell studies. All the patients are on beta-blocker treatment, usually propranolol 80-
160 mg/day or b isoprolol 5-10 mg/day.  Other than CPVT, the patients are healthy.  All the patients have already earlier 
participated studies about CPVT and for this study they are contacted either by phone or by a letter, where they will be 
informed about the study and the potential risks.  All the patients will receive written information about the study as well 
as the informed consent form.  The consent form will be signed during the first visit for the study.  All participants will 
be on their regular medication during the entire study. This study does not affect the medication of the participants after 
the study.  The participants do not benefit from this study at least in the near future, but the study aims at producing new 
data for future medicat ion.  
All the participants are Finnish speaking and they are all over 18 years of age, no pregnant nor lactating 
individuals are recruited. A ll the participants have performed earlier stress exercise tests  and no problems or 
complications have been experienced with the previous tests. The following laboratory tests will be analyzed during the 
the first day before the first exercise test as well as on the morning of the second day: PVK, K, Na, fs -Ca, Krea. During 
dantrolene test, all the part icipants have an intra-venous (iv) in fusion and thus a route for additional medication if 
needed during the tests in this proposal. The participants are covered by the insurance of the hospitals.  
 
Exclusion criteria 
- Calcium b locker treatment 
- Pregnancy 
- Any musculoskeletal prob lem affecting their performance 
- Systolic blood pressure over 160 or d iastolic over 95 mmHg  
- Previously diagnosed coronary artery disease, congenital heart problem, or a pacemaker implanted fo r bradycardia  
- ECG: PQ>200 ms, QRS>120 ms, RV5 or SV1>29 mm, delta-wave 
 
Study protocol 
 
1. day 
All the participants take their beta-blocker medication normally in the morning before coming to the hospital. An iv-
catheter is placed and saline is infused slowly during exercise test. The participants are in continuous ECG monitoring 
during all exercise test and during dantrolene infusion as well as 24 hours after the infusion. Blood pressure is 
monitored regularly with a cuff in the upper arm.  
 
During the first exercise test, participants cycle 30 W + 15W/one minute ramps until about 80% of the maximum 
beating rate for the age. Due to the beta-blocker medication, it is possible that the desired heart is not reached.  
 
The participants rest for at least 2 hours before the second exercise test.  Before that dantrolene is infused 1.5 mg/kg. 
Dantrolene concentrate (20 mg) is diluted into 60 ml and in fused in 5 minutes and thus the whole infusion time is about 
30 minutes. The heart rate in continuously monitored for the next 24 hours as well as blood pressure is regularly 
analyzed.  
 
2.  day 
The third exercise test is performed (about 18 hours after the second one).   
  
S2 Protocol. Trial study protocol in the original language (Finnish).  
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DANTROLEENI  KATEKOLIAMIINIHERKÄSSÄ KAMMIOTAKYKARDIASSA 
 
 
 
Tutkimus dantroleenin vaikutuksista perinnöllistä monimuotoista kammiotiheälyöntisyttä 
sairastavien potilaiden rytmihäiriöiden ilmaantuvuuteen sekä sydämen sähköiseen 
repolarisaatioon 
Koejärjestelyllä pyritään saamaan vastaus seuraaviin kysymyksiin :  
- estääkö tai vähentääkö suonensisäisesti annettu kerta-annos dantroleenia kammioperäisten lisälyöntien ilmaantumista 
submaksimaalisessa rasituksessa perinnöllistä monimuotoista kammiotiheälyöntisyyttä sairastavilla verrattuna ennen 
lääkkeen antoa vallinneeseen tilaan (beetasalpaajalääkityksen käytössä ollessa) 
- vaikuttaako dantroleeni leposykkeeseen, johtumiseen tai QTc-aikaan  perinnöllistä monimuotoista 
kammiotiheälyöntisyyttä sairastavilla  
 
Tutkimuksessa mitataan seuraavia tekijöitä: 
- sinustaajuus levossa 
- kammiolisälyöntien määrä levossa 5 minuutin aikana  
-syketaso, jossa kammiolisälyönnit ilmaantuvat ens i kertaa rasituksen aikana  
-kammiolisälyöntien määrä/minuutti kunkin rasitusportaan aikana 
-pisimmän perättäisten kammiokompleksien sarjan pituus  kunkin rasitusportaan (á 1 min) aikana  
-sydämen sähköisen palautumisen muutoksia mitataan lepo-EKG:sta sekä rasituksen ja sitä seuraavan palautumisen 
aikana rekisteröidystä EKG:sta QT -ajan p ituutta seuraamalla. 
- rasituksen kesto minuuteissa 
- sinustaajuus kunkin kuormaportaan päättyessä  
- saavutettu maksimaalinen sinustaajuus 
 
Tutkittavat potilaat 
Pilottiluonteiseen tutkimukseen otetaan mukaan 5-6 genotyypiltään tunnettua RYR2 -potilasta, jo illa  on kliinisesti 
todettu RYR2 -mutaatiosta johtuva perinnöllinen monimuotoinen kammiot iheälyöntisyys. Ensisijaisesti tutkimukseen 
kutsutaan potilaita, joista on jo iPS-soluviljelmät in vitro-tutkimuksia varten. Tutkimukseen otettavilla on jo käytössään 
beetasalpaajalääkitys, tavallisesti propranololia 80-160 mg/vrk tai bisoprololia 5-10 mg/vrk ja he ovat perinnöllistä 
monimuotoista kammiot iheälyöntisyyttä lukuunottamatta muuten terveitä. Tutkittavia, jotka ovat olleet jo 
tutkimusryhmän muissa tutkimuksissa aiemmin mukana,  pyydetään tutkimukseen puhelimitse, jollo in heille selostetaan 
tutkimuksen kulku ja mahdolliset riskit suullisesti ja heidän alustavan suostumuksensa jälkeen heille to imitetaan 
kirjallinen informaat io tutkimuksesta postitse. Tutkittavat allekirjo ittavat suostumuslomakkeensa tutkimukseen 
saapuessaan. Tutkittavien hoito jatkuu tutkimuksen ajan ja sen jälkeen ennallaan. Tutkimus ei vaikuta tutkittavien 
potilaiden hoitoon välittömästi mutta saattaa mahdollistaa täydentävän hoidon käyttöönoton olemassa  olevan lisäksi 
lisätutkimusten jälkeen tutkittaville tai heidän perheenjäsenilleen.  
Tutkittavat ovat kaikki suomenkielisiä. Tutkimus ei kohdistu vajaakykyisiin, alaikäisiin, ras-kaana oleviin eikä 
imettäviin naisiin, eikä vankeihin. Tutkittavissa ei ole muita myöskään muita hen -kilöryhmiä, joiden vapaaehtoisuus 
voidaan kyseenalaistaa. Tutkittaville on tehty rasituskokeita toistu-vasti aiemmin eikä niiden suorittamiseen ole liittynyt 
ongelmia tai komplikaatio ita. Rasituskokeen yh-teydessä on tavanomaisen komplikaat ioiden hoitovalmiuden lisäksi 
myös nopea mahdollisuus suonen-sisäiseen nesteen- ja lääkkeenantoon tutkimuksen alussa asetettavan laskimokanyylin 
vuoksi. Tutkit-tavien vakuutusturva sisältyy sairaalalle projektipotilaista maksettaviin käynti- ja toimenpidemaksuihin. 
 
Poissulkukriteereinä on  
- kalsiumkanavasalpaaja- tai metoklopramidilääkitys 
- raskaus 
- liikuntaa rajoittava tuki- ja liikuntaelimistön sairaus 
- tarve ku ljettaa moottoriajoneuvoa lääkkeen antoa seuraavan vuorokauden aikana  
- verenpaine levossa yli 160 (S) tai y li 95 (D)  
- aiemmin  todettu sepelvaltimotauti, läppävika, synnynnäinen sydänvika, tahdistinhoito  
- EKG: PQ>200 ms, QRS>120 ms, RV5 tai SV1>29 mm, delta-aalto  
 
TUTKIMUKSEN KULKU 
 
1. päivä 
Tutkittavat ottavat tutkimukseen tullessaan ja tutkimuksen aikana beetasalpaajalääkityksensä tavanomaiseen tapaan. 
Tutkittavalle asetetaan laskimokanyyli, jonka kautta infusoidaan hitaasti fysiologista ke ittosuolaa kunkin rasituskokeen 
aikana. Potilailla on lääkkeiden annon, rasituskokeiden ja niiden jälkeisen palautumisvaiheen ajan jatkuva EKG -
seuranta sekä olkavarsimansetilla suoritettava verenpaineseuranta. 
 
Suoritetaan ensimmäinen rasituskoe polkupyöräergometrilla, jossa potilas polkee 30 W + 15 W/1 min portain 
syketasolle, joka on n. 80 % iänmukaisesta maksimista. Koska potilailla on jo käytössään beetasalpaajalääkitys, saattaa 
saavutettava syketaso jäädä kuitenkin tätä matalammaksi.  
Vähintään 2 tunnin lepotauon jälkeen suoritetaan toinen rasituskoe, jota ennen infusoidaan dantroleenia 1.5 mg/kg. 
Kukin 20 mg:n infuusiokonsentraattipakkaus laimennetaan 60 ml:n nestemäärään, joka infusoidaan n. 5 minuutissa, 
jolloin painon mukainen kokonaislääkeannoksen infuusion kesto on n. 30 minuuttia. Tutkittavia seurataan sairaalassa 
sydämen rytmiä monitoro iden seuraavaan aamuun asti. 
 
3.  päivä 
Suoritetaan edellä kerrotulla tavalla kolmas rasituskoe (n. 18 tuntia edellisestä).   
 
Tutkimuskeskukset 
Tutkimus suoritetaan HYKSin Kard iologian klin ikassa Sydäntutkimusosastolla tai Kolmiosairaalan vuodeosastolla (3-4 
potilasta) sekä TAYSissä (2 potilasta).  
 
POTILAIDEN JA VERROKKIHENKILÖIDEN S UOS TUMUS  
Potilaille  ja verrokkihenkilöille kerrotaan tutkimuksen tarkoitus, sen kulku  ja mahdolliset haitat suullisesti ja 
tiedotteella, joka on tämän tutkimussuunnitelman liitteenä. Tutkimuksiin osallistuville ei makseta palkkiota.  
 
TIEDOTE TUTKIMUKSESTA 
 
DANTROLEENI  KATEKOLIAMIINIHERKÄSSÄ KAMMIOTAKYKARDIASSA  
 
Sinua pyydetään mukaan tutkimukseen, jonka tarkoituksena on selvittää, vähentääkö sydänlihassolujen 
kalsiumkanaviin vaikuttava dantroleenilääke rasituksessa ilmeneviä rytmihäiriöitä rytmihäiriösairaudessasi. 
Olemme arvioineet, että soveltuisit mukaan tutkimukseen, koska sairastat perinnöllistä 
katekoliamiiniherkkää kammiotakykardiaa (CPVT). Tämä tiedote kuvaa tutkimusta ja osuuttasi siinä. 
Osallistumisen vapaaehtoisuus 
Osallistuminen tähän tutkimukseen on täysin vapaaehtoista. Voit kieltäytyä osallistumasta tutkimukseen tai 
keskeyttää osallistumisesi syytä ilmoittamatta milloin tahansa. Sinun ei tarvitse osallistua tähän tutkimukseen 
saadaksesi hoitoa. Lääkärisi kertoo Sinulle sairautesi hoitovaihtoehdoista. Tutkijalääkäri voi joutua 
keskeyttämään osallistumisesi. Jos näin tapahtuu, kanssasi keskustellaan lopettamiseen liittyvistä 
jatkotoimenpiteistä. 
Lue rauhassa tämä tiedote. Jos Sinulla on kysyttävää, voi olla yhteydessä tutkijalääkäriin tai 
tutkimushoitajana. Jos päätät sallistua tutkimukseen, pyydämme Sinua allekirjoittamaan liitteenä olevan 
suostumuslomakkeen. 
Tutkimuksen toteuttaja 
Tämän tutkimuksen toteuttavat HYKSin Meilahden sairaalassa dos. Heikki Swan ja TAYSin 
Sydänkeskuksessa dos Katriina Aalto-Setälä. Tutkimuksen rekisterinpitäjä on dos Heikki Swan 
tutkimusryhmineen, joka vastaa tutkimuksen yhteydessä tapahtuvan henkilötietojen käsittelyn 
lainmukaisuudesta.  
Tutkimuksen tausta ja tarkoitus 
Perinnöllinen polymorfinen kammiotakykardia on harvinainen, pahanlaatuinen rytmihäiriösairaus. Kyseessä 
on sydämen sähköisen toiminnan häiriö. Rakenteellista sydänvikaa ei ole todettavissa ja levossa tutkittu 
EKG:kin (sydänfilmi) on tautia kantavilla normaali. Potilaiden rytmihäiriöt ilmenevät tyypillisesti aina 
syketason noustua tietyn yksilöllisen kynnyksen yläpuolelle. Taudin toteamisessa keskeinen menetelmä 
onkin rasituskoe, jossa alun normaalin rytmin kiihtyessä rasituksen myötä alkaa ilmaantua 
kammiolisälyöntisyyttä yhä enenevässä määrin. Rytmihäiriöalttius johtuu sydänlihassolujen sisäisestä 
kalsiumaineenvaihdunnan häiriöstä.  
 
Oireyhtymää sairastavien potilaiden hoidossa käytetään tavallisesti beetasalpaajalääkitystä, josta on parhaat 
kokemukset rytmihäiriöiden estossa. Beetasalpaajat ovat lääkkeitä, joita käytetään myös mm. 
sepelvaltimotautia ja verenpainetautia sairastavien hoidossa. Beetasalpaajat eivät yleensä poista 
rytmihäiriöiden ilmaantumista rasituksessa mutta kokemukset viittaavat siihen, että alttius 
pahemmanlaatuisiin rytmihäiriöihin, joiden seurauksena verenkierto saattaisi romahtaa, pienenee. 
Beetasalpaajalääkityksen aikana on harvoin esiintynyt tajunnanmenetyskohtauksia. Eräät 
beetasalpaajalääkkeet ovat vasta-aiheisia mm. astmaa sairastavilla. Vain harvoin beetasalpaajalääkitystä ei 
voida käyttää sen sivuvaikutusten vuoksi.  
 
Tarkoituksenamme on selvittää, vähentääkö sydänlihassolujen kalsiumkanaviin vaikuttava dantroleenilääke 
rasituksessa ilmeneviä rytmihäiriöitä rytmihäiriösairaudessasi. Mikäli rytmihäiriöiden ilmaantuminen 
tutkimuslääkkeen antamisen jälkeen olisi vähäisempää kuin beetasalpaajalääkityksen käytössä ollessa, 
voitaisiin kyseistä lääkettä edelleen tutkimalla mahdollisesti löytää lisälääke niille perinnöllistä 
monimuotoista kammiotiheälyöntisyyttä sairastaville potilaille, joille beetasalpaajalääkitys ei yksinään ole 
joko riittävä tai jotka eivät sitä sivuvaikutusten vuoksi voi käyttää. 
Tutkimukseen pyydetään mukaan henkilöitä, jotka ovat täysi-ikäisiä ja joilla on RYR2-geenin mutaatiosta 
johtuva perinnöllinen katekoliamiiniherkkä kammiotiheälyöntisyys ja sen hoidoksi käytössään 
beetasalpaajalääkitys mutta ei muita rytmihäiriölääkkeitä eikä muita merkittäviä sydän- ja 
verisuonisairauksia. Tutkimukseen osallistuu noin 5-6 tutkittavaa.  
Tutkimusmenetelmät ja tutkimuksen toimenpiteet  
Tutkimukseen osallistuminen kestää runsaan vuorokauden, jonka ajan olet sairaalassa. Ensimmäisenä 
tutkimuspäivänä otetaan verinäyte ja asetetaan laskimoon muovikanyyli (”tippa”) tutkimuslääkkeiden antoa 
varten. Ensimmäisenä päivänä suoritat rasituskokeen kahdesti. Ennen toista rasituskoetta, annetaan 
laskimoon dantroleenilääkettä. Kolmas rasitus-koe tehdään seuraavana päivänä, minkä jälkeen voit kotiutua. 
Lääkkeen vaikutusta verenpai-neeseen ja sykkeeseen seurataan tutkimuksen aikana EKG:n ja 
verenpainemittausten avulla.  
 
Käyttämistäsi lääkkeistä tutkimuksen alkaessa sinun tulee ilmoittaa tutkijoille. Tutkimuksen aikana 
mahdollisesti potilaan tai koehenkilön tarvitsemien muiden lääkkeiden sekä tupakan tai alkoholin käyttöön 
on pyydettävä tutkijoiden lupa.Tutkimuksen aikana kaikkien hedelmällisessä iässä olevien naisten on 
käytettävä luotettavaa ehkäisyä. Tutkijalääkäri keskustelee tarvittaessa kanssasi käyttämästäsi 
ehkäisymenetelmästä. Raskaana olevat, imettävät tai raskautta suunnittelevat naiset eivät voi osallistua tähän 
tutkimukseen. 
Tutkimuksen mahdolliset hyödyt 
Dantroleenilääkkeen tutkiminen ei vaikuta välittömästi hoitoosi mutta tutkimus voi auttaa uuden lääkehoidon 
löytymisessä rytmihäiriöiden ehkäisemiseksi. Tutkittavasta sairaudesta voidaan myös saada hyödyllistä 
lisätietoa. Saat tietoa terveydentilastasi tutkimuksen aikana tehtävistä lääkärintarkastuksista ja 
laboratoriokokeista. 
Tutkimuksesta mahdollisesti aiheutuvat haitat ja epämukavuudet 
Tutkimuksessa tarvittavan laskimokanyylin asettaminen on tavallinen toimenpide sydänpot ilaiden 
tutkimuksessa ja hoidossa mutta joskus toimenpiteeseen saattaa liittyä paikallista kipua tai verenpurkauman 
muodostumista ihonalaiskudokseen. Lääkkeen sivuvaikutuksena saattaa esiintyä lyhytaikaista lihasvoiman 
heikentymistä tai paikallista laskimoärsytystä lääkkeenantokohdassa. Rasituskokeeseen liittyvä 
rytmihäiriöriski on samankaltainen kuin muussakin samalla tavalla kuormittavassa liikunnassa. Mahdollisiin 
rytmihäiriöongelmiin ja verenpaineen laskuun on varauduttu kuten rasituskoetta suoritettaessa yleensäkin 
varaudutaan.Tutkijalääkäri voi kertoa Sinulle muista mahdollisista haitoista. 
 
Tutkimuslääkkeen käyttöön saattaa liittyä ennalta tuntemattomia riskejä. Jos tutkimuksen aikana saadaan 
turvallisuutesi kannalta oleellista uutta tietoa tutkimusvalmisteesta, tutkijalääkäri ottaa Sinuun välittömästi 
yhteyttä ja keskustelee kanssasi siitä, haluatko edelleen jatkaa tutkimuksessa. 
Tietojen luottamuksellisuus ja tietosuoja 
Tutkimuksessa henkilöllisyytesi sekä muut tunnistettavat tiedot ovat ainoastaan tutkimuksen henkilökunnan 
tiedossa, ja he kaikki ovat salassapitovelvollisia. Tutkimukseen liittyvistä tutkimustuloksista, selvityksistä tai 
julkaisuista ei yksittäisiä tutkittavia voi tunnistaa.  
Tutkimusrekisteristä on laadittu henkilötietolain 10 §:n mukainen rekisteriseloste, jonka saat halutessasi 
nähtäväksi. 
Terveydentilaasi koskevia ja tutkimuksen kannalta tarpeellisia tietoja voidaan luvallasi kerätä myös muista 
terveydenhuollon toimintayksiköistä. Tutkijalääkäri voi tällöin hankkia tarvitsemansa tiedot 
henkilötunnuksesi avulla. Sinulla on oikeus tarkastaa omat henkilötietosi ja tarvittaessa pyytää niihin 
korjauksia.  
Suomessa lääkevalvontaviranomaisella (Lääkealan turvallisuus- ja kehittämiskeskus Fimea) on oikeus 
varmistaa, että tutkimustiedot on hankittu ja tutkimus toteutettu asianmukaisella tavalla. Kaikissa tapauksissa 
tietojasi käsitellään luottamuksellisesti.  
Jos osallistumisesi tutkimukseen jostain syystä keskeytyy, keskeyttämiseen mennessä kerättyjä tietoja 
käytetään osana tutkimusaineistoa ja lääkkeen turvallisuusarviointia.  
Tutkimuksen kustannukset ja taloudelliset selvitykset 
Tutkimus on Sinulle maksuton. Tutkimuskäynneistä aiheutuvat mahdolliset matkakustannukset korvataan 
todellisten kustannusten mukaan tositteiden perusteella.   
Tutkimus rahoitetaan sairaalan tutkimusmäärärahoista ja Suomen Sydäntutkimussäätiön apurahalla. 
 
Tutkittavien vakuutusturva  
Jos tutkimuslääkkeestä tai tutkimuksen takia tehdystä toimenpiteestä aiheutuu Sinulle henkilövahinko, voit 
hakea korvausta potilasvakuutuksesta. Se korvaa potilasvahinkolain mukaisesti terveyden ja sairaanhoidon 
yhteydessä aiheutuneita henkilövahinkoja laissa tarkemmin säädellyin edellytyksin. Potilasvakuutuskeskus 
huolehtii potilasvahinkojen korvauskäsittelystä. 
Tutkimuksen päättyminen 
Hoitosi jatkuu nykyisellään tutkimuksen jälkeen. Tarvittaessa tutkijalääkäri keskustelee kanssasi hoidostasi 
tutkimuksen päättymisen jälkeen. 
Lisätietoja 
Jos Sinulla on kysyttävää tutkimuksesta, voit olla yhteydessä tutkijalääkäriin tai muuhun tutkimuksen 
henkilökuntaan. Heidän kanssaan voit keskustella kaikista tutkimuksen aikana mahdollisesti ilmenneistä 
haittavaikutuksista, epäilyttävistä oireista ja muista mieltäsi askarruttavista asioista.  
 
Tutkimukseen liittyvissä asioissa yhdyshenkilönä on  Meilahden sairaalassa dos. Heikki Swan, HYKS 
Sydäntutkimusosasto, Haartmanink. 4, 00290 Helsinki, puhelin 050-4286591 tai 09-4711, Tampereen 
Yliopistosairaalassa dos. Katriina Aalto-Setälä, TAYS Sydänkeskus, Biokatu 6, 33520 Tampere, puhelin03 - 
311 66088 tai 040-5829567. 
SUOSTUMUS LÄÄKETUTKIMUKSEEN 
 
 
Minua on pyydetty osallistumaan dantroleeni-lääkkeellä suoritettavaan rytmihäiriöiden hoitotutkimukseen.  
 
Olen saanut, lukenut ja ymmärtänyt tutkimuksesta kertovan tiedotteen 23.11.2012. Tiedotteesta olen saanut 
riittävän selvityksen tutkimuksesta (dantroleeni katekoliamiiniherkässä kammiotakykardiassa) ja sen 
yhteydessä suoritettavasta tietojen keräämisestä, käsittelystä ja luovuttamisesta. Tiedotteen sisältö on 
kerrottu minulle myös suullisesti ja olen saanut riittävän vastauksen kaikkiin tutkimusta koskeviin 
kysymyksiini. Tiedot antoi ________________________________ , ___/___/ 20__ . Minulla on ollut 
riittävästi aikaa harkita osallistumistani tutkimukseen. 
 
Minulle kerrotaan, mistä minua koskevia tietoja hankitaan. Annan luvan itseäni koskevien, tutkimuksen 
kannalta tarpeellisten tietojen keräämiseen perinnöllisten rytmihäiriösairauksien tutkimusrekisteriin. Tietoja 
voidaan lääketutkimuksen sitä edellyttäessä pyytää niistä terveydenhoitopaikoista, joissa on potilastietojani. 
Tätä tarkoitusta varten lääkäri saa kirjata henkilötunnukseni sekä käyttää sitä tietojen saamiseksi.  
 
Kaikki minusta tutkimuksen aikana kerättävät tiedot käsitellään luottamuksellisina.  
 
Lääkevalvonnasta ja –turvallisuudesta vastaavan viranomaisen, Suomessa Lääkealan turvallisuus- ja 
kehittämiskeskus Fimean edustajilla on oikeus varmistaa tutkimustietojen totuudenmukaisuus ja tutkimuksen 
asianmukainen suorittaminen. Tämä tapahtuu vertaamalla tutkimustietoja alkuperäisiin sairaskertomuksiini 
ja terveydentilaani koskeviin tietoihin. edellä mainitut tahot ovat velvollisia pitämään tiedot salassa. 
  
Tässä tutkimuksessa kerättäviä tietoja voidaan käsitellä muualla kuin tiedot keränneen tutkijalääkärin tiloissa 
ja laitteissa. Tällöin tiedot ovat koodatussa muodossaan.  
 
Tässä lääketutkimuksessa kerättävä tieto voi olla hyödyksi myös selvitettäessä dantroleeni-lääkkeen uutta 
käyttötarkoitusta, josta tämän suostumuksen antamisen hetkellä ei ole tietoa. Hyväksyn, että minusta 
kerättäviä tietoja voidaan viranomaisen luvalla käyttää tällaiseen tarkoitukseen. 
 
Ymmärrän, että osallistumiseni tähän tutkimukseen on täysin vapaaehtoista. Minulla on oikeus milloin 
tahansa tutkimuksen aikana ja syytä ilmoittamatta keskeyttää tutkimukseen osallistuminen. Tutkimuksesta 
kieltäytyminen tai sen keskeyttäminen ei vaikuta jatkohoitooni. Olen tietoinen siitä, että minusta 
keskeyttämiseen mennessä kerättyjä tietoja käytetään osana tutkimusaineistoa ja lääkkeen 
turvallisuusarviointia. 
  
Allekirjoituksellani vahvistan osallistumiseni tähän tutkimukseen ja suostun vapaaehtoisesti 
tutkimushenkilöksi. 
 
 
 
 
________________________  _________________________ 
Allekirjoitus     Päiväys 
 
 
_________________________  _________________________ 
Nimen selvennys    Syntymäaika 
 
 
__________________________________________________________ 
Osoite 
 
 
 
 
Suostumus vastaanotettu 
 
 
 
_________________________  __________________________ 
Tutkijalääkärin allekirjoitus   Päiväys 
 
 
_________________________ 
Nimen selvennys 
 
 
 
 
Alkuperäinen allekirjoitettu tutkimushenkilön suostumus sekä kopio tutkimushenkilötiedotteesta jäävät 
tutkijalääkärin arkistoon. Tutkimushenkilötiedote ja kopio allekirjoitetusta suostumuksesta annetaan 
tutkimushenkilölle.  
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S1 Table. Primer sequences for EB RT-PCR. 
 
  
Gene Forward Primer Reverse Primer 
Endodermal    
AFP AGAACCTGTCACAAGCTGTG GACAGCAAGCTGAGGATGTC 
SOX-17 CGCACGGAATTTGAACAGTA  CACACGTCAGGATAGTTGCAG 
Ectodermal    
Nestin CAGCTGGCGCACCTCAAGATG AGGGAAGTTGGGCTCAGGACTGG 
SOX-1  AAAGTCAAAACGAGGCGAGA  AAGTGCTTGGACCTGCCTTA  
Mesodermal    
VEGF-R2 GGAGTTATGGTGGGTATGGGTC AGTGGTGACAAAGGAGTAGCCA 
S2 Table. Differences between RyR2 mutations in their Ca2+ transient properties during 
baseline and adrenaline perfusion. CL indicates cluster numbers. Upward pointing arrow 
indicates significantly (p<0.05) higher and downward pointing arrow significantly lower diastolic 
Ca2+ level or beating frequency of the first mentioned mutation when compared to the second 
mentioned mutation. NS indicates that there was no statistical significance between mutations. As 
parallel pointing arrows between comparison groups indicate, the average of the beating frequency 
and diastolic Ca2+ level inside one mutation group corresponded and the average of these 
parameters decrease when moving from P2328S towards transmembrane area mutations.  
 
 
 
  
CLUSTERS  
 
MUTATIONS 
BAS ELINE ADRENALINE 
Diastolic 
Ca
2+ 
 level  
Beating 
frequency 
Diastolic 
Ca
2+ 
 level  
Beating 
frequency 
Exon 3 deletion 
versus 
point mutations  
CL 1 vs. CL 2 exon 3 del vs. P2328S ↓ ↓ ↓ ↓ 
CL 1 vs. CL2-3 exon 3 del vs. T2538R ↓ ↓ ↓ ↓ 
CL 1 vs. CL 3 exon 3 del vs. L4115F  ↓ ↓ ↓ ↓ 
CL 1 vs. CL3 exon 3 del vs. Q4201R ↓ ↓ ↓ ↓ 
CL 1 vs. CL 4 exon 3 del vs. V4653F NS ↓ NS ↓ 
Comparison of 
point mutations 
exceeding 
towards 
trans membrane 
area 
CL 2 vs. CL 2-3 P2328S vs. T2538R NS NS ↑ ↑ 
CL 2 vs. CL 3 P2328S vs. L4115F ↑ ↑ ↑ ↑ 
CL 2 vs. CL 3 P2328S vs. Q4201R ↑ ↑ ↑ ↑ 
CL 2 vs. CL 4 P2328S vs. V4653F ↑ ↑ ↑ ↑ 
CL 2-3 vs. CL 3 T2538R vs. L4115F ↑ NS ↑ NS 
CL 2-3 vs. CL 3 T2538R vs. Q4201R ↑ ↑ ↑ NS 
CL 2-3 vs. CL 4 T2538R vs. V4653F ↑ NS ↑ NS 
CL 3 vs. CL 3 L4115F vs. Q4201R NS NS NS NS 
CL 3 vs. CL 4 L4115F vs. V4653F ↑ NS ↑ NS 
CL 3 vs. CL 4 Q4201R vs. V4653F ↑ NS ↑ NS 
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Abstract
Comprehensive functioning of Ca2+ cycling is crucial for excitation–contraction coupling of
cardiomyocytes (CMs). Abnormal Ca2+ cycling is linked to arrhythmogenesis, which is
associated with cardiac disorders and heart failure. Accordingly, we have generated spon-
taneously beating CMs from induced pluripotent stem cells (iPSC) derived from patients
with catecholaminergic polymorphic ventricular tachycardia (CPVT), which is an inherited
and severe cardiac disease. Ca2+ cycling studies have revealed substantial abnormalities
in these CMs. Ca2+ transient analysis performed manually lacks accepted analysis criteria,
and has both low throughput and high variability. To overcome these issues, we have devel-
oped a software tool, AnomalyExplorer based on interactive visualization, to assist in the
classification of Ca2+ transient patterns detected in CMs. Here, we demonstrate the usability
and capability of the software, and we also compare the analysis efficiency to manual analy-
sis. We show that AnomalyExplorer is suitable for detecting normal and abnormal Ca2+
transients; furthermore, this method provides more defined and consistent information
regarding the Ca2+ abnormality patterns and cell line specific differences when compared to
manual analysis. This tool will facilitate and speed up the analysis of CM Ca2+ transients,
making it both more accurate and user-independent. AnomalyExplorer can be exploited in
Ca2+ cycling analysis to study basic disease pathology and the effects of different drugs.
Introduction
Calcium (Ca2+) cycling plays an essential role in the excitation-contraction coupling of cardio-
myocytes (CMs) and is therefore vital for cardiac functionality. However, cardiac diseases and
different drugs can cause changes and variability in Ca2+ cycling that can affect the function
and phenotype of CMs. Characterizing these disturbances and abnormalities is vital to improv-
ing the studies of the disease pathology and disease prevention and treatment. Intracellular
PLOSONE | DOI:10.1371/journal.pone.0135806 August 26, 2015 1 / 17
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Ca2+ cycling of CMs is analyzed in vitro with Ca2+ sensitive dyes that change their fluorescence
properties when binding to Ca2+ ions.
Induced pluripotent stem cell (iPSC) technology, in which pluripotent stem cells are gener-
ated by reprogramming differentiated cells back into the pluripotent state, provides a method
for studying the pathophysiology of various disorders in human cells.[1] iPSCs can be differen-
tiated into the desired cell type and retain the original genotype. New insights into the Ca2+
cycling of different cardiac diseases have been achieved since the invention of iPSC technology.
The functionality of CMs and their drug responses could be studied more thoroughly with
investigation of Ca2+ transients. Disease modeling with iPSCs has been successfully exploited
to study cardiac diseases such as catecholaminergic polymorphic ventricular tachycardia
(CPVT) [2–9], dilated cardiomyopathy [10], hypertrophic cardiomyopathy [11,12] and Timo-
thy syndrome [13]. In these studies, Ca2+ cycling analyses have revealed substantial defects and
abnormalities in CMs that reflect the cardiac phenotype observed in patients. However, analyz-
ing these Ca2+ transient abnormalities, which consist of cycling patterns that vary in shape and
frequency, is difficult, and their quantification is very challenging. To the best of our knowl-
edge, Ca2+ cycling abnormality patterns have thus far only been subjectively analyzed based on
visual information, which is labor-intensive, slow and often user-dependent. Manual data anal-
ysis performed with visual recognition is also a bottleneck for high-throughput screening and
can occasionally be unreliable because of the poor quality of the Ca2+ transients. Having gen-
eral criteria for Ca2+ cycling abnormality analysis could simplify the comparison between dif-
ferent studies and facilitate the analysis of Ca2+ cycling parameters. In addition, an automated
Ca2+ cycling classification software would be beneficial for the future analysis of Ca2+ cycling
of CMs on a large scale to screen for adverse cardiac effects of new potential compounds.
The aim of the study was to develop and test a Ca2+ cycling abnormality analysis software
based on interactive visualization with a direct manipulation user interface (UI). The software,
AnomalyExplorer, can user-independently assist in the classification of the Ca2+ transient pat-
terns detected in CMs by using criteria that are similar to those used in manual analyses that
are performed with visual recognition. We demonstrate the usability and capability of the soft-
ware using iPSC-derived CMs that were generated from patients with cardiac ryanodine recep-
tor (RyR2) gene mutations causing CPVT. Opening of RyR2 Ca2+ channels underlies
intracellular Ca2+ release from the sarcoplasmic reticulum in CMs. CPVT is an exercise-
induced arrhythmogenic cardiac disease with intracellular Ca2+ cycling defects [14]; therefore,
CPVT-specific CMs [5,9] are suitable for evaluating this program. The usability of the Anom-
alyExplorer is demonstrated with the data generated by two different Ca2+ imaging recording
software programs with different sampling frequencies. The analysis of data using AnomalyEx-
plorer is compared with the manual analysis results to establish the reliability of the analysis
software. This software tool will improve the accuracy, reliability and throughput rate for Ca2+
cycling data analysis.
Materials and Methods
Generation of patient-specific iPSCs and cardiac differentiation
The study was approved by the ethical committee of Pirkanmaa Hospital District (R08070).
Patient-specific iPSC lines were established as described earlier and written informed consent
was obtained from all the participants.[1] The studied RyR2 mutated CPVT cell lines
were UTA.05605.CPVT, generated from a patient with exon 3 deletion (c.168–301_c.273+
722del1128 mutation); UTA.05208.CPVT, generated from a patient with a p.P2328S
(c.6982C>T) mutation; UTA.07001.CPVT, from a patient with a p.T2538R (c.7613C>G)
mutation; UTA.03701.CPVT, from a patient with a p.L4115F (c.12343C>T) mutation;
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UTA.05503.CPVT, from a patient with a p.Q4201R (c.12602A>G) mutation; and UTA.05404.
CPVT, from a patient with a p.V4653F (c.13957G>T) mutation. UTA.04602.WT cell line was
generated from a healthy control. Mutation nomenclature was based on RyR2 reference
sequence NM_001035.2. The results of the characterization of iPSC lines have been previously
described.[5,9] For illustration of the RyR2 protein and locations of the mutations, see [9].
Differentiation into CMs was performed by co-culturing iPSCs with murine visceral endo-
derm-like (END-2) cells (Humbrecht Institute, Utrecht, The Netherlands) as previously
described.[15] For Ca2+ cycling measurements, CMs were dissociated by mechanically excising
the beating areas of the cell colonies and treating them with collagenase A (Roche Diagnostics)
[15].
Ca2+ imaging recordings and data analysis
Ca2+ imaging was conducted in spontaneously beating Fura-2 AM (Life Technologies, Molecu-
lar Probes) loaded, dissociated CMs that were perfused with extracellular solution as previously
described.[5] Ca2+ measurements were performed on an inverted IX70 microscope (Olympus
Corporation, Hamburg, Germany) and CMs were visualized with a UApo/340 x20 air objective
(Olympus). Images were recorded with an ANDOR iXon 885 CCD camera (Andor Technol-
ogy, Belfast, Northern Ireland) that was synchronized with a Polychrome V light source by a
real-time DSP control unit and TillVision (TILL Photonics, Munich, Germany) or Live Acqui-
sition software (FEI, OR, USA). TillVision and LiveAcquisition are further referred as Record-
ing Software 1 and 2, respectively. Fura-2 AM in CMs was excited at 340 nm and 380 nm light
and the emission was recorded at 505 nm. For Ca2+ analysis, regions of interest were selected
for spontaneously beating cells and background noise was subtracted before further data pro-
cessing. The Ca2+ transients were acquired as the ratio of the emissions at 340/380 nm wave-
lengths and presented as Fura-2 ratio units of F340/F380. Throughout the remainder of this
manuscript, the Ca2+ recording of a single cell is called the Ca2+ signal.
The data were generated with two separate softwares (Recording Software 1 and 2) with dif-
ferent sampling frequencies that affected the noise level of the recordings. Therefore, the Ca2+
signals were divided into two groups and analyzed separately depending on the recording soft-
ware. The Ca2+ signals were manually analyzed with visual recognition by identifying the sig-
nals as normal or abnormal and categorizing the abnormalities into six subgroups according to
their abnormality patterns. In manual analysis, a criterion for the double peak group was a
Ca2+ peak with paired peaks that did not reach the baseline. Oscillation was detected if Ca2+
fluctuated for three or more peaks without reaching the baseline. For the low peaks group, the
presence of a small amplitude Ca2+ peak of at least 10% of the preceding Ca2+ peak amplitude
was required. In the middle Ca2+ peaks, 30 to 80% amplitude of the preceding Ca2+ peak ampli-
tude was required. Plateau abnormality was detected if the rise or decay time of the Ca2+ peak
was prolonged, and an irregular beating rhythm was required for the irregular phase group.
Here, the Ca2+ peak represents a Ca2+ transient consisting of Ca2+ rise and decay. For compari-
son studies, the Ca2+ data was analyzed with AnomalyExplorer, in which suitable user-defined
percentage limits for each abnormality subgroup were selected for both recording software
data groups.
Software tool description
AnomalyExplorer is an interactive software tool that can assist in the visual classification of
Ca2+ signals. It is based on the information visualization approach with the following two
major components: representation of data and interaction with the data. The representation
component of AnomalyExplorer is based on the detail+overview design pattern, and an
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overview and detailed view of an information space are displayed simultaneously. Generally,
the overview provides a high-level view of the information space, and the detailed view shows
the current focus of interest in full detail.
The detailed view in AnomalyExplorer is a conventional 2D plot of the signal value over
time. The plot is similar to what a human observer would use to detect anomalies in the shape
of a signal. The idea in AnomalyExplorer is to express the human observer’s criteria for abnor-
mality as rules that can be programmed into AnomalyExplorer. The tool then highlights the
detected anomalies in a plot, which allows the user to adjust the sensitivity of anomaly detec-
tion by user-defined parameters for signal noise and six different abnormality subgroups.
The most important qualitative aspect in AnomalyExplorer is to define whether the signal is
normal or not, and to further analyze the quality and distribution of detected anomalies. Thus,
the overview in AnomalyExplorer was designed to be a stacked bar chart of detected anomalies
where a bar represents the number of anomalies in a signal, and stacking shows how the anom-
alies are distributed. Only the abnormal signals are present in the bar chart because the signals
deemed normal are not of interest. Information in such a bar chart can be acquired rapidly,
and the conventional representation allows for further insight-generating interactions.
User interface (UI). Fig 1 shows the UI of AnomalyExplorer and illustrates the workflow.
The current UI design has the following elements: a file chooser to open the signals that will
undergo analysis, the stacked bar chart of observed anomalies (overview), dynamic controllers
for the anomaly detection sensitivity, and the currently open set of detailed signal views. After
these main components there is a section showing how the currently open signals are classified
as normal and abnormal (as two text lists, not shown in the Fig 1), and a text view summarizes
the anomalies found in the current set.
The designed workflow with AnomalyExplorer starts by choosing the signal files that will
undergo analysis. The open file dialog allows for the selection of a single file, multiple files, or
all of the files in the current directory. AnomalyExplorer then updates the overview to show the
anomalies with the current default settings. Subsequently, the user may open one or more sig-
nals in the detailed view for closer inspection by clicking on a file name of the signal above the
detailed view (Fig 1D) or if the signal includes anomalies, also by clicking a bar in the overview
(Fig 1B). User can also adjust the dynamic controllers for the anomaly detection, observe the
changes in both the overview and detailed view, and sort the overview according to any of the
abnormality subgroup. The manipulation of dynamic controllers is immediately reflected in
both the overview and detailed view and allow for a rapid what-if exploration of anomaly
thresholds. When the satisfactory user-defined parameters for anomaly detection of a certain
data set are found, the AnomalyExplorer tool can be used as a rapid user-independent classifier.
The preset values of dynamic controllers serve only as a starting point to seek the best parame-
ter set for the current data set. Once the parameter values that correspond the analyst’s view of
the anomalies are found, the presets can easily be made default to facilitate easy classification of
multiple files without changing the parameters.
Anomaly detection. AnomalyExplorer is designed to detect the anomalies in the same
fashion as a human observer. The automated analysis software is based on the concepts of sec-
tions and regression lines, which act as points of reference for the rules defining the anomaly
subgroups. A section is a part of a signal which ascends or descends monotonously; it thus
marks and separates the Ca2+ rise and decay, which together comprise a Ca2+ transient. Sec-
tions allow for a small amount of noise in the signal. The noise threshold determines how
much the signal may exhibit direction changes without considering it to be a change in monot-
onous movement. The regression lines are needed as a reference for the anomaly rules because
the amplitude of a Ca2+ signal may fade over time from the Ca2+ indicator photobleaching.
The software uses the following three regression lines (Fig 1): one that approximates the
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signal’s local maximum (in a transient, top), another for signal’s local minimum (bottom), and
a third one that is averaged from these two, which approximates the local middle of the signal
(middle). The computation of the simple linear regression lines is based on the local maximum
and minimum data values in each section, and it is meant to approximate how a human
observer would place them. In addition to the regression height, the section heights are also
used in the computations. The section height is simply the data range in the section (i.e., the
local maximum data value minus the local minimum data value), and the regression height is
the distance between the top and bottom regression lines in the current section. With these ref-
erence values the anomaly subgroups can be defined. In addition, the anomaly definitions refer
to predefined and user-defined parameters. The predefined ones are implementation-depen-
dent constants and the user-defined are values that can be manipulated via the UI to corre-
spond to Ca2+ measurement settings such as the frame-rate of the recordings.
The current implementation of AnomalyExplorer detects the following six abnormality sub-
groups: low, middle, oscillating and double peak anomalies as well as irregular phase and pla-
teau abnormality (Fig 2).[16] Each of these anomaly subgroups are described in more detail
below. User-defined parameters can be manipulated by using the dynamic controllers in the
UI.
An ascending signal section is flagged to have a low peak (Fig 2) if the following conditions
are met: 1) the transient minimum value is within 15% of the local regression height from the
local bottom regression line, 2) the transient maximum value is between user-defined percent-
age limits of the local regression height, and 3) the previous and the following transient do not
contain double peak anomalies. Once the ascending section is classified as a low peak, the fol-
lowing descending section is also flagged as a low peak if its minimum value is within ±10% of
the current section’s minimum, i.e., the peak is fairly symmetrical.
Themiddle peak anomaly (Fig 2) is flagged if the following conditions are met: 1) the section
height is within the user-defined percentage limits of the local regression height, 2) the tran-
sient maximum value is within 60% of the local middle regression line, 3) the transient mini-
mum value is within 40% of the local middle regression line, 4) the section height is less than
75% of the height of the surrounding sections, and 5) there is no low peak anomaly in the pre-
vious or this section.
When determining the oscillation (Fig 2) of the Ca2+ signal the software compares the sec-
tion and transient heights and lengths, and the consecutive transients that are dwarfed below
the user-defined percentage limit are flagged as oscillating. The oscillating transients are not
analyzed for any further anomalies. Oscillations can also be generated by a double peak anom-
aly, which is discussed below.
A double peak anomaly (Fig 2) is flagged if the transient does not descend sufficiently low
before ascending to the next peak, such that only the descending sections are considered. The
double peak anomaly is flagged if the following conditions are met: 1) the section maximum
value is within 40% of the section height of the local top regression line, 2) the height of the sec-
tion is within user-defined percentage limit of the local regression height, 3) the upper percent-
age limit determines how deep the double peak can be (where 100% is the local bottom
regression line and 50% is the local middle regression line), and 4) the height of the section is
Fig 1. AnomalyExplorer program. A) Overview of the software. B) Each bar presents a single Ca2+ signal of a single cell and shows the distribution of
abnormality patterns in the recording. The total number of anomalies in all of the files can be observed on the right. C) Dynamic controllers for the anomaly
detection. D) The detailed view of one Ca2+ signal plot showing color-coded anomalies detected with the help of three yellow regression lines (top, bottom
and middle) and the sections subsequently rising and decaying separated with small grey vertical lines above the signal showing how the Ca2+ transients
ascend (light bars) and descend (dark bars).
doi:10.1371/journal.pone.0135806.g001
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within ±25% of the height of the following section. There can only be two consecutive peaks in
a double peak anomaly and sequences of more than two peaks are flagged as oscillations.
Irregular phase (Fig 2) is flagged if the distance of peaks differs by a user-defined percentage
(for example, 90%) from the median of the peak distances. Only those peaks that do not exhibit
any anomalies are considered, except the peaks that exhibit double peaks anomaly which are
treated as a single peak that has the mean of the positions of double peaks as its reference value.
Treating a double peak as a single peak prevents the overlap of irregularity and double peak
anomaly.
Plateau abnormality (Fig 2) is flagged if the transient changes its rate of ascent or descent
more than a user-defined percentage (for example 75%) within a section. Its recognition is also
affected by the setting of the noise ratio, i.e., how much of the signal noise is tolerated.
Availability of Software. The AnomalyExplorer conforms to the Open Source Definition
and has been designed to facilitate the abnormality analysis of Ca2+ recordings obtained from
CMs. Website for downloading the program: https://github.com/siirtola/AnomalyExplorer.
More information about the software can be found from S1 Supporting Information.
Fig 2. Detected Ca2+ signal abnormality patterns from AnomalyExplorer analysis. Examples of the color-coded abnormality subgroups that
AnomalyExplorer detects as well as normal Ca2+ signals as follows: low peaks, double peaks, middle peaks, oscillation, irregular phase, plateau abnormality,
and a signal with multiple different abnormalities. Abnormalities are detected with the help of three yellow regression lines and subsequently rising and
decaying sections separated with small grey vertical lines above the signal showing how the Ca2+ transient ascends and descends monotonously. The same
abnormality patterns were detected in a manual analysis made with visual recognition.
doi:10.1371/journal.pone.0135806.g002
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Results
Ca2+ transient abnormality patterns of CMs derived from iPSC lines with RyR2 mutations
causing CPVT varied remarkably as a function of time. We investigated the reliability and effi-
ciency of the AnomalyExplorer in detecting the normal and abnormal Ca2+ transients and cate-
gorized the abnormal signals into pattern specific subgroups, and compared these results to the
manual analysis.
The data were generated with two different Ca2+ transient recording software programs. As
a result, the signals were recorded with various sampling frequencies, which ranged from 9 to
10 Hz on Recording Software 1 and from 23 to 26 Hz on Recording Software 2. This affected
the noise level of the recordings, and it was thus necessary to find the optimal AnomalyExplorer
user-defined anomaly detection parameters for both recording software groups. In total, 132
Ca2+ signals were recorded with Recording Software 1 and 212 Ca2+ signals with Recording
Software 2, and the lengths of recordings varied from approximately 11 to 23 s.
Each Ca2+ signal was manually analyzed with visual recognition and compared with the
results obtained from AnomalyExplorer. On both manual and AnomalyExplorer analysis, the
Ca2+ signals were categorized as abnormal if at least one abnormality pattern was visualized in
the signal and as normal if no abnormalities were found in the recordings. Abnormal signals
were further categorized into different subgroups based on the following types of Ca2+ abnor-
malities observed visually: double peaks, oscillating peaks, low amplitude peaks, plateau abnor-
malities with prolonged Ca2+ rise or decay time or irregular phase in the beating rhythm (Fig
2). Then, the total numbers of subgroup specific abnormalities were quantified from the Ca2+
signals. One signal could belong to more than one abnormality subgroup and could include
several abnormalities.
At first, in AnomalyExplorer analysis, optimal analysis parameters were found for both
recording software programs. For signals generated with Recording Software 1 the user-defined
percentage limits for analysis were the following: noise 5%, low peaks 7–61%, middle peaks
0–70%, plateau abnormality 70%, oscillation 31%, double peaks 20–88%, and irregular phase
100%. For signals generated with Recording Software 2, the user-defined percentage limits
were the following: noise 8%, low peaks 10–61%, middle peaks 0–70%, plateau abnormality
70%, oscillation 31%, double peaks 20–88%, and irregular phase 100%. When comparing the
detection of normal and abnormal Ca2+ signals between the manual analysis and AnomalyEx-
plorer (S1 Fig), there was only 2% inconsistency between the manual and AnomalyExplorer
analysis for Recording Software 1 signals. This inconsistency was specified as false abnormal,
which indicated that they were manually categorized as normal but that the AnomalyExplorer
categorized them as abnormal. For Recording Software 2 signals, there was 9% inconsistency
with manual analysis; 4% were false abnormal and 5% were false normal, which indicated that
they were manually categorized as abnormal but that the software categorized them as normal.
The majority of the spontaneously beating control WT and CPVT CMs were categorized as
normal in both the manual analysis (66% and 58% of Recording Software 1 and 2 signals,
respectively) and the AnomalyExplorer analysis (64% and 57% of Recording Software 1 and 2
signals, respectively), without any observed abnormalities. Overall, 17% of the control WT
CMs (n = 23) were categorized as abnormal with AnomalyExplorer analysis and 13% with
manual analysis. Table 1 summarizes the overall percentage of detected abnormal signals with
both recording software programs as well as the consistency of the manual and AnomalyEx-
plorer analysis of different Ca2+ transient abnormality subgroups. To visualize the same results,
see S2 Fig. Many signals that were categorized as abnormal presented with various Ca2+ tran-
sient abnormalities, which can be observed from the detailed analysis results in the Anomaly-
Explorer overview in Fig 3.
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When comparing the manual and AnomalyExplorer analysis of different RyR2 mutated
CPVT cell lines, analyses revealed that there were mutation-specific differences in the Ca2+
transient abnormalities with both analysis methods (Fig 4). Double peaks were common
abnormality types in all RyR2 mutated CPVT cell lines with some small differences between
mutations. In AnomalyExplorer analysis double peaks were seen in 31 to 37% of the signals
with mutations located with N-terminal or central cytosolic region of the RyR2 protein (exon 3
deletion, P2328S, T2538R, L4115F) and in 21 to 26% of the signals with mutations in or near
the transmembrane domain (Q4201R and V4653F). Oscillation was also common abnormality
type in all of the mutated cell lines in AnomalyExplorer analysis, particularly in V4653F and
T2538R mutated CMs (47% and 52%, respectively). Low peaks were rather common in P2328S
and Q4201R mutated CMs (16% and 23%, respectively), and plateau abnormalities in Q4201R
and exon 3 deletion mutated CMs (25% to 38%, respectively) in AnomalyExplorer analysis.
Middle peaks and irregular phases were least common abnormality types in all mutated CPVT
CMs. When comparing the consistency of the manual and AnomalyExplorer, it was shown that
in P2328S and L4115F mutated CMs the analyses were comparable. Over 5% difference
between analyses was seen in low peak abnormalities (with exon 3 deletion, T2538R and
V4653F mutated CMs) with difference of 7–15%, irregular phase abnormalities (with exon 3
deletion, T2538R and V4653F mutated CMs) with difference of 6–10%, plateau abnormalities
(with exon 3 deletion and Q4201R CMs) with difference of 10–18% and double peak abnor-
malities (with T2538R and Q4201R CMs) with difference of 8–14%.
Discussion
Ca2+ cycling is fundamental for the electrical signaling and mechanical contraction of the
heart. It is controlled via ion currents, channels, and exchangers. Comprehensive functioning
of Ca2+ cycling is essential for the excitation–contraction coupling of CMs.[17] Ca2+ cycling
abnormalities may cause arrhythmic features such as delayed after depolarizations (DADs),
where depolarizing oscillations in the membrane potential follow an action potential after com-
pletion of repolarization [18], or early afterdepolarizations (EADs) which occur during repo-
larization.[19–21] Dysfunction in Ca2+ cycling may also produce Ca2+ alternans, a beat-to-beat
alternation in the amplitude of the intracellular Ca2+ transient.[22] Previous studies have
shown that disease-specific iPSC-derived CMs with Ca2+ cycling abnormalities manifest
Table 1. Comparison of detected Ca2+ transient abnormalities and different abnormality subgroups analyzedmanually and with AnomalyExplorer
software. Each analyzed signal represents a recording from a single cell. The percentages show the amount of each subgroup specific abnormality when
compared to the amount of all the abnormalities in all the signals. One signal could belong to more than one abnormality subgroup and could include several
abnormalities. Last row of the table shows the overall percentage of the abnormal signals from all the analyzed signals. The signal was analyzed as abnormal
if there were one or more Ca2+ transient abnormalities in the whole signal.
Recording Software 1 Recording Software 2
Manual analysis,
abnormalities (n = 171)
AnomalyExplorer analysis,
abnormalities (n = 157)
Manual analysis,
abnormalities (n = 301)
AnomalyExplorer, analysis
abnormalities (n = 284)
Double peaks 29% 30% 33% 34%
Low peaks 20% 15% 15% 6%
Middle peaks 5% 6% 9% 9%
Oscillations 26% 30% 26% 28%
Plateau abn. 6% 6% 7% 15%
Irregular phase 14% 13% 13% 8%
Signals categorized
as abnormal
34% (n = 132) 36% (n = 132) 43% (n = 212) 42% (n = 212)
doi:10.1371/journal.pone.0135806.t001
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arrhythmic features such as DADs or EADs in their action potential [2–6,11,13]. Additionally,
simultaneous AP and Ca2+ recordings of long QT-specific CMs have revealed that Ca2+ cycling
is involved in prolonging the AP duration and in the formation of EADs as demonstrated by
comparable changes in the APs and Ca2+ transients.[23] Therefore, disease phenotype-specific
changes in electrophysiology can be mirrored by changes in Ca2+ cycling, thereby highlighting
the importance of the analysis of these transients and abnormalities.
After the invention of iPSC technology, disease modeling with patient-specific CMs has
been constantly increasing and has revealed Ca2+ transient abnormalities in many CM disease
phenotypes. Consistent rules for the analysis of Ca2+ transient abnormalities are currently lack-
ing; thus, the results obtained from different studies cannot be compared. Thus far, the detec-
tion of Ca2+ cycling abnormalities has been based on how the researchers categorize data based
Fig 3. Detailed results in the AnomalyExplorer overview. View of the AnomalyExplorer analyzed Ca2+ signals summarizing the results recorded with A)
Recording Software 1 and B) Recording Software 2. It shows the detailed number of subgroup specific abnormalities in each Ca2+ signal in one bar and the
total number and percentages of all abnormality subgroups. Each bar represents a single cell (signal) and only signals presenting with abnormalities are
shown. Altogether, 132 Ca2+ signals were recorded with Recording Software 1, 47 which (36%) presented abnormalities. The corresponding number from
212 Ca2+ signals recorded with Recording Software 2 was 88 (42%).
doi:10.1371/journal.pone.0135806.g003
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on the individual’s reasoning, experience and observations. Previously in our study and in
other studies, earlier classification methods have involved categorizing a Ca2+ signal as abnor-
mal if at least one abnormality is detected without indicating the absolute amount or duration
of Ca2+ abnormalities in each signal.[3–6,11,12] In some cases, abnormalities have been
divided into subgroups that do not necessarily consider that one signal can express different
abnormal patterns and can thus belong to several subgroups.[4–6] A common problem has
also been that the naming and/or illustration of the abnormalities differ between studies and
they have been categorized, for example as after-contractions or triggered contractions [3], as
significant Ca2+ transient irregularities, such as multiple events [11], or as significant irregulari-
ties in Ca2+ transients, including at least an irregular rhythm and multiple peaks.[12] Addition-
ally, no specific analysis criteria have been reported because the nature of the analysis has been
visual inspection. Therefore, it is unclear whether all of the patterns have been calculated as
abnormalities and how these abnormalities have been considered in the numerical analysis of
the data. Additionally, with the traditional method of presenting signal abnormalities, it is not
possible to identify disease-specific Ca2+ abnormality patterns when comparing the already
published reports.
The human visual system is an ingenious pattern recognizer, and our cognitive activity is
largely based on this capability.[24] Detecting patterns is easy for a human, and the brain does
it effortlessly on the subconscious level. For example, the activity of analyzing and classifying
signals is trivial to those who know what to look for. However, regardless of the ability to cate-
gorize patterns manually, it is highly subjective. Two people might make different classifica-
tions, and the same person might classify signals differently at different times. Therefore, there
is a huge demand for specific criteria for different subgroups of Ca2+ abnormalities with spe-
cific analysis software that could automatically classify and calculate the abnormal signals
according to preset specifications. For these reasons, AnomalyExplorer, an interactive software
tool that can assist in the visual classification of Ca2+ signals was developed to help researchers
working with Ca2+ data of CMs. AnomalyExplorer is based on interactive visualization with a
direct manipulation UI, in which the analysis and classification approach of the researcher has
been transferred into a software tool to improve the accuracy, reliability and throughput rate
for Ca2+ cycling analysis. The user can set the user-defined anomaly detection parameters for
each subgroup and the background noise level of the recordings. This direct manipulation of
the UI allows for the use of AnomalyExplorer with different measurement settings wherein the
recording software, sampling frequency or environment of the measurement setup can vary
and optimal settings can be found for each occasion. Once the optimal user-defined anomaly
detection parameters have been identified for recordings made with specific measurement set-
tings, there is no need to manipulate the UI.
The purpose of information visualization is to use perception to amplify cognition. The idea
of AnomalyExplorer was to generate task-specific visual representations of data with which the
user can interact, thereby amplifying users’ cognition. The means to amplify users’ cognition
are numerous, and here the most relevant ones were enhancing the pattern recognition, facili-
tating the comparisons, and supporting the short-term memory by using external representa-
tions. [25] The interaction component of the software allowed the user to have a dialog with
Fig 4. Comparison of AnomalyExplorer andmanual Ca2+ signal analysis of the different RyR2mutated
CPVT cell lines. Pie charts indicate the percentage of the Ca2+ cycling abnormalities and showmutation
specific differences in the abnormalities with both analysis methods. One Ca2+ signal can belong to several
subgroups and consist of many abnormalities. The numbers of the signals analyzed from different RyR2
mutation specific CMs are the following: exon 3 del n = 46, P2328S n = 32, T2538R n = 51, L4115F n = 106,
Q4291R n = 57 and V4653F n = 29.
doi:10.1371/journal.pone.0135806.g004
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the data, and this exploration uncovered insights.[26] The representation component of Anom-
alyExplorer was based on the detail+overview design pattern, and an overview and detailed
view of an information space are displayed simultaneously.[27] Overview has been defined to
imply a qualitative awareness of one aspect of some data, preferably acquired rapidly and pre-
attentively without cognitive effort. [28] The most important qualitative aspect in AnomalyEx-
plorer was to define whether the signal is normal or not, and to further analyze the quality and
distribution of detected anomalies. Therefore overview in AnomalyExplorer was designed to be
a stacked bar chart of detected anomalies where a bar represents the number of anomalies in a
signal, and stacking shows how the anomalies are distributed. The first question in the design
of an interactive visualization tool is if often whether we need to support a workflow from the
overview to detailed view or vice versa. Shneiderman [29] advocated for the former approach
in designing visualization tools by stating “overview first, zoom and filter, then details-on-
demand”. In AnomalyExplorer, the free movement between the overview and detailed views
must be supported to reduce the cognitive load. In addition, the views need to be tightly cou-
pled. In the detailed view, the appropriate parameters for anomaly detection are sought, and it
must be continuously monitored how this affects the overall outcome, until suitable parameters
for data analysis are found. In the overview, the inspection may reveal signals that seem to be
outliers or that are otherwise suspicious, and the details on the demand need to be seen.
It can be roughly estimated that manual analysis of one Ca2+ signal takes from 10 to 120 sec-
onds, and the overall manual analysis time in this study was approximately 90 minutes and 140
minutes with Recording Software 1 and 2 signals, respectively. With AnomalyExplorer, the
analysis of the Ca2+ signals is much faster, and was approximately only 10 seconds in this study
with both Recording Software 1 and 2 signals, because the analysis results are immediately
shown after loading the signals into the software regardless of the number of signals. Therefore,
with AnomalyExplorer, the saved time compared with manual analysis increases with the num-
ber of analyzed signals. Other benefits of AnomalyExplorer include the fact that the classifica-
tions are repeatable and user-independent and that the accuracy and repeatability of the
analysis can be enhanced. The definition of signal abnormalities in terms of visual properties,
is more flexible than numerical or analytical specification. However, it needs to be highlighted
that this type of abnormality analysis does not exclude the need for the numerical analysis of
different Ca2+ cycling parameters, such as the amplitude, frequency and peak duration. Anom-
alyExplorer is anyhow a good tool for screening through the Ca2+ recordings for more exten-
sive analysis and it can facilitate the numerical analysis by determining the abnormality
analysis criteria that can be exploited when defining how abnormalities should be considered
in numerical analysis, such as when calculating the duration of double or oscillating peaks. To
further analyze the mechanism behind different Ca2+ cycling abnormalities, combined electro-
physiology and other functional methods together with Ca2+ imaging measurements are
needed.
When Ca2+ signals are analyzed with AnomalyExplorer, the results are more comparable
between different studies than they are with manual analysis because the user-defined anomaly
detection parameters are specifically determined. Once the optimal user-defined parameters
have been identified for specific measurement settings, there is no need for manipulating these
parameters. With AnomalyExplorer exploiting the interactive visualization, it is easy to catch
all of the abnormalities in a sample and obtain a more accurate and complete classification. In
this study, we have shown that optimal analysis parameters can be found for data recorded
with two different recording software programs and that the detection of normal and abnormal
signals as well as the abnormality patterns with AnomalyExplorer is quite consistent with the
manual analysis. Some variation in the manual and AnomalyExplorer analysis was observed in
the categorization of abnormalities. When classifying the signals as normal or abnormal,
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inconsistency of the analysis could be seen in 2% and 9% of signals with Recording Software 1
and 2, respectively, which was quite reasonable. When categorizing the abnormalities into sub-
groups and calculating the number of different subgroup specific abnormalities, the abnormali-
ties were detected with 0 to 5% difference between the manual and AnomalyExplorer analyses.
The exception was in the amount plateau and low peak abnormalities in Recording Software 2
signals with 8 and 10% differences between manual and AnomalyExplorer analysis. When com-
paring manual and AnomalyExplorer analyses of different RyR2 mutated CPVT cell lines it
was shown that detection of oscillation and middle peaks were equivalent with 0 to 5% differ-
ences in addition to double peak detection, which was quite similar between analyses with 0 to
5% differences in 4 out of 6 mutations. Detection of low peaks, irregular phases and plateau
abnormalities differed the most between analyses. Overall, the inconsistency between manual
and AnomalyExplorer analysis may be due to differences between human and software analyses
because the accuracy of the manual analysis varies since it is performed only by visual recogni-
tion without clear abnormality detection rules. Higher percentages of low peak abnormalities
were detected in manual analysis than in AnomalyExplorer analysis. This could be explained
with background noise of the Ca2+ recordings, which is challenging to recognize visually in the
manual analysis. Also irregularity of the beating rhythm as well as the prolonged rise and decay
time (plateau abnormalities) of Ca2+ transients are challenging to detect visually in manual
analysis since criteria for these abnormality types is difficult to define. With AnomalyExplorer
the noise and abnormality detection rules are clearly defined and therefore the anomaly detec-
tion is more compatible between signals. Inconsistency between manual and AnomalyExplorer
analysis can also be seen due to problems in the Ca2+ recording setup, such as with photo-
bleaching of the Ca2+ indicator or its toxicity together with UV light to CMs, which can inter-
fere with the loading of the cells and cause the transients and thus the whole signal to have
extra noise. This can also affect the validity of AnomalyExplorer analysis and may be stated as
one limitation of this study.
When comparing the analysis of different CPVT cell lines generated from patients carrying
different RyR2 mutations the percentage of different abnormality subgroups varied between
cell lines. Overall, double peaks and oscillations were most common and middle peaks and
irregular phases least common abnormality types in all CPVT mutations. Other than that, no
specific trend between abnormality subgroup percentages and different mutations could be
seen and it could be concluded that there were mutation-specific differences in the Ca2+ tran-
sient abnormalities like we have previously shown with these cell lines [9].This finding showed
the future usefulness of AnomalyExplorer for detecting cell line- and mutation-specific variabil-
ity in the Ca2+ transient abnormalities. These types of differences reflect the mutation specific
pathology of the disease and reveal that the location of the mutation can affect the disease phe-
notype. This result is in accordance with our previous study [9], where we showed that the
Ca2+ abnormalities of these different CPVT cell lines are more common in some mutations
than in others and that these Ca2+ cycling abnormalities can be rescued or reduced with a spe-
cific drug as in actual patients. In the future, AnomalyExplorer can speed up and improve the
accuracy of the analysis of this type of drug study, where the effect of a specific type of drug on
the amount Ca2+ cycling abnormalities is quantified. Further Ca2+ cycling studies combined
with electrophysiological studies, are needed to assess how different Ca2+ cycling abnormalities
reflect the mechanism of the disease or drug effect because these are not yet known. Presum-
ably, at least some Ca2+ cycling abnormalities reflect the arrhythmogenic features such as
DADs and EADs. Because electrophysiological studies are time-consuming and challenging
and because only a restricted number of cells can be measured, these methods are not often
combined and more optimization is needed.
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AnomalyExplorer was designed for the data analysis of<50 Hz sampling frequency data
with recording duration of tens of seconds, and it performs flawlessly under these require-
ments. AnomalyExplorer is able to analyze data with higher sampling frequencies, at least to
100 Hz, but it could be improved to suit for analysis of even higher frequency data in the future.
With functional recordings it is problematic to set a certain recording duration limit that is suf-
ficient to define the overall behavior of a cell and there is always uncertainty how well the
recording reflects the overall behavior of the cell. In our study the recording duration was
implemented for our specific use case with varying recording durations of 11 to 23 seconds.
The analysis software does not have a limit for the recording length, but it can be estimated
that responsiveness and user experience will suffer with several minute recordings. Short dura-
tion signals may not represent the long-term behavior of the cell correctly and for the future
Ca2+ cycling analysis, the use of longer recordings with standard duration could be more bene-
ficial, if it would be suitable for the study design. Ín these analyses, the duration of each abnor-
mal Ca2+ transient could be compared to the duration of the whole signal to see the percentage
of the abnormal Ca2+ transients in the recording. To improve the analysis of long-term behav-
ior of the cells, long recordings could be also broken up into a series of segments and analyzed
separately before averaging. Sampling frequency and recording duration of this study can be
stated as a limitation of this study and the current prototype, as it was designed and imple-
mented for a specific use case and for the specific digitization systems. Nevertheless, recording
durations of tens of seconds and sampling frequencies of<50 Hz have been utilized success-
fully before, when studying Ca2+ cycling of iPSC derived disease specific CMs [2,5,9,23].
As the use of iPSC-derived CMs for disease modeling and drug screening continues to
increase, there is a significant demand for faster and more consistent analysis methods. Anom-
alyExplorer is suitable for analyzing high number of Ca2+ signals, which can be a bottleneck for
high-throughput Ca2+ imaging analysis and screenings in manual data analysis. This tool will
facilitate and speed up the analysis of CM Ca2+ transients; furthermore it should be more accu-
rate and user-independent. At present, we are not aware of any similar software that is suitable
for single Ca2+ signal analysis that is recorded with any type of recording software. In the
future, iPSC-derived CMs can be exploited for screening of potential new chemical compounds
and this software and analysis method can be exploited for evaluating different drug responses
and in Ca2+ cycling analysis to study basic disease pathology. This method will also be benefi-
cial when analyzing Ca2+ cycling of CMs on a large scale for screening the adverse cardiac
effects of new potential compounds.
Conclusions
In this study, the AnomalyExplorer tool was developed to assist in analyzing and classifying
Ca2+ signal abnormalities of disease specific human iPSC-derived CMs. Ca2+ cycling has a cen-
tral role in CM contraction-relaxation, and it also is essential in the electrical signaling of CMs.
As a result, detailed characterization of the abnormal Ca2+ transients present in different car-
diac diseases would allow for a more detailed evaluation of the physiological function of the
diseased CMs. Because Ca2+ transient abnormalities are difficult to specify and analyze by
computational methods, in the AnomalyExplorer tool the abnormalities are recognized by the
visual features alone, using interactive visualization with a similar approach as in traditional
manual analysis. It is based on the multiple coordinated views paradigm and a direct manipula-
tion UI. Using AnomalyExplorer the classifications are repeatable and user-independent. The
software is also capable of screening large datasets faster than manual analysis. By utilizing fast
kinetic fluorescence imaging of intracellular Ca2+ levels, together with AnomalyExplorer, the
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Ca2+ transient abnormalities of spontaneously contracting CMs can be detected and classified,
which provides more information regarding the Ca2+ cycling phenotype in these cells.
Supporting Information
S1 Fig. Consistency of the manual analysis and AnomalyExplorer analysis. Totally 132 Ca2+
signals recorded with Recording Software 1 (A) and 212 Ca2+ signals recorded with Recording
Software 2 (B) were analyzed.
(TIF)
S2 Fig. Comparison of manual and AnomalyExplorer Ca2+ signal analysis of the data gener-
ated with Recording Software 1 and 2. A) Pie charts indicate the percentage of normal
(white) and abnormal (black) Ca2+ signals in manual and AnomalyExplorer analyzed signals.
B) Color-coded pie charts indicate the percentage of the different abnormalities in both manu-
ally and AnomalyExplorer analyzed signals. One Ca2+ signal can belong to several subgroups
and consist of many abnormalities. In Recording Software 1 signals, totally 171 and 157 abnor-
malities were found in manual and AnomalyExplorer analysis, respectively. In Recording Soft-
ware 2 signals, totally 301 and 284 abnormalities were found in manual and AnomalyExplorer
analysis, respectively.
(TIF)
S1 Supporting Information. Availability of software including link to the software licensed
under MIT, documentation for running and installing the software, and a test dataset for
running the software.
(DOCX)
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SUPPORTING INFORMATION 
STUDY IV 
  
  
 
S1 Fig. Consistency of the manual analysis and AnomalyExplorer analysis. Totally 132 Ca2+ signals 
recorded with Recording Software 1 (A) and 212 Ca2+ signals recorded with Recording Software 2 (B) were 
analyzed. 
  
  
S2 Fig. Comparison of manual and AnomalyExplorer Ca
2+ 
signal analysis of the data generated with 
Recording Software 1 and 2. A) Pie charts indicate the percentage of normal (white) and abnormal (black) 
Ca2+ signals in manual and AnomalyExplorer analyzed signals. B) Color-coded pie charts indicate the 
percentage of the different abnormalities in both manually and AnomalyExplorer analyzed signals. One Ca2+ 
signal can belong to several subgroups and consist of many abnormalities. In Recording Software 1 signals, 
totally 171 and 157 abnormalities were found in manual and AnomalyExplorer analysis, respectively. In 
Recording Software 2 signals, totally 301 and 284 abnormalities were found in manual and AnomalyExplorer 
analysis, respectively. 
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AnomalyExplorer software 
The AnomalyExplorer (AE) is a HTML5-based analysis tool for calcium cycling. It is based on the 
earlier Java implementation (Siirtola et al. 2014). 
   
AE is a one-page web application implemented mainly in JavaScript. It should run on any modern 
web browser, but it has been specifically tested with Google Chrome and Safari. Software conforms 
the Open Source Definition.  
 
The Latest Version 
AE can be found on the AnomalyExplorer project page under 
https://github.com/siirtola/AnomalyExplorer 
 
Documentation  
Currently, the only documentation is the accepted PLOS-One article. The distribution contains test 
dataset files demonstrating the anomaly types that can be detected with AE. The most up-to-date 
documentation can be found at https://github.com/siirtola/AnomalyExplorer 
 
Installation  
AE does not require any installation beyond copying the test dataset files and the folder structure 
into a new location. AE does not require a web server as it can be run from a local copy. 
 
Running of the software  
Files include test dataset, which can be uploaded to AE from “Choose files” function. Suitable 
control parameter settings for this test dataset are set as default but can be as well controlled by 
user. Immediately after the files to be analyzed are uploaded to the software, results with the default 
parameter settings are shown.   
 
Licensing 
AE is distributed under MIT license.  
 
Contacts 
 For questions related to biomedical aspects of AE,  
please contact Kirsi Penttinen, kirsi.penttinen@uta.fi 
 For questions related to technological aspects of AE,  
       please contact Harri Siirtola, harri.siirtola@uta.fi 
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